Key word Index For Volume 52

A
AA amyloidosis. 1543
ACE gene polymorphism 60:S-28
ACE gene polymorphisms 278
ACE-genotype 559
ACE inhibition 561, 1622, 63:S-15, 63:S-23, 63:S-32
ACE inhibitors. 1261, 63:S-19, 63:S-58
Acetate free biofiltration 560
Acid/base status 1126
Acidification 265
Acidosis. 264, 275, 1117, 1428, 61:S-47
Acid phosphatase 1291
Acrenocorticotrophic hormone. 1651
Activated antigens. 1160
Activation antigens 1141
Acute phase reaction 62:S-53
Acute rejection 1120, 1131, 1157, 1160, 63:S-71
Acute renal failure. 864, 1127, 1139, 1140, 61:S-36, 61:S-39
Acute renal injury. 61:S-52
Acute thrombosis 1154
Adenosine. 1169
Adenosine triphosphate 61:S-47
ADPKD 33
Adrenergic system. 1147
Adult polycystic kidney disease. 279
Advanced glycation endproduct 274
Advanced glycation end products 1302
Advanced glycation endproducts (AGEs). 1645
Advanced glycosylation end products 60:S-60
Afferent arterioles. 63:S-128
Agonist. 61:S-2
Albumin 264
Albumin excretion rate. 63:S-87
Albuminuria 240
Alcoholic pancreatitis 1137
Aldosterone. 63:S-7, 63:S-115
Allograft dysfunction 273
Allograft rejection. 1424
α_{2A}-adrenergic receptor gene 1136
Alpha 2-macroglobulin 1579
Alpha-glucosidase 1532
Alport's syndrome. 208
Aluminum 1143, 1150
Ambulatory blood pressure. 63:S-15
Ambulatory hemodialysis 1155
Amino acid metabolism 62:S-41
Amino acids 1332
Amino acids in dialysate 1663
Aminopeptidase A 1250
Amyloid fibrils 1543
ANCA. 277, 1130
ANCA positive vasculitis 268
Androgens. 1152, 1153
Androgen therapy. 1148
Anemia. 195, 217, 1152, 62:S-83
Angiotensin 63:S-7
Angiotensin-converting enzyme 270, 1120, 63:S-132
Angiotensin converting enzyme inhibitors 1159, 61:S-14, 63:S-198
Angiotensin II. 572, 1423, 1497, 61:S-18, 63:S-19, 63:S-67, 63:S-132, 63:S-140, 63:S-221, 63:S-226
Angiotensin II in diabetes. 63:S-107
Angiotensin II receptor. 87, 63:S-208
Angiotensin II receptor antagonist 63:S-136
Angiotensin II receptor antagonists 63:S-185
Angiotensin II receptor blockers. 63:S-218
Angiotensinogen. 229
Angiotensin receptor antagonist 63:S-140
Angiotensins. 1250
Angiotensin type 2 receptor 63:S-201
Anteroventral third ventricle 61:S-22
Antibodies. 1124, 62:S-79
Antibody. 1375
Anticardiolipin antibodies. 1155
Anti-fibrotic effect. 63:S-239
Anti-GBM antibody 1579
Anti-GBM disease 1122
Antigen. 1469
Antihypertension regimen. 63:S-75
Antihypertensive drugs 1158
Antihypertensives 575
Antihypertensive treatment 1142, 61:S-74, 63:S-49
Antilymphocyte globulin 1157
Anti-myeloperoxidase 1124
Anti-neutrophil cytoplasmic antibodies. 276
Antiotensin II 1458
Antioxidant activity. 275
Antioxidants 60:S-46
Antiphospholipid syndrome 1138
APACHE II score 1140
Apheresis 1159
Apolipoprotein B 63:S-98
Apolipoprotein B (ApoB). 1645
Apolipoprotein E 864, 62:S-75
Apoptosis 263, 564, 1511, 1626
Aquaporin-2 . . . . . 570, 61:S-6
Arginase activity 261
Arginine transport 1593
Arginine vasopressin 61:S-6, 61:S-22
Arteriolopathy. 1426
Arteriosclerosis. 10
Ascites 61:S-77
Asian children. 275
AST-120 . . . . . 63:S-188
Asymmetric dimethylarginine 1593
Atenolol 61:S-74
Atheromatous renal artery stenosis 268
Atheromatous renovascular disease 267
Atherosclerosis. 864, 1119, 1147, 1685, 62:S-90, 63:S-120
Atherosclerotic renal disease 1133
ATP 140
AT receptor antagonists 63:S-111
Atrial natriuretic factor. 559
Atrial natriuretic peptide 202, 565, 1635, 60:S-33
Autoantigen 1340

Key word Index For Volume 52

A
AA amyloidosis. 1543
ACE gene polymorphism 60:S-28
ACE gene polymorphisms 278
ACE-genotype 559
ACE inhibition 561, 1622, 63:S-15, 63:S-23, 63:S-32
ACE inhibitors. 1261, 63:S-19, 63:S-58
Acetate free biofiltration 560
Acid/base status 1126
Acidification 265
Acidosis. 264, 275, 1117, 1428, 61:S-47
Acid phosphatase 1291
Acrenocorticotrophic hormone. 1651
Activated antigens. 1160
Activation antigens 1141
Acute phase reaction 62:S-53
Acute rejection 1120, 1131, 1157, 1160, 63:S-71
Acute renal failure. 864, 1127, 1139, 1140, 61:S-36, 61:S-39
Acute renal injury. 61:S-52
Acute thrombosis 1154
Adenosine. 1169
Adenosine triphosphate 61:S-47
ADPKD 33
Adrenergic system. 1147
Adult polycystic kidney disease. 279
Advanced glycation endproduct 274
Advanced glycation end products 1302
Advanced glycation endproducts (AGEs). 1645
Advanced glycosylation end products 60:S-60
Afferent arterioles. 63:S-128
Agonist. 61:S-2
Albumin 264
Albumin excretion rate. 63:S-87
Albuminuria 240
Alcoholic pancreatitis 1137
Aldosterone. 63:S-7, 63:S-115
Allograft dysfunction 273
Allograft rejection. 1424
α_{2A}-adrenergic receptor gene 1136
Alpha 2-macroglobulin 1579
Alpha-glucosidase 1532
Alport's syndrome. 208
Aluminum 1143, 1150
Ambulatory blood pressure. 63:S-15
Ambulatory hemodialysis 1155
Amino acid metabolism 62:S-41
Amino acids 1332
Amino acids in dialysate 1663
Aminopeptidase A 1250
Amyloid fibrils 1543
ANCA. 277, 1130
ANCA positive vasculitis 268
Androgens. 1152, 1153
Androgen therapy. 1148
Anemia. 195, 217, 1152, 62:S-83
Angiotensin 63:S-7
Angiotensin-converting enzyme 270, 1120, 63:S-132
Angiotensin converting enzyme inhibitors 1159, 61:S-14, 63:S-198
Angiotensin II. 572, 1423, 1497, 61:S-18, 63:S-19, 63:S-67, 63:S-132, 63:S-140, 63:S-221, 63:S-226
Angiotensin II in diabetes. 63:S-107
Angiotensin II receptor. 87, 63:S-208
Angiotensin II receptor antagonist 63:S-136
Angiotensin II receptor antagonists 63:S-185
Angiotensin II receptor blockers. 63:S-218
Angiotensinogen. 229
Angiotensin receptor antagonist 63:S-140
Angiotensins. 1250
Angiotensin type 2 receptor 63:S-201
Anteroventral third ventricle 61:S-22
Antibodies. 1124, 62:S-79
Antibody. 1375
Anticardiolipin antibodies. 1155
Anti-fibrotic effect. 63:S-239
Anti-GBM antibody 1579
Anti-GBM disease 1122
Antigen. 1469
Antihypertension regimen. 63:S-75
Antihypertensive drugs 1158
Antihypertensives 575
Antihypertensive treatment 1142, 61:S-74, 63:S-49
Antilymphocyte globulin 1157
Anti-myeloperoxidase 1124
Anti-neutrophil cytoplasmic antibodies. 276
Antiotensin II 1458
Antioxidant activity. 275
Antioxidants 60:S-46
Antiphospholipid syndrome 1138
APACHE II score 1140
Apheresis 1159
Apolipoprotein B 63:S-98
Apolipoprotein B (ApoB). 1645
Apolipoprotein E 864, 62:S-75
Apoptosis 263, 564, 1511, 1626
Aquaporin-2 . . . . . 570, 61:S-6
Arginase activity 261
Arginine transport 1593
Arginine vasopressin 61:S-6, 61:S-22
Arteriolopathy. 1426
Arteriosclerosis. 10
Ascites 61:S-77
Asian children. 275
AST-120 . . . . . 63:S-188
Asymmetric dimethylarginine 1593
Atenolol 61:S-74
Atheromatous renal artery stenosis 268
Atheromatous renovascular disease 267
Atherosclerosis. 864, 1119, 1147, 1685, 62:S-90, 63:S-120
Atherosclerotic renal disease 1133
ATP 140
AT receptor antagonists 63:S-111
Atrial natriuretic factor. 559
Atrial natriuretic peptide 202, 565, 1635, 60:S-33
Autoantigen 1340

Autoregulation of GFR 1369
Autosomal dominant polycystic kidney disease 1126, 1196
Azithromicyn 1159

B

B-galactosidase 63:S-201
B7 costimulatory molecules 1678
Bacterial contamination in the dialysate 862
Bacterial peritonitis 1123
Baculovirus 564
Bandeiraea simplifolia-1 lectin 1279
BANFF criteria 1157
Baroreflex 61:S-22
Bartter syndrome 570
Baseline predictors of ESRD 63:S-54
Basement membranes 1302
Basic fibroblast growth factor 1671
Bayesian Belief Network 1120
Benazepril 63:S-63, 63:S-159
Beta blockers 63:S-58
β2-glycoprotein I 1155
β2-microglobulin 1543, 62:S-75
Bicarbonate 266
Binding sites 93
Biocompatibility 1148, 62:S-101
Bioimpedance norms 1617
Blood flow 1359, 1656, 61:S-45
Blood pressure 270, 575, 1118, 1119, 1136, 1158, 63:S-7, 60:S-33, 63:S-58
Blood volume change 1428
Body composition 1617, 63:S-166
Body mass index 63:S-169
Bone cell 1142
Bone density 1134
Bone disease 1134, 1143
Bone loss 1133
Bone marrow transplantation 1139
Bone mass 1149, 1428, 62:S-69
Bone metabolism 62:S-72
Bosentan 1426
Bradykinin 1261
Bradykinin B2 receptor 1430
Breath ammonia 223
Brush border membrane 1550
Brushite 1291
BSC-1 cells 1291

C

C5b-9 and endothelial injury 1570
Caeruloplasmin 1124
Calcitriol 1149, 62:S-60, 62:S-65
Calcitriol receptor 39, 79
Calcium 1149, 61:S-27
Calcium channel blockers 1381, 63:S-19
Calcium oxalate 1135, 1602
Calcium oxalate crystals 1291
Calcium regulation 62:S-5
Calpain 1271
cAMP signaling pathway 152
Candesartan 575, 63:S-226, 63:S-229
Candesartan cilexetil 63:S-136
Candesartan cilexitil 63:S-185
CAPD 62:S-105
Captopril 61:S-14
Cardiac complications of dialysis 62:S-90
Cardiac function 61:S-47
Cardiac hypertrophy 1118
Cardiomyopathy 62:S-12
Cardiovascular damage 63:S-163
Cardiovascular disease 1133
Cardiovascular disease risk factor 10
Cardiovascular events 267
Cardiovascular risk 240
Carpal tunnel syndrome 62:S-75
Cartilage 45
Casts 61:S-67
Catheter 568
Catheter brushes 266
Catheter infection 1119, 1155
Catheters 266, 1140, 1154
Cell culture 229, 1126
Cell growth 1497
Cell isolation 1279
Cell-mediated immunity 278
Cell-specific gene expression 61:S-85
Cellular differentiation 1125
Cellulose acetate hemodialyzers 1381
Central venous access 266
Ceramide 60
C-fos 130
Chemiluminescence 1700
Chondrotin sulfate 60:S-42
Chromosome 17 1196
Chronic ACE-inhibition 1423
Chronic dialysis 1119
Chronic dysfunction 1159
Chronic Graft-versus-Host disease 563
Chronic hemodialysis 1147, 1425, 1656
Chronic hypotension 1147
Chronic illness 267
Chronic renal allograft failure 1427
Chronic renal allograft rejection 1424
Chronic renal disease 63:S-54
Chronic renal failure 3, 171, 263, 264, 269, 560, 1119, 1142, 1550, 62:S-5, 62:S-41, 62:S-45, 62:S-60, 62:S-83, 60:S-100, 63:S-136, 63:S-140, 63:S-239
Chronic renal insufficiency 63:S-63, 63:S-159
Chymase 63:S-132
Cirrhosis 864, 61:S-41, 61:S-77
Citraturia 1135
Clearance 1395
Clinical trials 63:S-87, 63:S-151, 63:S-155
Cloning 61:S-6
CMV infection 273
Coagulation 1156
Cochrane Systematic Reviews 1117
Collagen type I 1561
Collagen type IV 1302
Collecting duct 1469
Collecting ducts 1206
Complement 1122, 1375
Complement factor D 863
Complement factor H 1122
Complications 1129
Computed tomography 1635
Congestive cardiac failure 272
Connecting tubules 1206
Conscious rats 244
Continuous ambulatory peritoneal dialysis 274, 1144, 62:S-108

Corneal erosion 208
C-reactive protein 62:S-53
Creatinine 1425
Creatinine clearance 63:S-166, 63:S-188
Crescentic glomerulonephritis 52
Cross-talk 61:S-45
Crystallization 1602
CV11974 ..... 63:S-205
Cyclooxygenase mRNA 1242
Cyclosporine ... 248, 863, 1133, 1135, 1158, 1426, 1428, 61:S-27
Cyclosporine A 1138
Cystic kidney disease 63:S-93
Cytokine gene transcription 1116
Cytokines 575, 1127, 1313, 1439, 1521, 60:S-3, 63:S-2
Cytomegalovirus 1120
Cytoprotection 140
Cytosolic calcium 62:S-45
Cytotoxicity 1626

D
D/P ratio 1609
Decoy receptor 1224
Delayed-type hypersensitivity 52
Dementia 1128
Depolarization 157
Desferrioxamine 1142, 1150
Desmin 1279
Development 1469
Dextran sulfate 1622
D-glucose 1121
Diabetes 240, 270, 1369, 60:S-3, 60:S-7, 60:S-20, 60:S-23, 60:S-28, 60:S-33, 60:S-42, 60:S-46, 60:S-54, 60:S-66, 60:S-70, 61:S-83, 62:S-39, 63:S-32, 63:S-107
Diabetes mellitus 60:S-12, 63:S-36
Diabetes mellitus and vascular complications 60:S-77
Diabetic dialysis patients 1146
Diabetic ESRD 1645
Diabetic nephropathies 63:S-198
Diabetic nephropathy ... 111, 270, 1121, 1122, 1124, 1137, 1302, 1429, 60:S-60, 60:S-91, 63:S-27, 63:S-49, 63:S-87, 63:S-155
Diacylglycerol 60:S-77
Diagnostic markers 272
Dialysate 1381, 1663
Dialysate filter 862
Dialysis 267, 273, 1117, 1128, 1129, 1143, 1145, 1148, 62:S-72, 62:S-93, 62:S-108, 63:S-169
Dialysis adequacy 1427, 62:S-96
Dialysis and cardiac mortality 62:S-12
Dialysis delivery 269
Dialysis dose 1129
Dialysis efficiency 560
Dialysis fluid 265, 1150
Dialysis fluids 566
Dialysis membranes 1147, 62:S-101
Dialysis needles 1154
Dialysis patients 1146
Dialysis-related amyloidosis 62:S-75
Dialysis therapy 62:S-105
Diet 865, 62:S-41, 62:S-48
Dietary salt 1242
Differentiation 229
Dimethyl sulfoxide 1430
Diptheria 212
Dipyridamile 1671
Distal convoluted tubule 1125
Distal tubule cell 1321
Diuretics hypermagnesiuria 1180
DNA hybridization 1120
Dominant polycystic kidney disease 1131
Dopamine 152
Doxorubicin 571
Drug delivery 1693, 61:S-85
Drug therapy for hypertension 63:S-75
Dyslipidemia 1645
Dyslipidemias 62:S-53

E
Early onset 33
Economic evaluation 63:S-159
Edema 1406
Effective peritoneal surface area 1127
Egr-1 130
Embryogenesis 1242
Embryonic development 1196
Enalapril 560, 1137, 61:S-74
Enalaprilat 1137
Endocrine gland 3
Endocytosis 1121, 61:S-18
Endothelial cell regulation 157
Endothelial cells 262, 1332
Endothelin 277, 571, 61:S-27
Endothelin 1 ..... 61:S-22, 61:S-56
Endothelin receptors 277
Endothelium 182, 63:S-102
Endotoxemia 270
Endotoxin 1579
Endpoints in clinical trials 63:S-155
End-stage renal disease 10, 273, 1685, 61:S-83, 62:S-12, 62:S-96, 63:S-144, 63:S-169, 63:S-236
End-stage renal failure 223, 274, 1118, 1126, 1127, 63:S-54
Energy 140
Environmental works of art 62:S-111
Enzymes 1458
Epithelial cell 63:S-171
Epithelial cells 1511, 61:S-39, 61:S-52
Epithelial repair 61:S-36
Epitope mapping 1116
Erythrocyte 195
Erythrocytes 62:S-83
Erythrocytosis 864
Erythropoietin 217, 274, 576, 1150, 1423
Erythropoietin receptor 271
Essential hypertension 63:S-163
Excretion 1180
Exercise rehabilitation 1128
Experimental autoimmune glomerulonephritis 268, 1117
Extracellular matrix 111, 1532, 1561, 60:S-91, 60:S-100
Extracellular matrix genes 60:S-70

F
Familial amyloid polyneuropathy 1543
Fas (CD95) 573
FcγRIIA 1375
Femoral vein 1155
Fetal morbidity 21
Fibrils 1543
Fibrinogen 62:S-53
Fibrinolysis 1156
Fibroblasts 262, 1486

Fibronectin 574, 1127, 63:S-195
Fibrosis 61:S-60, 62:S-32, 63:S-211
5-HT 152
Flow cytometry 1141
Fluid transport 1609
Fluid volume 1120
Fluvastatin 1156
FMLP 1390
Focal glomerulosclerosis 1159
Fracture incidence 576
Fractures 577
Free radicals 60:S-46
Fucosyltransferase 863
Functional iron deficiency 273
Furosemide 62:S-56

G

Gene expression 130, 1224, 62:S-15, 63:S-215
Gene targeting 63:S-7
Gene Therapy 60:S-86, 61:S-85
Gene therapy in diabetes 60:S-100
Genetic expression of IGFBP 1216
Genetics 120, 60:S-28, 62:S-69
Genetics of diabetes 63:S-27
GFR decline 63:S-54
GH/IGF axis in diabetes 60:S-12
Gingival hyperplasia 1159
Gitelman syndrome 560
Glomerular basement membrane 265, 1313, 60:S-42
Glomerular cells 1439, 61:S-45
Glomerular cysts 33
Glomerular epithelial cell proliferation 270
Glomerular filtration 563
Glomerular filtration rate 1369, 63:S-49, 63:S-151, 63:S-166, 63:S-179
Glomerular hemodynamics 63:S-205
Glomerular injury 1579
Glomerular pathology 564
Glomerular permselectivity 1622, 63:S-78
Glomerular phagocytes 1116
Glomerulointerstitial infiltrate 1157
Glomerulonephrides 1439
Glomerulonephritis 103, 261, 271, 276, 561, 571, 572, 865, 1224, 63:S-2
Glomerulosclerosis 262, 1532, 1561, 62:S-32, 60:S-100, 63:S-120, 63:S-140, 63:S-171, 63:S-182
Glucose 79, 87, 60:S-20, 60:S-66
Glucose 6-phosphate 79
Glucose and mechanical strain 60:S-70
Glucose tolerance 62:S-48
Glucose transport 1532
Glucose transporters 60:S-91
Glycated LDL 60:S-54
Glycation 1302
Glycemia 63:S-36
Glycine 140, 1271
Glycoprotein 1340
Glycoprotein apolipoprotein(a) 1685
Glycosphingolipids 61:S-32
Glyoxylate 39
Goodpasture's disease 265, 1124
Graft failure 1159
Graft occlusion 1671
Graft survival 63:S-71, 63:S-84
Granzyme B 564
Growth 3
Growth factor 1216, 63:S-2
Growth factors . . 1439, 60:S-3, 60:S-7, 60:S-91, 61:S-36, 63:S-93
Growth hormone 1429, 60:S-12, 62:S-41
Growth promotion 1250

H

H^+ ATPase 265
Hantaviruses 575
HCV infection 1148
Heart lesions 62:S-12
Heat-sterilization of dialysate 1626
Helicobacter pylori 1145
Hematocrit 195, 62:S-83
Hematocrit level 1152
Hematuria 563, 569, 865
Hemin 261
Hemodiafiltration 1119, 1425
Hemodialysis 212, 217, 266, 273, 275, 562, 567, 575, 576, 862, 1119, 1129, 1140, 1145, 1146, 1150, 1152, 1390, 1395, 1406, 1478, 1543, 1617, 1651, 1663, 62:S-69, 62:S-79
Hemodialysis membrane 1148
Hemodialyzers 1381
Hemodynamics 165, 1242, 1250, 1261, 1635, 60:S-3, 61:S-18, 61:S-39, 61:S-45, 63:S-132
Hemoglobin 195
Hemolytic uremic syndrome 182, 1122, 1130
Hemorrhagic diathesis 62:S-87
Hemostasis 1180
Henoch Schönlein purpura 272
Heparan sulfate 563
Heparan sulfate proteoglycan 60:S-42
Heparin 1143, 1148, 1428
Heparinoid therapy 63:S-120
Hepatic disease 33
Hepatitis C virus 1141
Hepatocytes 62:S-5
High density lipoprotein 63:S-102
High-flux membranes 863
Histologically defined cell origin 1321
HLA class I region genes 1124
Homeostasis 60:S-33
Homocysteine 1132, 1133
Hormones 61:S-2
Hormone secretion 3
HSP47 . . . . . 63:S-232
Human mesangial cells 1116, 1521
Human peritoneal mesothelial cell 1127
Hydrochlorothiazide 61:S-74
Hydrogen peroxide 1137
Hypercatabolism 1147
Hypercholesterolemia 1156
Hypercholesterolemic diet 1135
Hyperfiltration 1427
Hyperglycemia 263, 60:S-91, 62:S-39, 62:S-48
Hyperhomocyteinemia 10
Hyperinsulinemia 1532
Hyperlipidemia 60:S-54, 62:S-36, 63:S-236
Hyperosmotic stress 1332
Hyperparathyroidism 3, 1149, 1152, 62:S-60, 62:S-90
Hyperplasia 1550
Hypertension 165, 171, 248, 269, 561, 566, 569, 1131, 1136, 1169, 1364, 1369, 61:S-22, 61:S-71, 63:S-49, 63:S-124

Hypertension treatment 63:S-75
Hypertensive glomerulosclerosis 63:S-229
Hypertriglyceridemia 1532, 1651
Hypertrophy 1135, 60:S-7
Hypoalbuminemic CAPD 1120
Hypoparathyroidism 62:S-72
Hypotension 567, 1145
Hypoxia 140, 1271
Hypoxic injury 130

I
Ibesartan 63:S-218
ICAM-1 262
IDDM 63:S-15, 63:S-195
Idiopathic membranous nephropathy 1130
IFN-γ receptor 1424, 1430
IgA nephropathy 563, 1122, 61:S-67, 63:S-182
IgG2 1375
IL-6 release 1125
IL-8 272
Iliac artery histology 1158
Imaging 63:S-144
Immune dysfunction 62:S-79
Immune response 1124
Immunization 212
Immunocomplex formation 1340
Immunocytochemistry 1206
Immunomagnetic separation 1321
Immunomodulatory effects 1141
Immunosuppression 1155, 1157, 61:S-63, 63:S-177
Immunosuppressive drugs 1156, 63:S-81
Indo-Asian dialysis 276
Indoxyl sulfate 62:S-15, 63:S-211
Inducible nitric oxide synthase 61:S-41
Infants 265
Infection 61:S-56
Inflammation 120, 1521, 61:S-60
Inflammatory kidney diseases 562
Injury 140, 171, 60:S-70, 61:S-52, 63:S-67, 63:S-107, 63:S-221, 63:S-236
Injury and complement cascade 1570
Inner medulla 1279
Insertion/deletion polymorphism 63:S-23
Insulin 87, 264, 566, 1532
Insulin-like growth factor 60:S-12
Insulin-like growth factor 1 . . . . . 165, 62:S-45
Insulin-like growth factor binding proteins 1216, 1486
Insulin metabolism in uremia 62:S-48
Integrins 93, 103, 1511, 61:S-52
Interleukin 52, 1224
Interleukin-1β 1124
Interleukin-12 278
Interleukin-6 1313
Interstitial fibrosis 1138, 63:S-232
Interstitial fluid 1132
Interstitial infiltration 562
Interstitial nephritis 865
Intoxication 62:S-2
Intracellular calcium 152
Intracellular pH 61:S-47
Intrafamilial variability 33
Intrarenal heterogeneity 63:S-128
Intra-uterine growth retardation 63:S-124
Intravenous iron therapy 274
Inulin clearance 63:S-151
Ion channels 157
Iron 576
Iron kinetics 1151
Iron status 217
Ischemia 1584, 61:S-39
Ischemia/reperfusion 1678
Ischemic acute renal failure 60, 1139
Ischemic kidney 93
Islet cell transplantation 1430
Isolated perfused kidney 130

J
Japanese salt culture 62:S-111
Juxtaglomerular cells 63:S-102

K
Kallikrein-kinin system 1261
Kidney 1584, 63:S-67, 63:S-132
Kidney cortex physiology 1486
Kidney disease 61:S-83
Kidney fibrosis 279
Kidney function 1430
Kidney transplant 862, 865
Kidney transplantation 562, 576, 1155, 1160, 1427, 63:S-71, 63:S-84
Kidney volume 1359
Kinetic modeling 62:S-96
Kinins 61:S-14
Knockout mice 63:S-2
Kt/V 1129

L
Laminin 60:S-60
Late renal allograft loss 63:S-81
LDL particle size 269
Left ventricular hypertrophy 1118
Lesions 573, 63:S-236
Lesions in diabetes 63:S-191
Leukocyte migration 1123
Leukocyte recruitment 1117
Leukocytes 1478
Lipid laden cells 1279
Lipid levels 1133
Lipid profile 1144
Lipids 62:S-36
Lipoprotein 1651, 62:S-90
Lipoprotein (a) 267, 1148, 1150, 1685, 62:S-53
Lipoproteins 1148, 63:S-98
Liposome 60:S-86
Liposome-mediated gene therapy 61:S-85
Lisinopril 1622, 63:S-232
L-NAME 564, 566
Losartan 562, 864
Low density lipoprotein 278, 1132, 60:S-54
Low density lipoprotein (LDL) 1645
Lung density 1635
Lupus 1375
Lupus nephritis 269, 563, 574
Lymphocytes 1521
Lymphocyte subsets 1153
Lymphoproliferative disorders 862
Lysosome 1291
Lysozyme 1693

M
Macrophage 52, 265

Macrophage proliferation 63:S-221
Macrophages 262
Macrophages/monocytes 63:S-111
Magnesium transport 1180
Magnetic resonance angiography 268
Magnetic resonance imaging 1359
Maintenance dialysis 62:S-93
Malignant neoplasia 1158
Malnutrition 62:S-41
Matrix metalloproteinase-3 . . . . . 111, 120
Matrix protein mRNA 1131
Measurement of GFR 63:S-151
Measurement of renal function 63:S-144
Membrane 1139
Membraneous nephropathy in Japan 63:S-177
Membrane proteins 61:S-32
Membranes 62:S-101
Membrane transport 1332
Membranous nephropathy 270, 278, 61:S-63
Mercuric chloride 574
Mesalazine 865
Mesangial cell activation 1139
Mesangial cell proliferation 1313
Mesangial cells 561, 1250, 1426, 1521, 1561, 63:S-102
Mesangial extracellular matrix 60:S-54
Mesangial matrix 60:S-42
Mesothelial cells 1123
Metabolic acidosis 62:S-45
Metabolic clearance of glucose 62:S-48
Metabolic clearance rate of calcitriol 79
Metalloproteinase 1302
Metallo-proteinases 1425
Metanephric endothelia 263
Metanephros 1196
Microalbuminuria 240, 63:S-15, 63:S-32, 63:S-40, 63:S-163
Microperfusion 63:S-128, 63:S-205
Mineral bone density 1143
Mineralocorticoid resistance 61:S-10
Minimal change disease 271, 562
Mitochondria 140, 61:S-47
Mitogen-activated protein kinase 60:S-66
Modeling 1395
Monoclonal antibodies 1469
Monocyte/macrophages 60:S-20
Monocyte bonding 278
Monocyte chemotactic peptide-1 . . . . . 60:S-20
Monocytes/macrophages 1439
Monocytic cytokines 862
Monolayer 1127
Monomethyl-L-arginine 1593
Morbidity and mortality 1663
Morbidity in dialysis 62:S-96
Morphometry 1532
Mortality 1144, 63:S-10
Mortality in renal disease 63:S-63
Mouse physiology 1364
mRNA 271
mRNA estimation 263
Multivariable analysis 63:S-84
Mycophenolate mofetil 562
Myeloperoxidase 572, 1116
Myofibroblast 1279

N

Na,K-ATPase 1135
Na^+ reabsorption 570
Naproxen 1693
Natriuretic peptide receptor 202
Necrosis 1626
Neointimal formation 61:S-10
Neoral 1430
Nephrectomy 575, 1550
Nephritic glomeruli 261
Nephritis 261, 272, 278, 564, 1425, 1579
Nephrogenesis genes 1124
Nephrogenic repair 61:S-36
Nephrolithiasis 1291
Nephrons 63:S-124
Nephropathy 559, 63:S-36
Nephrotic syndrome 264
Nephrotoxic nephritis 1313
Nerve conduction speed 1145
Neuropathy 567
Neutrophil function 1127
Neutrophils 276
NIDDM 63:S-49, 63:S-191
Nifedipine 577
Nitrendipine 61:S-74
Nitric oxide 171, 195, 564, 1123, 1169, 60:S-46, 61:S-39, 61:S-41, 63:S-102
Nitric oxide radicals 571
Nitric oxide synthase 270, 63:S-208
Nitric oxide system 60:S-23
Nonaluminic adynamic bone disease 1149
Non-diabetic renal disease 561
Non-insulin dependent diabetes 63:S-40
Non-insulin dependent diabetes mellitus 1369, 61:S-83
NOS inhibition 571
NSAID 1693
Nuclear factor -κB 63:S-111
Nutrition 1663, 62:S-108
Nutritional parameters 1153, 1427
Nutritional status 275
Nutritional status in hemodialysis 1617

O

Obstruction 93
Obstructive uropathy 21
Occlusion 1406
Ocular defects 208
OKT3 1132
1α 79
$1,25(OH)_2D_3$ 45
Opossum kidney cells 152
Oral-facial-digital syndrome type I 1131
Organ blood flow 1395
Organ damage 61:S-56
Organ dysfunction 1678
Osmotic minipumps 1313
Osteoblastic-like cells 1134
Osteopontin 1169, 63:S-215
Osteoporosis 62:S-69
Ouabain 130
Oxalate assay 1700
Oxidative stress 1140
Oxygen radicals 63:S-102

P

Paraoxonase 1119
Parathyroid 3

Parathyroid gland ... 1232
Parathyroid glands ... 1142
Parathyroid hormone ... 62:S-5, 62:S-12, 62:S-72
Parathyroid hyperplasia ... 62:S-60
Parenteral iron ... 1152
Patients on dialysis ... 1146, 1147
p-cresol ... 62:S-8
Pediatric unit ... 267
Pentosan polysulfate ... 63:S-120
Peptides ... 1458, 60:S-33
Percutaneous ethanol injection therapy ... 62:S-60
Percutaneous renal biopsy ... 1137
Perfusion culture ... 1469
Peripheral mononuclear cells ... 277
Peripheral vascular disease ... 267, 1136
Peritoneal dialysis ... 265, 567, 568, 1123, 1144, 1609, 62:S-93, 62:S-105
Peritoneal dialysis fluids ... 1626
Peritoneal membrane ... 1123
Peritoneal membrane function ... 274
Peritonitis ... 265, 1428
Perlecan ... 564
Peroxynitrite ... 1119, 1122
P-glycoprotein expression ... 1157
Pharmacokinetics ... 1395, 1428, 1693
Phosphate ... 1332
Phosphate homeostasis ... 266
Phosphate resorption ... 571
Phosphate transport ... 61:S-32
Phosphodiesterase inhibitor ... 261
Phospholipase A_2 ... 71, 1139
Phospholipid ... 60
Phosphorus restriction ... 1550
PI 3-kinase ... 1121
PKD1 gene ... 1196
Plasma Leptin ... 269
Platelet ... 182
Platelet-derived growth factor ... 1671, 63:S-195
Pneumonia ... 1157
Podocyte injury ... 63:S-171
Polycystic kidney disease ... 1425, 61:S-71
Polycystic kidney disease 1 ... 559
Polycystic kidney disease type 2 ... 1122
Polycystin ... 1196
Polycystine ... 559
Polymeric IgA ... 572
Polymorphism ... 60:S-28
Polymorphonuclear cells ... 575, 1626
Polymorphonuclear leukocytes ... 1390, 61:S-56, 62:S-79
Polytetrafluoroethylene ... 1478
Post-transplant erythrocytosis ... 562
Potassium channel ... 1126
Potassium depletion ... 265
Potassium homeostasis ... 1126
Prediction of creatinine clearance ... 63:S-166
Predictors of renal disease ... 63:S-169
Prednisolone ... 63:S-177
Prednisone ... 1160
Pre-end-stage renal failure ... 1129
Preservation solutions ... 864
Pressure diuresis ... 1364
Pressure natriuresis ... 1169, 1364
Pretransplantation immunosuppression ... 61:S-89
Primary culture ... 1279
Probes ... 93
Prognosis in liver disease ... 61:S-77
Progression ... 60:S-28, 61:S-67, 62:S-36, 62:S-39, 63:S-87, 63:S-115, 63:S-226
Progression of renal disease ... 1439, 63:S-27, 63:S-58, 63:S-144, 63:S-179, 63:S-182
Progression of renal injury ... 63:S-136
Progression to chronic renal insufficiency ... 63:S-63
Progression to ESRD ... 63:S-98
Progression to renal failure ... 62:S-8, 62:S-15, 63:S-211
Progressive glomerulosclerosis ... 63:S-215
Progressive renal disease ... 1486, 63:S-23
Progrssive renal disease ... 63:S-19
Prophylactic ureteric stents ... 1424
Prostaglandins ... 1242
Protein ... 1340
Protein-A column ... 1579
Protein-calorie malnutrition ... 62:S-45
Protein farnesylation ... 264
Protein kinase ... 61:S-2
Protein kinase A ... 863
Protein kinase C ... 1511, 60:S-66, 60:S-77
Protein synthesis ... 62:S-41
Protein uptake ... 1123
Proteinuria ... 264, 269, 278, 562, 565, 566, 1429, 1622, 61:S-60, 61:S-74, 62:S-29, 63:S-10, 63:S-40, 63:S-54, 63:S-78, 63:S-87, 63:S-98
Proteolysis proteases ... 62:S-32
Proton NMR spectroscopy ... 863, 864
Proto-oncogenes ... 63:S-93
Protoonocogene expression ... 60:S-70
Proximal tubular cell ... 1321
Proximal tubular cells ... 262, 263, 1121, 1123, 62:S-29
Proximal tubule ... 71, 87, 229, 1216, 1584, 61:S-18, 61:S-32
Proximal tubule cells ... 1126
Proximal tubules ... 1271
Pseudohypoaldosteronism ... 61:S-10
PTFE vascular access dysfunction ... 1656
PTH ... 45, 71
PTH mRNA synthesis ... 1143
Pyramids of salt ... 62:S-111
Pyridoxine ... 62:S-56
Pyruvate ... 87

Q

Quality of life ... 269, 1146
Quality standards ... 274

R

RAAS ... 63:S-115
Radiocephalic fistula ... 1154
RANTES ... 574
RAS ... 269
Rat mesangioproliferative glomerulonephritis ... 63:S-226
Reactive oxygen species ... 275
Rebound ... 1395
Recanalization of occlusion ... 1406
Receptor (VDR) ... 62:S-65
Receptor activation ... 61:S-18
Receptor antagonists AT-1 and AT-2 ... 63:S-111
Receptors ... 1206, 1458, 1486, 60:S-7, 63:S-67
Reciprocal creatinine ... 63:S-188
Recirculation ... 1154
Recombinant human erythropoietin ... 1390
Recombinant proteinase 3 ... 277
Recurrent idiopathic calcium renal stone ... 1429

Recurrent renal stone 1426
Referral policies 1128
Refractory hyperparathyroidism 1142
Rejection 62:S-36, 63:S-71, 63:S-81
Remission 63:S-177
Renal 63:S-2
Renal ablation 63:S-221
Renal allograft 1157, 1158
Renal allograft rejection 1131, 1429
Renal allografts 1132, 1159
Renal arteriography 569
Renal artery stenosis 273, 565, 569, 570, 1133, 1136, 1137
Renal Association 1129
Renal Association standards 1118, 1129
Renal biopsy 1139
Renal blood flow 1364
Renal cadaveric allograft 1158
Renal circulation 63:S-198
Renal cortex 71
Renal cysts 63:S-93
Renal development 1584
Renal dysfunction 269, 61:S-77
Renal epithelial cells 279
Renal failure 39, 1128, 1132, 62:S-29, 62:S-39, 62:S-56, 62:S-83
Renal fibroblasts 1279
Renal fibrosis 1497
Renal function . . . 244, 564, 1120, 1144, 1423, 61:S-67, 63:S-179
Renal functional 1430
Renal Grafts 1426
Renal hemodynamic response 561
Renal hemodynamics 63:S-185
Renal inflammation 572
Renal insufficiency 1142, 1232, 61:S-63, 63:S-93
Renal interstitial fibroblasts 1497
Renal kallikrein 1206
Renal medulla 130, 1169
Renal microcirculation 63:S-201
Renal myofibroblasts 278
Renal osteodystrophy 577
Renal repair 61:S-52
Renal replacement therapy 280, 1130, 1146, 1423
Renal scarring 1130
Renal structure 63:S-40, 63:S-155
Renal survival 61:S-71
Renal transplant 275, 572, 1131, 1132, 1133, 1160
Renal transplantation . . 276, 559, 1118, 1132, 1133, 1134, 1156, 1158, 1423, 1428, 61:S-89, 63:S-78
Renal tubular function 560
Renal vascular resistance 564
Renal vein 1359
Renin 63:S-128
Renin-angiotensin-aldosterone system 61:S-71, 63:S-115
Renin-angiotensin system 248, 565, 573, 1147, 1250, 1458, 60:S-23, 63:S-19, 63:S-27, 63:S-107, 63:S-218, 63:S-229
Renography 570
Renovascular disease 271, 272
Renovascular effects 202
Reperfusion 863
Reticulocyte 217
Retinal ischemia 1130
Retinopathy 63:S-40
Reverse transcriptase-polymerase chain reaction 263
RGD peptides 93
rHuEPO 1151, 1152
rHu-EPO therapy 1142
Risk factors for ESRD 63:S-10
ROSIT 1584

S

Salt 1169, 62:S-111
Salt and water diuresis 1423
Salt intake 1135
Salt sensitivity 1364
Sandimmun 1430
Schiff base 79, 62:S-65
Sclerosis 63:S-191
Secondary hyperparathyroidism 1149, 1232
Serum albumin 577, 1120
Serum hemoglobin 577
Serum lipids 1132
Serum oxalate assay 1700
Serum potassium 1120
Sexual performance 1160
Sickle cell disease 565, 566
Signal transduction 60:S-66
Sinoaortic denervation 61:S-22
α-smooth muscle actin 1279
Smooth muscle cells 1478
Smooth muscle proliferation 61:S-10
Sodium 1242
Sodium-hydrogen antiporter 1486
Sodium-phosphate cotransport 152
Sodium status 63:S-23
Sodium transport 1609
Soluble complement receptor 1 574
Solute clearance 1127
Solute excretion 1425
Solute transport 1425
Sphingosine 60
Spiral computer tomography angiography 1137
Spiral CT angiography 565
Spontaneous voiding 244
Staphylococci 1117
Staphyococcal peritonitis 274
Starvation 1117
Steroid resistance 61:S-10
Steroids 1116
Stone forming 1602
Streptozotocin induced diabetes 60:S-23
Stromelysin-1 120
Superoxide production 1390
Supraventricular arrhythmias 1145, 1152
SV 40 large T antigen 229
Symmetric dimethylarginine 1593
Sympathoinhibitory presyncope 567
Synechia 63:S-171
System A 1332
Systemic arterial blood pressure 61:S-22
Systemic lupus erythematosus 1138, 1375
Systemic vasculitis 272

T

Tacrolimus 276, 1132
Tamm-Horsfall glycoprotein 1340
TATI 63:S-179
T-cell 52, 1122, 1424
T cell activation 273
T-cell adhesion 276

T-cell receptor 563
T cells 1125, 1439, 1678
T cell-specific chemokines 1521
TCV-116 ..... 63:S-208, 63:S-232
Terminal ileon exclusion surgery 1135
TGFβ 572, 63:S-239
TGF-β1 ..... 262, 276, 63:S-111
Thiazides 1137
Thick ascending limb of Henle 863
Thin GBM nephropathy 569
Thrombosis 1656
Thrombotic events in dialysis 62:S-87
Thrombotic microangiopathy 182, 1570
Tissue remodeling 120
TNFα-primed neutrophils 268
TNF receptor 574
TNF receptors 567
Total lymphoid irradiation 61:S-89
Toxicity 1381, 62:S-8
Toxins 62:S-2
Trandolapril 1140
Transforming growth factor-β 60:S-7, 60:S-100, 63:S-182, 63:S-211, 63:S-226, 63:S-229
Transforming growth factor-β1 ..... 60:S-60
Transforming growth factor-beta 63:S-195
Transgene expression 60:S-86
Transgenic mice 229
Transglutaminase 279
Transplantation 276, 1232, 1622, 1678, 63:S-124
Transplant failure 63:S-78
Transplant hypertension 63:S-75
Transplant rates 276
Transplant rejection 61:S-89
Transport 152, 1332, 1340, 61:S-32
Trends in dialysis therapy 62:S-93
Triglycerides 1532, 1651
Tubular epithelial cells 573, 574
Tubular function 1550
Tubular injury 1511
Tubuloglomerular feedback 1169, 1593
Tubulointerstitial disease 182, 63:S-93
Tubulointerstitial fibrosis 62:S-15, 62:S-29, 62:S-32
Tubulointerstitial injury 61:S-60
Tubulointerstitial lesions 63:S-191
Tubulointerstitium 103
Tumor necrosis factor-α 1478
Tumor necrosis factor receptor 1 263
Tunnel catheters 1155
24-hydroxylase 39
25-dihydroxyvitamin D-24-hydroxylase 79
Type IV collagen 111, 60:S-60, 62:S-39
Tyrosine kinase 62:S-45

U

Ultrafiltration 1428, 62:S-108
Ultrafiltration coefficient 1121
Ultrasonography 21
Unilateral ureteral obstruction 63:S-232
Uninephrectomy 1359
Upper limit of metastability 1602
Urea kinetics 562, 1395
Urea rebound 1128
Uremia 171, 264, 271, 1139, 1232, 1645, 1651, 62:S-65, 62:S-69, 62:S-79, 62:S-87
Uremic bone 62:S-72
Uremic fetor 223
Uremic plasma 262, 275
Uremic serum 1134
Uremic syndrome 268
Uremic toxicity 62:S-83
Uremic toxins 39, 62:S-2, 62:S-101
Ureteric anastomosis 1424
Uric acid 62:S-8
Urinary albumin excretion 63:S-15
Urinary nitrate 1131
Urinary protein excretion 577, 63:S-54
Urinary proteins 278
Urinary sediment 569
Urinary sediments 572
Urinary supersaturation 1429
Urinary tissue factor 271
Urinary tract 571
Urinary tract infection 1130
Urine biochemistry 21
Urine endothelin-1 1423
Urine specific gravity screening 240

V

Vaccination 212
Valsalva maneuver 576
Valvular heart calcification 1147
Vascular access 1154, 1406
Vascular access thrombosis 1656, 62:S-87
Vascular complications in diabetes 60:S-77
Vascular endothelial growth factor 277
Vascular permeability factor 271
Vascular resistance 195
Vascular smooth muscle 61:S-27
Vascular smooth muscle cells 1671
Vascular tone 61:S-45
Vasculitis 272, 1130
Vasoactive agents 165
Vasoconstrictionm mesangial cell 63:S-201
Vasodilation 195, 202, 567, 61:S-41
Vasopressin 570, 1426, 61:S-2
Vasopressin receptor 1206
Vena cava ultrasound 1635
Venous access 267
Verapamil 566, 1140
Veratran 1140
Verocytotoxin 279, 573
Vesicoureteric reflux 1124, 1125
Viral vector 60:S-86
Vitamin B6 ..... 62:S-56
Vitamin D 39, 45, 62:S-60, 62:S-65, 62:S-69
Vitamin D therapy 1134
Vitamin E 275
Volume 1332

W

Water channels 61:S-6
Water permeability 61:S-2
Water transport 61:S-39
Wistar-Furth rat model 61:S-10
Wistar Kyoto rats 268
WKY rat 1117
Wound repair 120

Author Index For Volume 52

A
Abaterusso C *See* Brocco E et al. ... 63:S-40
Abboud HE: Growth factors and diabetic nephropathy: An overview. ... 60:S-3
Abe K *See* Endo Y et al ... 63:S-205
Abe K *See* Ito S et al. ... 63:S-128
Academic Subcommittee of the Network 9 Peritonitis Study *See* Bunke CM et al. ... 524
Ackermann D (abst) ... 1429
Adams JE (abst). ... 1133, 1134
Adelé C *See* Argilés A et al ... 530
Adler S: Structure-function relationships in diabetic nephropathy: Lessons and limitations ... 60:S-42
Adler S *See* Nangaku M et al ... 182
Adler S *See* Nangaku M et al ... 1570
Adu D (abst) ... 268, 272, 276
Agarwal A *See* del Castillo D et al ... 460
Agarwal S (abst) ... 261
Agarwal SK *See* Dash SC et al ... 482
Agodoa L, Eknoyan G, Ingelfinger J, Keane W, Mauer M, Mitch W, Striker G, Wilcox C: Assessment of structure and function in progressive renal disease . 63:S-144
Agraz I (abst) ... 1159
Aguilar D (abst) ... 1138
Aguilar M (abst) ... 1138
Aiello S, Noris M, Todeschini M, Zappella S, Foglieni C, Benigni A, Corna D, Zoja C, Cavallotti D, Remuzzi G: Renal and systemic nitric oxide synthesis in rats with renal mass reduction ... 171
Aigner J *See* Strehl R et al ... 1469
Aingorn E *See* Nagler A et al ... 1561
Aitman TJ (abst). ... 268
Akagaki Y (abst). ... 863
Akagi Y *See* Isaka Y et al ... 60:S-100
Akagi Y *See* Moriyama T et al ... 63:S-232
Akiba T, Ando R, Kurihara S, Heishi M, Tazawa H, Marumo F: Is the bone mass of hemodialysis patients genetically determined? ... 62:S-69
Akiba T *See* Akizawa T et al. ... 62:S-72
Akizawa T, Kinugasa E, Akiba T, Tsukamoto Y, Kurokawa K: Incidence and clinical characteristics of hypoparathyroidism in dialysis patients ... 62:S-72
Akuta N, Lloyd SE, Igarashi T, Shiraga H, Matsuyama T, Yokoro S, Cox JPD, Thakker RV: Mutations of CLCN5 in Japanese children with idiopathic low molecular weight proteinuria, hypercalciuria and nephrocalcinosis. ... 911
Akyürek LM *See* Melin J et al ... 985
Alaupovic P *See* Attman P-O et al ... 63:S-98
Alberca I (abst). ... 1156
Alberti D *See* Locatelli F et al ... 63:S-63
Albiston A *See* Butkus A et al. ... 628
Alcorn D *See* Butkus A et al. ... 628
Alcorn D *See* Dean R et al ... 1261
Alcoy E (abst). ... 1154
Alfison J (abst) ... 1124
Algaba F (abst) ... 1159
Alitalo K (abst). ... 263
Aljama P (abst) ... 1136, 1142
Allan DR *See* De'Oliveira JM et al. ... 771
Allen A (abst) ... 1122
Allen AC (abst). ... 272
Allen AC *See* Olive C et al ... 1047
Allen DA (abst) ... 271
Allen TJ *See* Jerums G et al ... 63:S-87
Almendral J (abst) ... 1145, 1152
Almond MK (abst). ... 273, 1134
Alonso JR (abst) ... 1139
Alper SL *See* Joannidis M et al. ... 130
Alpers CE *See* Nangaku M et al ... 182
Alpers CE *See* Nangaku M et al ... 1570
Alsina J (abst) ... 1156
Altmann P (abst). ... 1129
Alvarez G (abst) ... 1157
Alvarez V (abst) ... 1139, 1143, 1145, 1155
Alvarez-Grande J (abst) ... 1136
Alvariño J (abst) ... 1144
Alvestrand A: Carbohydrate and insulin metabolism in renal failure ... 62:S-48
Amenabar JJ (abst) ... 1140, 1157, 1158, 1159, 1160
Amin J *See* Ito S et al ... 63:S-128
An MR *See* Choi KC et al. ... 60:S-23
Anaya F (abst). ... 1148, 1159
Anderson RJ, Ray C: Growth factor regulation of renal tubular epithelial cell motility ... 61:S-36
Anderson S: Role of local and systemic angiotensin in diabetic renal disease. ... 63:S-107
Anderton JG (abst) ... 275, 275
Ando A *See* Moriyama T et al. ... 63:S-232
Ando R *See* Akiba T et al. ... 62:S-69
Ando Y *See* Isaka Y et al ... 60:S-100
Andoh TF *See* Shihab FS et al ... 660
Andrassy K *See* Niemir ZI et al ... 393
Andrés E (abst) ... 1143, 1154
Andrews MJ (abst) ... 265
Andújar M (abst). ... 1135, 1138
Angielski S *See* Lewko B et al. ... 654
Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study *See* Locatelli F et al ... 63:S-63
Ankorina-Stark I *See* Schlatter E et al ... 454
Anlauf M *See* Kribben A et al. ... 61:S-74
Annichiarico C *See* Tramonti G et al ... 63:S-179
Ansell D (abst) ... 1118
Antao AJO (abst) ... 1130
Antolin A (abst) ... 1138
Aparicio M (abst) ... 865
Aperia A *See* Eklöf A-C et al ... 742
Aperia A *See* Serlachius E et al ... 901
Apperloo AJ (abst) ... 561
Apperloo AJ *See* van Essen GG et al ... 63:S-58
Aquilera A (abst) ... 1148
Arai J *See* Murakami K et al. ... 63:S-208
Arakawa M *See* Narita I et al ... 63:S-215
Arakawa M *See* Nishi S et al. ... 63:S-177
Arakawa M *See* Ueno M et al. ... 63:S-191

Araki S- *See* Haneda M et al. 60:S-66
Aranda P (abst) 1136, 1142
Archer DC *See* Pham K et al 725
Ardaillou R, Chansel D: Synthesis and effects of active fragments of angiotensin II 1458
Aresté N (abst) 1147
Arévalo M (abst) 1139, 1140
Argilés A, Ficheux A, Thomas M, Bosc JY, Kerr PG, Lorho R, Flavier JL, Stec F, Adelé C, Leblanc M, Garred LJ, Canaud B, Mion H, Mion CM: Precise quantification of dialysis using continuous sampling of spent dialysate and total dialysate volume measurement (Technical Note) 530
Arima S *See* Endo Y et al 63:S-205
Arima S *See* Ito S et al 63:S-128
Arnadottir M, Berg A-L, Dallongeville J, Fruchart J-C, Nilsson-Ehle P: Adrenocorticotrophic hormone lowers serum Lp(a) and LDL cholesterol concentrations but does not influence triglyceride metabolism in hemodialysis patients 1651
Arranz M (abst) 1150, 1150
Arrebola F (abst) 1135, 1157
Arrol S (abst) 1132
Asensio C (abst) 1157, 1157
Ashuntantang G (abst) 1426
Asplin JR, Parks JH, Coe FL: Dependence of upper limit of metastability on supersaturation in nephrolithiasis 1602
Assmann KJM (abst) 563
Assmann KJM *See* Wolf G et al 1250
Atkins RC *See* Wu LL et al 63:S-221
Attman P-O, Samuelsson O, Alaupovic P: Progression of renal failure: Role of apolipoprotein B-containing lipoproteins 63:S-98
August C *See* Heidenreich S et al 318
Autschbach F *See* Niemir ZI et al 393
Awazu M: Inhibition of platelet-derived growth factor receptor tyrosine kinase by atrial natriuretic peptide 356
Azuma H (abst) 273

B

Baboolal K (abst) 1121, 1126
Baboolal K, Ravine D, Daniels J, Williams N, Holmans P, Coles GA, Williams JD: Association of the angiotensin I converting enzyme gene deletion polymorphism with early onset of ESRF in *PKD1* adult polycystic kidney disease 607
Bäcker A *See* Meyer-Lehnert H et al 61:S-27
Badenas C *See* Torra R et al 33
Baelde JJ (abst) 563, 563, 564
Baer PC, Nockher WA, Haase W, Scherberich JE: Isolation of proximal and distal tubule cells from human kidney by immunomagnetic separation (Technical Note) 1321
Baggio B *See* Brocco E et al 63:S-40
Bahr BA *See* Edelstein CL et al 1271
Bailey E (abst) 270
Bailey MA (abst) 265
Bak M *See* Ringgaard S et al 1359
Baker F (abst) 270
Baker F *See* Stein A et al 1089
Baker LRI (abst) 267
Bakker MAH (abst) 560
Bakker WW (abst) 562, 564
Bakris GL *See* Tarif N et al 63:S-67
Banchereau J (abst) 562
Banks RA (abst) 266, 275
Barambio M (abst) 1152
Bariety J *See* Michel O et al 1532
Barlattier A (abst) 864
Barnas U, Mayer G: Glomerular proteinuria in renal transplant patients: Mechanisms and treatment 63:S-78
Barnas U *See* Borchhardt K et al 1622
Barnes WD *See* Maddox DA et al 446
Barratt TM (abst) 1124
Barreiro A (abst) 1136
Barrero MJ (abst) 1140
Barreto S (abst) 1143, 1150
Barreto-Chaves MLM, Mello-Aires M: Luminal arginine vasopressin stimulates Na^+-H^+ exchange and H^+-ATPase in cortical distal tubule via V1 receptor 1035
Barril G (abst) 1139, 1141, 1143, 1145, 1145, 1148, 1155
Bartlett C (abst) 1129
Bass P (abst) 271
Bates CM, Merenmies JM, Kelly-Spratt KS, Parada LF: Insulin receptor-related receptor expression in non-A intercalated cells in the kidney 674
Baum M *See* Sheu J-N et al 71
Baxter RC *See* Haffner D et al 802
Baxter RC *See* Johnson DW et al 1486
Baynes JW *See* Degenhardt TP et al 1064
Beattie TJ (abst) 272
Becker BN, Kondo S, Cheng H-F, Harris RC: Effect of glucose, pyruvate, and insulin on type 1 angiotensin II receptor expression in SV40-immortalized rabbit proximal tubule epithelial cells 87
Beek FJA (abst) 565
Beers KW *See* de Toledo FGS et al 152
Beeso JA (abst) 1133
Begher M *See* Grupp C et al 1279
Belair M-F *See* Michel O et al 1532
Bella F (abst) 1155
Belvis JJ (abst) 1153, 1153
Bending MR (abst) 1132
Bénévent D (abst) 862
Beneyto I (abst) 1159
Benigni A *See* Aiello S et al 171
Benigni A *See* Bruzzi I et al 62:S-29
Benjamin N (abst) 1131
Bennett PH *See* Nelson RG et al 63:S-45
Bennett T *See* Matsell DG et al 748
Bennett WM *See* Shihab FS et al 660
Bennett-Jones DN (abst) 1120
Benzimra R (abst) 1130
Berden JHM (abst) 559, 560, 563
Berden JHM: Lupus nephritis (Nephrology Forum) 538
Berendt A (abst) 274
Berg A-L *See* Arnadottir M et al 1651
Bergström J *See* Wang T et al 1068
Berisa F (abst) 1153, 1153
Berl T: Protein kinases in the action of vasopressin 61:S-2
Berl T, Linas SL: Introduction 61:S-1
Berland YF *See* Tabouy LJ et al 1381
Berndt TJ *See* de Toledo FGS et al 152
Bernis C (abst) 1139, 1143, 1145, 1145, 1155
Better O, Winaver JM, Knochel JP: Mannitol therapy revisited (1940–1997) 886
Beutler JJ (abst) 565
Bevington A (abst) 1117
Bewick M (abst) 1119

Bezante GP *See* Pontremoli R et al. 63:S-163
Beziau A *See* Daïkha-Dahmane F et al. 21
Bhandari B *See* Yee J et al 120
Bhandari S (abst). 269, 273, 274, 1126, 1126
Bhatnagar D (abst) 1132
Bhuyan UN *See* Dash SC et al 482
Bianchetti M (abst) 1424
Bianchi C *See* Donadio C et al 63:S-166
Bianchi C *See* Tramonti G et al. 63:S-179
Bianchi L *See* Brocco E et al. 63:S-40
Bianchi R *See* Tramonti G et al 63:S-179
Bicknell GR (abst) 263, 1131
Bilous RW (abst). 270
Binaut R (abst) 865
Binet I (abst) 1426, 1427
Binswanger U (abst) 1424, 1428, 1428
Biolo G *See* Guarnieri G et al. 62:S-41
Bircher G *See* Stein A et al 1089
Bisaccia C *See* De Santo NG et al. 62:S-111
Blagg C *See* Striker GE et al 63:S-120
Blankestijn PJ (abst) 560, 567
Blankestijn PJ *See* Bosman PJ et al. 1084
Blaydon DC (abst). 1124
Blum WF *See* Haffner D et al. 802
Bock A (abst) 1423
Bock HA (abst) 1423, 1427, 1427, 1430
Boereboom FTJ *See* Bosman PJ et al 1084
Bogdanova N (abst). 1122
Bokemeyer D *See* Meyer-Lehnert H et al. 61:S-27
Bolle J-F (abst) 1426
Bolliger C *See* Chini EN et al 917
Bolton EM (abst) 278
Bondía A (abst). 1155
Bono M (abst) 1136, 1147
Borchhardt K, Haas M, Yilmaz N, Oberbauer R, Schmidt A, Barnas U, Mayer G: Low dose ACE inhibition and glomerular permselectivity in renal transplant recipients. 1622
Bordessoule D (abst). 862
Borgstein PJ (abst) 568
Born GVR (abst) 262
Borrego Hinojosa J (abst) 1146, 1150
Borrego Utiel F (abst). 1149
Borrego Utiel FJ (abst). 1146, 1150, 1152
Borrego-Hinojosa J (abst) 1144
Borrego-Utiel FJ (abst) 1144
Bosc JY *See* Argilés A et al. 530
Bosman PJ, Boereboom FTJ, Smits HFM, Eikelboom BC, Koomans EA, Blankestijn PJ: Pressure or flow recordings for the surveillance of hemodialysis grafts? . 1084
Bostom AG, Lathrop L: Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes 10
Bottomley MJ (abst) 271, 277
Boulton-Jones JM (abst) 269
Bradley J (abst). 263
Braguer DL *See* Tabouy LJ et al. 1381
Brause M *See* Gleiter CH et al 338
Bremer V *See* Tojo A et al 1593
Brenchley PE (abst) 276
Brenchley PEC (abst). 271, 276, 277
Brenner BM, Mackenzie HS: Nephron mass as a risk factor for progression of renal disease 63:S-124
Brenner BM *See* Chertow GM et al 63:S-84
Brenner BM *See* Keane WF et al 63:S-1
Brenner BM *See* Mackenzie HS et al 63:S-140
Breuning M (abst). 1122
Breuning MH (abst) 559
Brew BK *See* Johnson DW et al 1486
Bridoux F (abst) 865
Brier ME *See* Bunke CM et al 524
Briner V *See* Pavenstädt H et al 157
Briner VA, Pfeilschifter J: The glomerular cell: Source and target of various mediators 61:S-45
Briner VA *See* Huwiler A et al 329
Briso-Montiano JM (abst) 1148
Brocco E, Fioretto P, Mauer M, Saller A, Carraro A, Frigato F, Chiesura-Corona M, Bianchi L, Baggio B, Maioli M, Abaterusso C, Velussi M, Sambataro M, Virgili F, Ossi E, Nosadi R: Renal structure and function in non-insulin dependent diabetic patients with microalbuminuria 63:S-40
Broekroelofs J (abst). 559
Broger Ribi VR (abst). 1424
Brooks CJ (abst) 272
Brosius FC III *See* Heilig CW et al. 60:S-91
Brown AA (abst). 1134
Brown EA (abst) 267, 1129
Brown J (abst). 1117
Brown K (abst) 272
Brownjohn AM (abst). 269, 269, 273, 274
Brú C *See* Torra R et al 33
Bruckdorfer KR *See* Kari JA et al. 468
Bruijn JA (abst) 559, 563, 563, 564
Brulez HFH (abst) 566
Brüne B *See* Sandau K et al 378
Brunet PJ *See* Tabouy LJ et al 1381
Brüngger M (abst). 1429
Brunskill N (abst) 1121
Brunskill NJ (abst) 264
Bruzzi I, Benigni A, Remuzzi G: Role of increased glomerular protein traffic in the progression of renal failure 62:S-29
Bucala R *See* Fishbane S et al. 1645
Budde K, Neumayer H-H, Salant DJ, Cybulsky AV, Coleman DL, Sterzel RB: Glomerular epithelial cell products stimulate mesangial cell proliferation in culture 733
Budreau AM *See* Matsell DG et al 748
Bunce T *See* Kari JA et al. 468
Bunke CM, Brier ME, Golper TA, Academic Subcommittee of the Network 9 Peritonitis Study: Outcomes of single organism peritonitis in peritoneal dialysis: Gram negatives versus gram positives in the Network 9 Peritonitis Study. 524
Buñuel C (abst) 1156, 1157
Burden R (abst). 1129
Burden RP (abst) 265, 1127, 1131
Burdeus R (abst) 1135, 1135
Burgos FJ (abst). 1147, 1158, 1158, 1158, 1160
Burkhart K *See* Zager RA et al. 942
Burkhart KM *See* Zager RA et al. 60
Burnett JC Jr. *See* Chini EN et al 917
Burrin J (abst) 1125, 1134
Burtin M *See* Laouari D et al 1550
Buscombe JR (abst) 1128
Buskens CAF (abst) 564
Bustamante J (abst). 1140, 1148, 1150, 1150
Bustamante R (abst). 1148, 1150, 1150
Buter H (abst). 565

Buter H, Navis G, de Zeeuw D, de Jong PE: Renal hemodynamic effects of candesartan in normal and impaired renal function in humans 63:S-185
Butkus A, Albiston A, Alcorn D, Giles M, McCausland J, Moritz K, Zhuo J, Wintour EM: Ontogeny of angiotensin II receptors, types 1 and 2, in ovine mesonephros and metanephros 628

C
Cabezuelo JB (abst) 1138
Cacciatore R (abst) 1429
Cadranel JF (abst) 864
Cahen R (abst) 863
Cain S (abst) 267, 271
Calls J (abst) 1136
Camacho-Reina MV (abst) 1144
Cameron JS (abst) 1130
Campbell M (abst) 1117
Canaud B *See* Argilés A et al 530
Canfield W *See* Fishbane S et al 217
Cannata JB (abst) 1142, 1143, 1150, 1150
Cano R (abst) 1155, 1155
Cano T (abst) 1147, 1149, 1158, 1158, 1158, 1160
Canteros A (abst) 1143, 1150
Canteros MA (abst) 1142, 1150
Cantley LG *See* Joannidis M et al 130
Caorsi CE *See* Gonzalez CB et al 1206
Capasso G *See* De Santo NG et al 62:S-111
Caramelo C, Farré AL, Riesco A, Casado S: Role of endothelin-1 in the activation of polymorphonuclear leukocytes 61:S-56
Carbarns IRI *See* Locatelli F et al 63:S-63
Cardonna-Sanclemente LE (abst) 262
Caritez JC (abst) 863, 864
Carles GP *See* Tabouy LJ et al 1381
Carmichael DJS (abst) 1134
Carmichael P (abst) 275
Carone FA *See* Kanwar YS et al 589
Carone FA *See* Kumar A et al 620
Carpenter CB (abst) 273
Carraro A *See* Brocco E et al 63:S-40
Carraro M *See* Guarnieri G et al 62:S-41
Carretero OA *See* Ito S et al 63:S-128
Carretier M (abst) 864
Carroll MC (abst) 1122
Carvia R (abst) 1157
Casado S *See* Caramelo C et al 61:S-56
Cases A (abst) 1136, 1147
Caslake MJ (abst) 269
Casley D *See* Dean R et al 1261
Caspers ML *See* Rossi NF et al 61:S-22
Cassidy M (abst) 1129
Cassidy MJD (abst) 1127, 1131
Castelao AM (abst) 1137, 1156
Castellano I (abst) 1138
Castiñeiras MJ (abst) 1156
Catalán C (abst) 1137
Caterson RJ *See* Ibels LS et al 61:S-67
Cattell V (abst) 261, 261
Cattell WR *See* Lipkin GW et al 792
Catto GRD (abst) 1127, 1131
Cavallone D *See* Malagolini N et al 1340
Cavallotti D *See* Aiello S et al 171
Cendoroglo M, Sundaram S, Groves C, Ucci AA, Jaber BL, Pereira BJG: Necrosis and apoptosis of polymorphonuclear cells exposed to peritoneal dialysis fluids *in vitro* 1626
Cha MK *See* Lee HB et al 60:S-60
Chakravorty SJ (abst) 276
Challú A, Martínez-Maldonado M: Latin American nephrology: Present state and future concerns 583
Chamberlain RM (abst) 264
Chan L *See* Jacob AD et al 755
Chan TM (abst) 1127
Chandna SM (abst) 1120
Chandraker A (abst) 273
Chandraker A, Takada M, Nadeau KC, Peach R, Tilney NL, Sayegh MH: CD28-B7 blockade in organ dysfunction secondary to cold ischemia/reperfusion injury 1678
Chang R (abst) 1132, 1132
Channa RS (abst) 278
Chansel D *See* Ardaillou R et al 1458
Chapman AB, Gabow PA: Hypertension in autosomal dominant polycystic kidney disease 61:S-71
Chapman PT (abst) 1116
Charonis AS *See* Kumar A et al 620
Chatterjee PK, Weerackody RP, Mistry SK, Hawksworth GM, McLay JS: Selective antagonism of the AT_1 receptor inhibits angiotensin II stimulated DNA and protein synthesis in primary cultures of human proximal tubular cells 699
Chaturvedi N *See* Viberti G et al 63:S-32
Chauveau D *See* Jungers P et al 871
Chauvet-Monges A-MT *See* Tabouy LJ et al 1381
Chazot C, Shabmir E, Matias B, Laidlaw S, Kopple JD: Dialytic nutrition: Provision of amino acids in dialysate during hemodialysis 1663
Checa MD (abst) 1147, 1154
Chen H *See* Rossi NF et al 61:S-22
Chen H-C, Tsai J-C, Tsai J-H, Lai Y-H: Recombinant human erythropoietin enhances superoxide production by FMLP-stimulated polymorphonuclear leukocytes in hemodialysis patients 1390
Chen L, Wang Y, Tay Y-C, Harris DCH: Proteinuria and tubulointerstitial injury 61:S-60
Chen S *See* Eklöf A-C et al 742
Cheng H- *See* Wang T et al 1068
Cheng H-F *See* Becker BN et al 87
Chertow GM, Brenner BM, Mori M, MacKenzie HS, Milford EL: Antigen-independent determinants of graft survival in living-related kidney transplantation. 63:S-84
Chertow GM, Lazarus JM, Lew NL, Ma L, Lowrie EG: Bioimpedance norms for the hemodialysis population.. 1617
Chesney RW *See* Matsell DG et al 748
Chesser AMS (abst) 267
Cheung PK (abst) 562, 564
Chevalier J *See* Michel O et al 1532
Chiesura-Corona M *See* Brocco E et al 63:S-40
Chine M (abst) 1142, 1155, 1155
Chini CCS *See* Chini EN et al 917
Chini EN, Chini CCS, Bolliger C, Jougasaki M, Grande JP, Burnett JC Jr., Dousa TP: Cytoprotective effects of adrenomedullin in glomerular cell injury: central role of cAMP signaling pathway 917
Chisholm M (abst) 271

Choi KC, Kim NH, An MR, Kang DG, Kim SW, Lee J-: Alterations of intrarenal renin-angiotensin and nitric oxide systems in streptozotocin-induced diabetic rats .. 60:S-23
Christensen PK, Hansen HP, Parving H-H: Impaired auatoregulation of GFR in hypertensive non insulin dependent diabetic patients 1369
Christiansen T *See* Ringgaard S et al 1359
Chumlea WC *See* Modification of Diet in Renal Disease Study Group et al 778
Ciocchi B *See* Guarnieri G et al 62:S-41
Cirillo M *See* De Santo NG et al. 62:S-111
Cirugeda A (abst) 1143, 1145, 1145, 1155
Ciudad J (abst) 1141, 1141, 1153, 1160
Clarke J (abst) 275
Clayton A (abst) 262
Clements S (abst) 280
Cochat P *See* Gaulier J-M et al 1700
Cockwell P (abst) 272, 276
Cody J (abst) 1117
Coe FL *See* Asplin JR et al 1602
Coffman TM: A role for T cell co-stimulation in ischemic acute renal failure? 1706
Coffman TM *See* Wada T et al 934
Cohen DI *See* Grupp C et al 1279
Cohen G (abst) 1129
Cohen G, Haag-Weber M, Hörl WH: Immune dysfunction in uremia 62:S-79
Cohen RM, Feldman GM, Fernandez PC: The balance of acid, base and charge in health and disease 287
Coleman DL *See* Budde K et al 733
Coles GA (abst) 1121, 1126
Coles GA *See* Baboolal K et al 607
Colombi A (abst) 1423
Colvin RB (abst) 1429
Combe C (abst) 865
Comper WD *See* Jerums G et al 63:S-87
Condiotti R *See* Nagler A et al 1561
Connolly JO (abst) 1133
Conrad DS *See* Zager RA et al. 60
Cook DI *See* Johnson DW et al 1486
Cook G (abst) 1133
Cook HT (abst) 261
Cook T (abst) 261
Cooper ME *See* Wu LL et al. 63:S-221
Corbacho L (abst) 1155
Corna D *See* Aiello S et al 171
Cosío J (abst) 1136
Couete S *See* Vrtovsnik F et al 1016
Coulshed S *See* Ibels LS et al 61:S-67
Couper L *See* Himmelfarb J et al 1671
Couser WG *See* Nangaku M et al 182
Couser WG *See* Nangaku M et al 1570
Couser WG *See* Shankland SJ et al. 404
Covarsi A (abst) 1138
Cox A (abst) 279
Cox J (abst) 270
Cox JPD *See* Akuta N et al 911
Craig KJ (abst) 269
Cramp HA (abst) 1118, 1119
Crary GS *See* O'Donnell MP et al. 63:S-218
Craven PA, DeRubertis FR, Melhem M: Nitric oxide in diabetic nephropathy 60:S-46
Crawford C (abst) 1128
Crespo C (abst) 1139
Crevat AD *See* Tabouy LJ et al. 1381
Cronin MJ *See* Haffner D et al 802
Crook D (abst) 274
Cross J (abst) 1117
Cruz JM (abst) 1159
Cuevas X (abst) 1142, 1155, 1155
Cunningham J (abst) 1125, 1134
Curtis JJ: Treatment of hypertension in renal allograft patients: Does drug selection make a difference? ... 63:S-75
Cybulsky AV *See* Budde K et al 733
Cybulsky AV *See* Kee N et al 309
Czerwinski G *See* Romanov V et al 93

D

Daha MR (abst) 561, 562, 563, 564
Daha MR *See* Heidenreich S et al 318
Daïkha-Dahmane F, Dommergues M, Muller F, Narcy F, Lacoste M, Beziau A, Dumez Y, Gubler M-C: Development of human fetal kidney in obstructive uropathy: Correlations with ultrasonography and urine biochemistry 21
Dallongeville J *See* Arnadottir M et al 1651
Dallyn P (abst) 270, 1119
Daly C (abst) 1117
Dämmrich J *See* Heidland A et al. 62:S-32
Daniels J (abst) 1126
Daniels J *See* Baboolal K et al 607
Danielson BG *See* Metry G et al. 1635
Darnell A (abst) 1136, 1147
Darnell A *See* Torra R et al 33
Dasgupta I (abst) 1127, 1131
Dash SC, Bhuyan UN, Dinda AK, Saxena S, Agarwal SK, Tiwari SC, Nundy S: Increased incidence of glomerulonephritis following spleno-renal shunt surgery in non-cirrhotic portal fibrosis 482
Date Y *See* Kinoshita H et al 1028
Daugirdas JT *See* HEMO Study Group et al. 1395
Dauwe SEH *See* Helbert MJF et al. 414
Davenport A (abst) 1123, 1128
Davies F (abst) 1122
Davies M (abst) 1123
Davies S, Spanel P, Smith D: Quantitative analysis of ammonia on the breath of patients in end-stage renal failure (Technical Note) 223
Davies SJ (abst) 1127
Davis JA *See* Weinberg JM et al. 140
Davison AM (abst) 275, 1120
Dawnay A (abst) 274
Dawnay ABS *See* Lipkin GW et al 792
de Boer E *See* de Vries PAM et al 244
De Broe ME *See* Helbert MJF et al 414
de Heer E (abst) 559, 563, 563, 563
de Jong PE (abst) 559, 561, 561, 562, 565, 566
de Jong PE *See* Buter H et al 63:S-185
de Jong PE *See* de Vries PAM et al 244
de Jong PE *See* Haas M et al 1693
de Jong PE *See* van der Kleij FGH et al. 63:S-23
de Jong PE *See* van Essen GG et al 63:S-58
de Miguel M *See* Lee S-K et al 1000
de Paula A (abst) 1140
De Santo LS *See* De Santo NG et al. 62:S-111
De Santo NG, Bisaccia C, De Santo RM, De Santo LS, Petrelli L, Gallo L, Cirillo M, Capasso G: Salt: A sacred substance 62:S-111
De Santo RM *See* De Santo NG et al. 62:S-111
de Takats D (abst) 1119, 1133

de Toledo FGS, Beers KW, Berndt TJ, Thompson MA, Tyce GM, Knox FG, Dousa TP: Opposite paracrine effects of 5-HT and dopamine on Na^+-Pi cotransport in opossum kidney cells 152
de Vries PAM (abst) 561
de Vries PAM, Navis G, de Boer E, de Jong PE, de Zeeuw D, Kluppel CA: A method for accurate measurement of GFR in conscious, spontaneously voiding rats (Technical Note) 244
de Vries PMJM (abst) 567
de Zeeuw D (abst) 559, 561, 561, 565, 566
de Zeeuw D *See* Buter H et al 63:S-185
de Zeeuw D *See* de Vries PAM et al 244
de Zeeuw D *See* Haas M et al 1693
de Zeeuw D *See* van der Kleij FGH et al 63:S-23
de Zeeuw D *See* van Essen GG et al 63:S-58
Dean R, Murone C, Lew RA, Zhuo J, Casley D, Müller-Esterl W, Alcorn D, Mendelsohn FAO: Localization of bradykinin B_2 binding sites in rat kidney following chronic ACE inhibitor treatment 1261
Deanfield JE *See* Kari JA et al 468
Dechaux M *See* Laouari D et al 1550
Deferrari G *See* Pontremoli R et al 63:S-163
Degenhardt TP, Grass L, Reddy S, Thorpe SR, Diamandis EP, Baynes JW: The serum concentration of the advanced glycation end-product N^{ε}-(carboxymethyl) lysine is increased in uremia (Technical Note) 1064
Dehouck B *See* Morinière P et al 1406
Deinum J (abst) 562
Deira J (abst) 1151, 1151, 1156
del Canto E (abst) 1140
del Castillo D, Agarwal A, Jaimes EA, Raij L: Glomerular and vascular tissues do not down-regulate nitric oxide synthesis during protracted endotoxemia ... 460
Del Moral RG (abst) 1135, 1138, 1157, 1157
Del Sette M *See* Pontremoli R et al 63:S-163
Delabar U *See* Gleiter CH et al 338
Deminiere C (abst) 865
Demontis R (abst) 864
Demura H *See* Murakami K et al 63:S-208
Denburg MR *See* Haseley LA et al 1375
Dennis MJ *See* Dixon BS et al 61:S-14
De'Oliveira JM, Price DA, Fisher NDL, Allan DR, McKnight JA, Williams GH, Hollenberg NK: Autonomy of the renin system in type II diabetes mellitus: Dietary sodium and renal hemodynamic responses to ACE inhibition 771
Depner TA *See* HEMO Study Group et al 1395
DeRubertis FR *See* Craven PA et al 60:S-46
Derzsiová K *See* Mydlík M et al 62:S-56
Dhillon SS (abst) 274
Diamandis EP *See* Degenhardt TP et al 1064
Diamond I (abst) 280
Díaz-Corte C (abst) 1136, 1143, 1150, 1150
Diego J (abst) 1145
Dieplinger H *See* Trenkwalder E et al 1685
Dieterle T (abst) 1423
Díez J (abst) 1142
Díez-Panero LM (abst) 1135
Dijk Mv (abst) 1122
Dijkhorst LT (abst) 560
Dinda AK *See* Dash SC et al 482
Ding H, Qing DP, Kopple JD: IGF-1 resistance in chronic renal failure: Current evidence and possible mechanism 62:S-45
Ding Y *See* Vaziri ND et al 1042
Distler A *See* Kribben A et al 61:S-74
Dittmer ID (abst) 266, 275
Dixon BS, Dennis MJ: Interaction of kinins and captopril in regulating arterial smooth muscle cell proliferation 61:S-14
Dockrell MEC (abst) 1126
Dodd S (abst) 1131
Dodd SM (abst) 1118, 1119, 1122
Doehring E *See* Vester U et al 478
Dommergues M *See* Daïkha-Dahmane F et al 21
Donadio C, Lucchesi A, Tramonti G, Bianchi C: Creatinine clearance predicted from body cell mass is a good indicator of renal function 63:S-166
Donadio C *See* Tramonti G et al 63:S-179
Donald AE *See* Kari JA et al 468
Donaldson C (abst) 1117
Donker AJM (abst) 560, 565, 566, 566, 567
Donohoe P (abst) 268, 1119
Donovan KL (abst) 1130
Dorado B *See* Kari JA et al 468
Dousa TP *See* Chini EN et al 917
Dousa TP *See* de Toledo FGS et al 152
Doyle T (abst) 268
Drew PJT (abst) 1128
Drewnowska K *See* Lewko B et al 654
D'Souza RJ (abst) 1132
Dudley JA (abst) 278
Dukes DC (abst) 276, 276
Dumez Y *See* Daïkha-Dahmane F et al 21
Durrington PN (abst) 1132
Dussel R *See* Endlich K et al 202
Dworacki G *See* Niemir ZI et al 393
Dysko R *See* Lee S-K et al 1000

E

Ebbehøj E *See* Poulsen PL et al 63:S-15
Eckardt K-U *See* Gleiter CH et al 338
Edelstein CL, Ling H, Gengaro PE, Nemenoff RA, Bahr BA, Schrier RW: Effect of glycine on prelethal and postlethal increases in calpain activity in rat renal proximal tubules 1271
Edmunds ME (abst) 276
Edward N (abst) 1127, 1131
Edwards A (abst) 1130
Edwards ME (abst) 276
Effiong C *See* Mattana J et al 1478
Egido J *See* Ruiz-Ortega M et al 1497
Ehrich JHH *See* Vester U et al 478
Eijsbouts Q (abst) 568
Eikelboom BC *See* Bosman PJ et al 1084
Ejea MV (abst) 1152
Eklöf A-C, Holtbäck U, Sundelöf M, Chen S, Aperia A: Inhibition of COMT induces dopamine-dependent natriuresis and inhibition of proximal tubular Na^+,K^+-ATPase 742
Eknoyan G *See* Agodoa L et al 63:S-144
El Nahas AM (abst) 263, 277, 278, 279
Eleno N (abst) 1135
Elkins N *See* Jacob AD et al 755
Elliot S *See* Striker GE et al 63:S-120
Elliott H (abst) 1118

Elorriaga R (abst) 1142
Endlich K, Steinhausen M, Dussel R: Natriuretic peptide receptors mediate different responses in rat renal microvessels 202
Endo F *See* Nakazato H et al 895
Endo K *See* Miyazaki T et al 63:S-211
Endo Y, Arima S, Yaoita H, Omata K, Tsunoda K, Takeuchi K, Abe K, Ito S: Function of angiotensin II type 2 receptor in the postglomerular efferent arteriole 63:S-205
Endoh M *See* Suzuki D et al 111
Enero J (abst) 1145
Enríquez R (abst) 1138
Epstein FH *See* Joannidis M et al 130
Escher G (abst) 1426
Escorsell A *See* Torra R et al 33
Esforzado N (abst) 1147
Esparza N (abst) 1147, 1154
Esper NE *See* Morinière P et al 1406
Estacio RO *See* Jeffers BW et al 473
Esteban R (abst) 1157
Estivill E (abst) 1122
Estivill X *See* Torra R et al 33
Eto T *See* Kinoshita H et al 1028
Eugene M (abst) 863, 864
Evans B *See* Wang Y et al 371
Evans DJ (abst) 268
Eynstone L (abst) 1121
Eynstone L *See* Phillips AO et al 973

F

Fabbro D *See* Huwiler A et al 329
Faccini L *See* Guarnieri G et al 62:S-41
Fagerudd JA, Groop P-H, Honkanen E, Teppo A-M, Grönhagen-Riska C: Urinary excretion of TGF-β1, PDGF-BB and fibronectin in insulin-dependent diabetes mellitus patients 63:S-195
Falk M (abst) 1122
Falk MC *See* Olive C et al 1047
Fardon NJM (abst) 1120
Farina K (abst) 1426
Farmer C (abst) 1119
Farmer CKT (abst) 270
Farré AL *See* Caramelo C et al 61:S-56
Farrington K (abst) 1119, 1120, 1128
Favre H (abst) 863
Fawcett J *See* Yap J et al 1216
Fdez-Vega F (abst) 1136
Fear H (abst) 1117
Feather SA (abst) 1124, 1131
Feehally J (abst) 270, 271, 272, 1122
Feehally J *See* Olive C et al 1047
Feest T (abst) 1118, 1130
Feldman GM *See* Cohen RM et al 287
Fellström BC *See* Melin J et al 985
Féraille E (abst) 863
Ferdeghini M *See* Tramonti G et al 63:S-179
Ferguson DJP *See* Maxwell PH et al 715
Fernández A (abst) 1143, 1145, 1155
Fernández G (abst) 1152
Fernández Martinez S (abst) 1149
Fernandez P *See* Klaus G et al 45
Fernandez PC *See* Cohen RM et al 287
Fernández-Juárez G (abst) 1158, 1158
Fernández-Martín JL (abst) 1150, 1150
Fernández-Rañada JM (abst) 1139
Fernando R (abst) 1123
Ferretti E *See* Vicanek C et al 614
Ferris G (abst) 1130
Ficheux A *See* Argilés A et al 530
Field MJ *See* Johnson DW et al 1486
Fielder PJ *See* Yap J et al 1216
Fievet P (abst) 864
Figuera A (abst) 1139
Figueroa CD *See* Gonzalez CB et al 1206
Fillioux-Morfaux V *See* Morinière P et al 1406
Fine LG *See* Kitamura M et al 60:S-86
Fine LG *See* Orphanides C et al 637
Finsinger D *See* Romanov V et al 93
Fiol C (abst) 1156
Fioretto P *See* Brocco E et al 63:S-40
Fioretto P *See* Mauer M et al 63:S-155
Fiotti N *See* Guarnieri G et al 62:S-41
Fischer K-G *See* Henger A et al 687
Fischer K-G *See* Pavenstädt H et al 157
Fishbane S, Bucala R, Pereira BJG, Founds H, Vlassara H: Reduction of plasma apolipoprotein-B by effective removal of circulating glycation derivatives in uremia .. 1645
Fishbane S, Galgano C, Langley RC Jr., Canfield W, Maesaka JK: Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients 217
Fisher NDL *See* De'Oliveira JM et al 771
Flavier JL *See* Argilés A et al 530
Fleming S (abst) 269
Fleury D (abst) 865
Floege J *See* Schwalbe S et al 1077
Floege J *See* Shankland SJ et al 404
Flores O (abst) 1140
Flyvbjerg A: Role of growth hormone, insulin-like growth factors (IGFs) and IGF-binding proteins in the renal complications of diabetes 60:S-12
Flyvbjerg A *See* Ringgaard S et al 1359
Födinger M, Mannhalter C, Wölfl G, Pabinger I, Müller E, Schmid R, Hörl WH, Sunder-Plassmann G: Mutation (677 C to T) in the methylenetetrahydrofolate reductase gene aggravates hyperhomocysteinemia in hemodialysis patients 517
Fogarty DG (abst) 1119, 1124, 1133
Foglieni C *See* Aiello S et al 171
Fogo A *See* Nishimura H et al 345
Fongoro S *See* Vester U et al 478
Font J (abst) 1135, 1135, 1153, 1153
Founds H *See* Fishbane S et al 1645
Fournier A *See* Morinière P et al 1406
Francis JL (abst) 271
Franke D *See* Vester U et al 478
Franz H-E *See* Grupp C et al 1279
Freemont A (abst) 1134
Frey BM (abst) 1426
Frey FJ (abst) 1426, 1428
Friedlander G *See* Iimura O et al 962
Friedlander G *See* Laouari D et al 1550
Friedlander G *See* Ledoux S et al 953
Friedlander G *See* Vrtovsnik F et al 1016
Friedrichs U *See* Meyer-Lehnert H et al 61:S-27
Frigato F *See* Brocco E et al 63:S-40
Frischmuth N (abst) 1424, 1427, 1430
Fruchart J-C *See* Arnadottir M et al 1651
Fujii S *See* Imanishi M et al 63:S-198
Fujimoto S *See* Kinoshita H et al 1028

Fujita N *See* Ishikawa S- et al 61:S-6
Fukagawa M, Kitaoka M, Kurokawa K: Resistance of the parathyroid glands to vitamin D in renal failure: Implications for medical management 62:S-60
Fukagawa M *See* Shimizu T et al 63:S-239
Fukiyama K *See* Iseki K et al 63:S-169
Fukuda R *See* Noda M et al 63:S-136
Fullwood Y (abst) 1125
Fulquet M (abst) 1142, 1155, 1155
Furness PN (abst) 263, 264, 270, 1120, 1131
Furuichi K *See* Segawa C et al 1054
Furuse A *See* Nakazato H et al 895

G

Gabbai F *See* Pham K et al 725
Gabow PA *See* Chapman AB et al 61:S-71
Gaciong Z *See* Heidland A et al 62:S-32
Gago E (abst) 1150
Gainza FJ (abst) 1137, 1140
Galanski M *See* Schwalbe S et al 1077
Galgano C *See* Fishbane S et al 217
Galiatsou E (abst) 1118
Galle J *See* Wanner C et al 62:S-53
Galle J *See* Wanner C et al 63:S-102
Gallego B (abst) 1140
Gallego E (abst) 1143
Gallego Valcarce E (abst) 1154
Gallivan L (abst) 275
Gallo L *See* De Santo NG et al 62:S-111
Ganesan A *See* Johnson DW et al 1486
Gans ROB (abst) 565, 566
Gao X-L *See* Kopple JD et al 486
Garabedian M *See* Laouari D et al 1550
Garbayo A (abst) 1156, 1157
García Cantón C (abst) 1147
García Cortes MJ (abst) 1146, 1149, 1150, 1152
García E, Santos F, Rodríguez J, Martínez V, Rey C, Veldhuis J, Jr. RJK: Impaired secretion of growth hormone in experimental uremia: Relevance of caloric deficiency 648
Garcia J (abst) 1159
García Marcos S (abst) 1146, 1152
García P (abst) 1155
Garcia R (abst) 1144
Garcia Ramón R (abst) 1144
García Ruiz C (abst) 1137
García Vadillo A (abst) 1143
García-Cantón C (abst) 1154
García-Chicano MJ (abst) 1135, 1138
García-Cortés MJ (abst) 1144
García-López F (abst) 1159
García-Marcos S (abst) 1144
Gardiner A (abst) 278
Garred LJ *See* Argilés A et al 530
Gärtner H *See* Kribben A et al 61:S-74
Gascón A (abst) 1135, 1135, 1141, 1141, 1153, 1153, 1156, 1160
Gaskin G (abst) 272, 1130
Gaspari F, Perico N, Remuzzi G: Measurement of glomerular filtration rate 63:S-151
Gaspari F *See* Ruggenenti P et al 63:S-54
Gasser T (abst) 1424
Gasser Th (abst) 1427
Gassman JJ *See* Modification of Diet in Renal Disease Study Group et al 778
Gaulier J-M, Cochat P, Lardet G, Vallon J-J: Serum oxalate microassay using chemiluminescence detection (Technical Note) 1700
Geighan CJ (abst) 269
Gejyo F, Kimura H, Suzuki S, Miyazaki R, Naiki H, Nakakuki K: Apolipoprotein E and α_1-antichymotrypsin in dialysis-related amyloidosis 62:S-75
Gengaro PE *See* Edelstein CL et al 1271
Genina O *See* Nagler A et al 1561
Gennari FJ *See* Maddox DA et al 446
Gerrish M (abst) 1129
Gerritsma JSJ (abst) 562
Gesualdo L *See* Schena FP et al 1439
Giansante C *See* Guarnieri G et al 62:S-41
Gilbert RE *See* Jerums G et al 63:S-87
Gilbert RE *See* Wu LL et al 63:S-221
Giles M *See* Butkus A et al 628
Gillespie KM (abst) 278
GilVernet S (abst) 1156
Gimeno I (abst) 1157
Ginès P, Martin P-Y, Niederberger M: Prognostic significance of renal dysfunction in cirrhosis 61:S-77
Ginzler EM *See* Haseley LA et al 1375
Gleeson NP (abst) 1128
Gleiter CH, Brause M, Delabar U, Zebski H, Eckardt K-U: Evidence against a major role of adenosine in oxygen-dependent regulation of erythropoietin in rats . . . 338
Glez-Portal C (abst) 1136
Glorieux G *See* Smet RD et al 62:S-8
Glowacki F (abst) 865
Godart C (abst) 864
Gohlke P (abst) 269
Goicoechea M (abst) 1149
Gokal R (abst) 1133, 1134
Goldsmith D (abst) 268, 1119
Goldsmith DJA (abst) 270
Goldsworthy M (abst) 1124
Goligorsky MS *See* Romanov V et al 93
Golper TA *See* Bunke CM et al 524
Gómez C (abst) 1143, 1154
Gómez F (abst) 1159
Gomez N (abst) 1155
Gómez Roldán C (abst) 1143, 1144
Gómez V (abst) 1147, 1158, 1158, 1158, 1160
Gomez-Martino JR (abst) 1138
Gómez-Morales M (abst) 1135, 1157
Gomez-Ullate P (abst) 1157, 1159, 1160
Gonick HC *See* Vaziri ND et al 1042
González C (abst) 1138, 1156, 1157
Gonzalez CB, Figueroa CD, Reyes CE, Caorsi CE, Troncoso S, Menzel D: Immunolocalization of V_1 vasopressin receptors in the rat kidney using anti-receptor antibodies 1206
González MT (abst) 1137
Goodship JA (abst) 268, 1122, 1125
Goodship THJ (abst) 264, 268, 1122, 1125
Goodyer C *See* Vicanek C et al 614
Goodyer P *See* Vicanek C et al 614
Gorrie MJ (abst) 278
Górriz JL (abst) 1137, 1154
Gorter A (abst) 563
Gotch FA *See* HEMO Study Group et al 1395
Goto A *See* Kimura K et al 63:S-201
Goto S *See* Narita I et al 63:S-215
Goujon JM (abst) 863

Gourley MF *See* Haseley LA et al. ... 1375
Goya T *See* Matsuo K et al ... 832
Goyal M *See* Lee S-K et al ... 1000
Grandaliano G *See* Schena FP et al ... 1439
Grande JP *See* Chini EN et al ... 917
Grande JP *See* Griffin MD et al ... 1196
Grant A (abst) ... 1117
Grantham JJ: Mechanisms of progression in autosomal dominant polycystic kidney disease ... 63:S-93
Grass L *See* Degenhardt TP et al ... 1064
Greene EL *See* Ibrahim HN et al ... 63:S-115
Greene T *See* HEMO Study Group et al ... 1395
Greene T *See* Modification of Diet in Renal Disease Study Group et al ... 778
Greenwald SE (abst) ... 1118
Greenwood RN (abst) ... 1119, 1128
Greger R *See* Henger A et al ... 687
Greger R *See* Pavenstädt H et al ... 157
Greiber S *See* Wanner C et al ... 63:S-102
Gretz N *See* Obermüller N et al ... 1584
Griffin M (abst) ... 279
Griffin MD, O'Sullivan DA, Torres VE, Grande JP, Kanwar YS, Kumar R: Expression of polycystin in mouse metanephros and extra-metanephric tissues ... 1196
Griffin SV (abst) ... 1124
Griffith ME (abst) ... 277
Griffiths RC *See* Wada T et al ... 934
Grimm RH Jr., Svendsen KH, Kasiske B, Keane WF, Wahi MM, MRFIT Research Group: Proteinuria is a risk factor for mortality over 10 years of follow-up ... 63:S-10
Griñó JM (abst) ... 1156
Groffen AJA (abst) ... 564
Grönhagen-Riska C *See* Fagerudd JA et al ... 63:S-195
Groop P-H *See* Fagerudd JA et al ... 63:S-195
Groshar D, Moskovitz B, Issaq E, Nativ O: Quantitative SPECT of DMSA uptake by the kidneys: Assessment of reproducibility (Technical Note) ... 817
Gross V, Lippoldt A, Luft. FC: Pressure-diuresis and natriuresis in DOCA-salt mice (Technical Note) ... 1364
Groves C *See* Cendoroglo M et al ... 1626
Gruber A *See* Trenkwalder E et al ... 1685
Grupp C, Lottermoser J, Cohen DI, Begher M, Franz H-E, Müller GA: Transformation of rat inner medullary fibroblasts to myofibroblasts in vitro ... 1279
"Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN) *See* Ruggenenti P et al ... 63:S-54
Gruss E (abst) ... 1139, 1143, 1155
Grüter E (abst) ... 1423
Gryseels B *See* Vester U et al ... 478
Guarnieri G, Toigo G, Fiotti N, Ciocchi B, Situlin R, Giansante C, Vasile A, Carraro M, Faccini L, Biolo G: Mechanisms of malnutrition in uremia ... 62:S-41
Gubler M-C *See* Daïkha-Dahmane F et al ... 21
Guerrero JE (abst) ... 1140
Guettier C (abst) ... 864
Guignard J-P (abst) ... 1425, 1430, 1430
Guillen M (abst) ... 1157
Guirado L (abst) ... 1159
Guo D-F *See* Obata J- et al ... 63:S-229
Gutiérrez Colón JA (abst) ... 1156, 1157
Guttormsen AB, Ueland PM, Svarstad E, Refsum H: Kinetic basis of hyperhomocysteinemia in patients with chronic renal failure ... 495
Gyory AZ *See* Ibels LS et al ... 61:S-67
György AZ *See* Johnson DW et al ... 1486
Gyr K (abst) ... 1423

H

Ha H, Kamanna VS, Kirschenbaum MA, Kim KH: Role of glycated low density lipoprotein in mesangial extracellular matrix synthesis ... 60:S-54
Ha H *See* Lee HB et al ... 60:S-1
Ha S-K, Seo J-K: Insertion/deletion polymorphism in ACE gene as a predictor for progression of diabetic nephropathy ... 60:S-28
Haag-Weber M *See* Cohen G et al ... 62:S-79
Haas M, Kluppel ACA, Wartna ES, Moolenaar F, Meijer DKF, de Jong PE, de Zeeuw D: Drug-targeting to the kidney: Renal delivery and degradation of a naproxen-lysozyme conjugate *in vivo* ... 1693
Haas M *See* Borchhardt K et al ... 1622
Haas M *See* van der Kleij FGH et al ... 63:S-23
Haase W *See* Baer PC et al ... 1321
Haberthür C (abst) ... 1423
Hack CE (abst) ... 564
Haddj-El Mrabet A (abst) ... 864
Haffner D, Tönshoff B, Blum WF, Vickers M, Siebler T, Cronin MJ, Baxter RC, Mehls O: Insulin-like growth factors (IGFs) and IGF binding proteins, serum acid-labile subunit and growth hormone binding protein in nephrotic children ... 802
Haginoshita S *See* Koda Y et al ... 1096
Hakim RM *See* May RE et al ... 1656
Hall LL (abst) ... 263, 1131
Hallett M (abst) ... 265
Halvorsen G (abst) ... 1131
Hamakawa S *See* Wada T et al ... 63:S-182
Han DC *See* Ziyadeh FN et al ... 60:S-7
Han X *See* Matsell DG et al ... 748
Hancock WW (abst) ... 273
HANE Trial Research Group *See* Kribben A et al ... 61:S-74
Haneda M, Araki S-, Togawa M, Sugimoto T, Isono M, Kikkawa R: Activation of mitogen-activated protein kinase cascade in diabetic glomeruli and mesangial cells cultured under high glucose conditions ... 60:S-66
Haneda M *See* Kikkawa R et al ... 62:S-39
Hansell P *See* Metry G et al ... 1635
Hansen HP, Nielsen FS, Rossing P, Jacobsen P, Jensen BR, Parving H-H: Kidney function after withdrawal of long-term antihypertensive treatment in diabetic nephropathy ... 63:S-49
Hansen HP *See* Christensen PK et al ... 1369
Hansen KW *See* Poulsen PL et al ... 63:S-15
Hara M *See* Inoue S et al ... 1543
Hara M *See* Kihara I et al ... 63:S-171
Harber M (abst) ... 1128
Hardisty CA (abst) ... 277
Hardman P (abst) ... 263
Harkins EW *See* Sheu J-N et al ... 71
Harnden P (abst) ... 269
Harper S (abst) ... 270, 271, 1122
Harper SJ (abst) ... 264, 272
Harper SJ *See* Olive C et al ... 1047
Harris DCH *See* Chen L et al ... 61:S-60
Harris FE (abst) ... 266, 1132
Harris KPG (abst) ... 262, 264, 1127
Harris RC *See* Becker BN et al ... 87
Harris SAC (abst) ... 1129
Harron JC (abst) ... 1124

Hartley B *See* Wang Y et al 371
Harwood SM *See* Lipkin GW et al 792
Hasegawa T *See* Kawaguchi Y et al 62:S-105
Haseley LA, Wisnieski JJ, Denburg MR, Michael-Grossman AR, Ginzler EM, Gourley MF, Hoffman JH, Kimberly RP, Salmon JE: Antibodies to Clq in systemic lupus erythematosus: characteristics and relation to FcαRIIA alleles 1375
Hasselwander O (abst) 1119
Hata S *See* Shimizu T et al 63:S-239
Hateboer N (abst) 1122
Hattori S *See* Nakazato H et al 895
Hauet T (abst) 863, 864
Hawksworth GM *See* Chatterjee PK et al 699
Haxelmans S *See* Schlatter E et al 454
Hayashi K *See* Murakami M et al 63:S-132
Haylor JL (abst) 277
Hebert SC (abst) 560
Hedenström H *See* Metry G et al 1635
Heeringa P (abst) 564
Heidenreich S, Sato T, Schmidt M, August C, Timmerman JJ, van Es LA, Daha MR: Induction of mesangial interleukin-6 synthesis by apoptotic U937 cells and monocytes 318
Heidland A, Sebekova K, Paczek L, Teschner M, Dämmrich J, Gaciong Z: Renal fibrosis: Role of impaired proteolysis and potential therapeutic strategies 62:S-32
Heilig CW, Brosius FC III, Henry DN: Glucose transporters of the glomerulus and the implications for diabetic nephropathy 60:S-91
Heim M (abst) 1424, 1430
Heimbürger O *See* Wang T et al 1068
Heimbürger O *See* Wang T et al 1609
Heinloth A *See* Wanner C et al 63:S-102
Heishi M *See* Akiba T et al 62:S-69
Helbert MJF, Dauwe SEH, Van der Biest I, Nouwen EJ, De Broe ME: Immunodissection of the human proximal nephron: Flow sorting of S1S2S3, S1S2 and S3 proximal tubular cells 414
Helin C *See* Loghman-Adham M et al 229
Hellberg O *See* Melin J et al 985
Hemmelder MH (abst) 565, 566
HEMO Study Group , Daugirdas JT, Depner TA, Gotch FA, Greene T, Keshaviah P, Levin NW, Schulman G: Comparison of methods to predict equilibrated Kt/V in the HEMO pilot study 1395
Henderson IS (abst) 1132
Hendry BM (abst) 264, 273, 277, 1126
Henger A, Huber T, Fischer K-G, Nitschke R, Mundel P, Schollmeyer P, Greger R, Pavenstädt H: Angiotensin II increases the cytosolic calcium activity in rat podocytes in culture 687
Henger A *See* Pavenstädt H et al 157
Henne K *See* Shankland SJ et al 404
Henry DN *See* Heilig CW et al 60:S-91
Hermle M (abst) 1424, 1424, 1430
Hernández A (abst) 1137, 1143
Hernandez MT (abst) 1138
Hernández T (abst) 1154
Hernanz-Schulman M *See* May RE et al 1656
Herruzo J (abst) 1150
Herruzo JA (abst) 1148, 1150
Hess B (abst) 1426, 1429, 1429
Hesse CJ (abst) 567
Heudes D *See* Michel O et al 1532
Hickling HM (abst) 277
Hicks J (abst) 1130
Hidalgo F (abst) 1140
Higgins RM (abst) 276, 276, 1119
Hillis G *See* Roy-Chaudhury P et al 103
Hillman KA (abst) 1134
Himmelfarb J, Couper L: Dipyridamole inhibits PDGF and bFGF-induced vascular smooth muscle cell proliferation 1671
Himmelfarb J *See* May RE et al 1656
Hinesley RS *See* Kempson SA et al 1332
Hiraoka M, Hori C, Tsukahara H, Kasuga K, Ishihara Y, Sudo M: Congenitally small kidneys with reflux as a common cause of nephropathy in boys 811
Hirasawa Y *See* Koda Y et al 1096
Hirata M *See* Miyazaki T et al 63:S-211
Hirata Y *See* Kimura K et al 63:S-201
Hirata-Dulas CA *See* Moore RR Jr. et al 240
Hisada Y *See* Segawa C et al 1054
Hisanaga S *See* Kinoshita H et al 1028
Hockenberry DM *See* Shankland SJ et al 404
Hodge A (abst) 266
Hoffman JH *See* Haseley LA et al 1375
Hohage H *See* Schlatter E et al 454
Holdsworth SR *See* Kitching AR et al 52
Hollenberg NK *See* De'Oliveira JM et al 771
Hollinger DL *See* Modification of Diet in Renal Disease Study Group et al 778
Holmans P (abst) 1122
Holmans P *See* Baboolal K et al 607
Holtbäck U *See* Eklöf A-C et al 742
Holzgreve H *See* Kribben A et al 61:S-74
Holzhauer M *See* Schwalbe S et al 1077
Honda M *See* Murakami M et al 63:S-132
Honkanen E *See* Fagerudd JA et al 63:S-195
Horber FF (abst) 1428
Hori C *See* Hiraoka M et al 811
Hori M *See* Moriyama T et al 63:S-232
Hori Y *See* Wada T et al 63:S-182
Horio M *See* Moriyama T et al 63:S-232
Hörl WH *See* Cohen G et al 62:S-79
Hörl WH *See* Födinger M et al 517
Hoshaw MJ *See* Kempson SA et al 1332
Hospital General (abst) 1153
Hostetter TH *See* Ibrahim HN et al 63:S-115
Howe P (abst) 274
Howie AJ (abst) 276, 1125
Hsu CH, Patel SR: Uremic toxins and vitamin D metabolism 62:S-65
Hsu CH *See* Patel SR et al 39
Hsu CH *See* Patel SR et al 79
Hsu CH *See* Smet RD et al 62:S-8
Hsu FW, Tsao T, Rabkin R: The IGF-I axis in kidney and skeletal muscle of potassium deficient rats 363
Huang XR *See* Kitching AR et al 52
Huber P (abst) 1423
Huber T *See* Henger A et al 687
Huber-Lang M *See* Pavenstädt H et al 157
Hudson BG *See* Mott JD et al 1302
Hudson JK *See* Mott JD et al 1302
Hügel U *See* Klaus G et al 45
Hughes J (abst) 1116
Hugo C *See* Shankland SJ et al 404
Huisman RM (abst) 562

Hulter HN (abst) 1429
Hulton SA (abst) 275
Hunter M (abst) 1126, 1126
Hurtado I (abst) 1156
Hutchison AJ (abst) 1133, 1134
Huwiler A, Briner VA, Fabbro D, Pfeilschifter J: Feedback regulation of extracellular ATP-stimulated phosphoinositide hydrolysis by protein kinase C-α in bovine glomerular endothelial cells 329

I
Ibeas J (abst) 1159
Ibels LS, Gyory AZ, Caterson RJ, Pollock CA, Mahony JF, Waugh DA, Roger SD, Coulshed S: Primary IgA nephropathy: Natural history and factors of importance in the progression of renal impairment .. 61:S-67
Ibrahim HN, Rosenberg ME, Greene EL, Kren S, Hostetter TH: Aldosterone is a major factor in the progression of renal disease 63:S-115
Ibrik O (abst) 1142
Ichikawa I *See* Nishimura H et al 345
Ichikawa I *See* Okubo S et al 63:S-7
Igarashi T *See* Akuta N et al 911
Igarashi Y *See* Zager RA et al 60
Iglesias E (abst) 1135, 1135, 1141, 1141, 1153, 1160
Ihm C-G: Monocyte chemotactic peptide-1 in diabetic nephropathy 60:S-20
Iimura O, Vrtovsnik F, Terzi F, Friedlander G: HMG CoA reductase inhibitors induce apoptosis in mouse proximal tubular cells in primary culture 962
Ikemiya Y *See* Iseki K et al 63:S-169
Ikizler TA, Schulman G: Adequacy of dialysis 62:S-96
Ikizler TA *See* May RE et al 1656
Iles-Smith H *See* Stein A et al 1089
Imai E *See* Isaka Y et al 60:S-100
Imai E *See* Moriyama T et al 63:S-232
Imanishi M, Yoshioka K, Okumura M, Konishi Y, Tanaka S, Fujii S, Kimura G: Mechanism of decreased albuminuria caused by angiotensin converting enzyme inhibitor in early diabetic nephropathy 63:S-198
Imura Y *See* Noda M et al 63:S-136
Inagami T *See* Obata J- et al 63:S-229
Inchaustegui L (abst) 1159
Inchaustegui L (abst) 1140
Ingelfinger J *See* Agodoa L et al 63:S-144
Ingelmo A (abst) 1135, 1135
Ingram AJ, Scholey JW: Protooncogene expression and diabetic kidney injury 60:S-70
Inishi Y, Katoh T, Okuda T, Yamaguchi T, Kurokawa K: Modulation of renal hemodynamics by IGF-1 is absent in spontaneously hypertensive rats 165
Inokuchi S *See* Kimura K et al 63:S-201
Inoue I *See* Loghman-Adham M et al 229
Inoue S, Kuroiwa M, Ohashi K, Hara M, Kisilevsky R: Ultrastructural organization of hemodialysis-associated β_2-microglobulin amyloid fibrils 1543
Isaka Y, Akagi Y, Ando Y, Imai E: Application of gene therapy to diabetic nephropathy 60:S-100
Isamat C (abst) 1142
Ise M *See* Miyazaki T et al 62:S-15
Ise M *See* Miyazaki T et al 63:S-211
Iseki K, Ikemiya Y, Fukiyama K: Predictors of end-stage renal disease and body mass index in a screened cohort 63:S-169
Ishihara Y *See* Hiraoka M et al 811
Ishii H *See* King GL et al 60:S-77
Ishikawa S-, Saito T, Fujita N, Sasaki S, Marumo F, Saito T: Expression and subcellular localization of water channel aquaporin-2 in conscious rats 61:S-6
Isono M *See* Haneda M et al 60:S-66
Isono M *See* Kikkawa R et al 62:S-39
Issaq E *See* Groshar D et al 817
Isshiki K *See* Kikkawa R et al 62:S-39
Ito S, Amin J, Ren Y, Arima S, Abe K, Carretero OA: Heterogeneity of angiotensin action in renal circulation 63:S-128
Ito S *See* Endo Y et al 63:S-205
Ito Y *See* Miyazaki T et al 63:S-211
Itoh N *See* Ozaki K et al 694
Iturralde E (abst) 1145
Iwasaki Y *See* Shimizu T et al 63:S-239
Iwata M *See* Zager RA et al 60

J
Jabari N (abst) 1150
Jabari NS (abst) 1148
Jabary NS (abst) 1150
Jaber BL *See* Cendoroglo M et al 1626
Jaccard A (abst) 862
Jacob AD, Elkins N, Reiss OK, Chan L, Shapiro JI: Effects of acetate on energy metabolism and function in the isolated perfused rat heart 755
Jacob HJ (abst) 566
Jacobs C: Current trends in dialysis therapy 62:S-93
Jacobsen P *See* Hansen HP et al 63:S-49
Jaeger Ph (abst) 1426, 1428, 1429
Jaimes EA *See* del Castillo D et al 460
James AF (abst) 277, 1126
James G *See* Stein A et al 1089
Janin G *See* Locatelli F et al 63:S-63
Jann K (abst) 563
Janssen MJFM (abst) 567
Jarava O (abst) 1147
Jardine A (abst) 1133
Jardine AG (abst) 1118
Jayne DRW (abst) 272, 1130
Jeffers BW, Estacio RO, Raynolds MV, Schrier RW: Angiotensin-converting enzyme gene polymorphism in non-insulin dependent diabetes mellitus and its relationship with diabetic nephropathy 473
Jeffery S (abst) 1122
Jenner S (abst) 1120
Jensen BL, Kurtz A: Differential regulation of renal cyclooxygenase mRNA by dietary salt intake 1242
Jensen BR *See* Hansen HP et al 63:S-49
Jerums G, Panagiotopoulos S, Tsalamandris C, Allen TJ, Gilbert RE, Comper WD: Why is proteinuria such an important risk factor for progression in clinical trials? . 63:S-87
Jimenez I (abst) 1145
Jinde K *See* Suzuki D et al 111
Joannidis M, Cantley LG, Spokes K, Stuart-Tilley AK, Alper SL, Epstein FH: Modulation of c-*fos* and *egr*-1 expression in the isolated perfused kidney by agents that alter tubular work 130
Jofre R (abst) 1142, 1145, 1146, 1146, 1146, 1152
Johnson DW, Saunders HJ, Brew BK, Ganesan A, Baxter RC, Poronnik P, Cook DI, Györ AZ, Field MJ, Pollock CA: Human renal fibroblasts modulate proximal tubule cell growth and transport via the IGF-I axis 1486

Johnson MH *See* Maxwell PH et al. 715
Johnson RJ: Cytokines, growth factors, and renal injury: Where do we go now? 63:S-2
Johnson RJ, Schreiner GF: Hypothesis: the role of acquired tubulointerstitial disease in the pathogenesis of salt-dependent hypertension 1169
Johnson RJ *See* Nangaku M et al 182
Johnson RJ *See* Nangaku M et al 1570
Johnson RJ *See* Shankland SJ et al 404
Johnson RW (abst) 276
Johnson TS (abst) 279
Johnstone J *See* Stein A et al 1089
Joles JA (abst) 564
Joles JA, Willekes-Koolschijn N, Koomans HA: Hypoalbuminemia causes high blood viscosity by increasing red cell lysophosphatidylcholine 761
Jones CH (abst) 1120
Jones MC (abst) 1132
Jones R (abst) 1426
Jones SJ (abst) 263
Jones V (abst) 1124
Jougasaki M *See* Chini EN et al 917
Joyeux V (abst) 864
Jr. RJK *See* García E et al 648
Juárez GF (abst) 1147, 1158, 1160
Juchem C *See* Vester U et al 478
Julian BA *See* Tomana M et al 509
Junco E (abst) 1140, 1145, 1148, 1152
Jungers P, Chauveau D: Pregnancy in renal disease 871
Jussila L (abst) 263

K

Kaatee R (abst) 565
Källskog O *See* Melin J et al 985
Källskog V *See* Metry G et al 1635
Kalra PA (abst) 267, 271, 272
Kamanna VS *See* Ha H et al 60:S-54
Kaname S *See* Wada T et al 63:S-182
Kang DG *See* Choi KC et al 60:S-23
Kang MJ *See* Park SK et al 706
Kanwar YS, Carone FA, Kumar A, Wada J, Ota K, Wallner EI: Role of extracellular matrix, growth factors and proto-oncogenes in metanephric development 589
Kanwar YS *See* Griffin MD et al 1196
Kanwar YS *See* Kumar A et al 620
Kapasi A *See* Mattana J et al 1478
Kapoian T, Steward CA, Sherman RA: Validation of a revised slow-stop flow recirculation method (Technical Note) 839
Karasawa R *See* Nishi S et al 63:S-177
Karasawa R *See* Ueno M et al 63:S-191
Karashima S *See* Nakazato H et al 895
Kardorff R *See* Vester U et al 478
Kari JA, Donald AE, Vallance DT, Bruckdorfer KR, Leone A, Mullen MJ, Bunce T, Dorado B, Deanfield JE, Rees L: Physiology and biochemistry of endothelial function in children with chronic renal failure 468
Karkar AM (abst) 1117
Karkar AM, Rees A: Influence of endotoxin contamination on anti-GBM antibody induced glomerular injury in rats (Technical Note) 1759
Karkar AM, Smith J, Tam FWK, Pusey CD, Rees AJ: Abrogation of glomerular injury in nephrotoxic nephritis by continuous infusion of interleukin-6 1313
Karkar AM *See* Tam FWK et al 1224
Kashi H (abst) 276, 276
Kasiske B *See* Grimm RH Jr. et al 63:S-10
Kasiske BL: Clinical correlates to chronic renal allograft rejection 63:S-71
Kasiske BL *See* Moore RR Jr. et al 240
Kasiske BL *See* O'Donnell MP et al 63:S-218
Kasuga K *See* Hiraoka M et al 811
Kato S *See* Mackenzie HS et al 63:S-140
Katoh T *See* Inishi Y et al 165
Katoh T *See* Wada T et al 63:S-182
Katz A *See* Nagler A et al 1561
Kaur D (abst) 265
Kaushal GP, Ueda N, Shah SV: RAPID COMMUNICATION: Role of caspases (ICE/CED 3 proteases) in DNA damage and cell death in response to a mitochondrial inhibitor, antimycin A 438
Kavanagh D (abst) 1133
Kawachi H *See* Nakamura T et al 63:S-226
Kawada N *See* Moriyama T et al 63:S-232
Kawagishi T *See* Nishizawa Y et al 62:S-90
Kawaguchi Y, Hasegawa T, Nakayama M, Kubo H, Shigematu T: Issues affecting the longevity of the continuous peritoneal dialysis therapy 62:S-105
Kawamura T *See* Ozaki K et al 694
Kawano T *See* Nakazato H et al 895
Kawashima S *See* Ueno M et al 63:S-191
Kazi JI (abst) 1120
Keane W *See* Agodoa L et al 63:S-144
Keane WF, Brenner BM, Kurokawa K: Introduction . . . 63:S-1
Keane WF *See* Grimm RH Jr. et al 63:S-10
Keane WF *See* Oda H et al 62:S-36
Keane WF *See* O'Donnell MP et al 63:S-218
Kee N, McTavish AJ, Papillon J, Cybulsky AV: Receptor protein tyrosine kinases in perinatal developing rat kidney 309
Keller GA *See* Yap J et al 1216
Kelley VR *See* Wada T et al 934
Kelly CJ *See* Pham K et al 725
Kelly-Spratt KS *See* Bates CM et al 674
Kemp GJ (abst) 266
Kempson SA, Hoshaw MJ, Hinesley RS, McAteer JA: Hyperosmotic stress up-regulates amino acid transport in vascular endothelial cells 1332
Kendall R (abst) 274
Kendall S (abst) 269
Keogh A (abst) 1129
Kerr PG *See* Argilés A et al 530
Keshaviah P *See* HEMO Study Group et al 1395
Kessler H *See* Romanov V et al 93
Khalifah RG *See* Mott JD et al 1302
Khan I (abst) 1117
Khan IH (abst) 1127
Kiernan L (abst) 269
Kihara I, Tsuchida S, Yaoita E, Yamamoto T, Hara M, Yanagihara T, Takada T: Podocyte detachment and epithelial cell reaction in focal segmental glomerulosclerosis with cellular variants. 63:S-171
Kikkawa R, Togawa M, Isono M, Isshiki K, Haneda M: Mechanism of the progression of diabetic nephropathy to renal failure 62:S-39
Kikkawa R *See* Haneda M et al 60:S-66
Killen PD *See* Lee S-K et al 1000
Kim J *See* Lee HB et al 60:S-60
Kim JH *See* Lee HB et al 60:S-60

Kim KH *See* Ha H et al 60:S-54
Kim NH *See* Choi KC et al 60:S-23
Kim SI *See* Lee HB et al 60:S-60
Kim SW *See* Choi KC et al 60:S-23
Kim W *See* Park SK et al 706
Kimberly RP *See* Haseley LA et al 1375
Kimoto M *See* Tojo A et al 1593
Kimura G *See* Imanishi M et al 63:S-198
Kimura H *See* Gejyo F et al 62:S-75
Kimura H *See* Nakamura T et al 63:S-226
Kimura K, Inokuchi S, Sugaya T, Suzuki N, Yoneda H, Shirato I, Mise N, Oba S, Miyashita K, Tojo A, Hirata Y, Goto A, Sakai T, Murakami K, Omata M: Location and action of angiotensin II type 1 receptor in the renal microcirculation 63:S-201
Kimura K *See* Tojo A et al 1593
Kimura S *See* Nakao A et al 63:S-236
King A (abst) 268
King GL, Ishii H, Koya D: Diabetic vascular dysfunctions: A model of excessive activation of protein kinase C 60:S-77
Kingswood JC (abst) 268, 270, 1119
Kinoshita H, Fujimoto S, Nakazato M, Yokota N, Date Y, Yamaguchi H, Hisanaga S, Eto T: Urine and plasma levels of uroguanylin and its molecular forms in renal diseases 1028
Kinugasa E *See* Akizawa T et al 62:S-72
Kirchner H *See* Kreft B et al 212
Kiroycheva M (abst) 863
Kirschenbaum MA *See* Ha H et al 60:S-54
Kisilevsky R *See* Inoue S et al 1543
Kiss D (abst) 1425
Kitamura H (abst) 863
Kitamura M, Fine LG: Gene transfer into the kidney: Promises and limitations 60:S-86
Kitaoka M *See* Fukagawa M et al 62:S-60
Kitching AR, Tipping PG, Huang XR, Mutch DA, Holdsworth SR: Interleukin-4 and interleukin-10 attenuate established crescentic glomerulonephritis in mice 52
Klaassen RJL (abst) 562
Klahr S: Remarks on behalf of the new editorial team of *Kidney International* 1
Klahr S, Morrissey JJ: Comparative study of ACE inhibitors and angiotensin II receptor antagonists in interstitial scarring 63:S-111
Klahr S *See* Morrissey JJ et al 926
Klaus G, May T, Hügel U, von Eichel B, Rodriguez J, Fernandez P, Reichrath J, Ritz E, Mehls O: Parathyroid hormone prevents $1,25(OH)_2D_3$ induced down-regulation of the vitamin D receptor in growth plate chondrocytes *in vitro* 45
Kleinknecht C *See* Laouari D et al 1550
Klok PA (abst) 562
Kloppenburg WD (abst) 562
Kloth S *See* Strehl R et al 1469
Klouche M *See* Kreft B et al 212
Kluppel AC (abst) 561
Kluppel ACA *See* Haas M et al 1693
Kluppel CA *See* de Vries PAM et al 244
Knights S *See* May RE et al 1656
Knochel JP *See* Better O et al 886
Knoers NAVM (abst) 560
Knoflach A (abst) 1428
Knox FG *See* de Toledo FGS et al 152
Kobayashi K- *See* Segawa C et al 1054
Koch B *See* Niemir ZI et al 393
Koch K-M *See* Schwalbe S et al 1077
Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M, Sakai S, Yuasa Y, Hirasawa Y, Nishi T: Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients 1096
Koehl N *See* Niemir ZI et al 393
Koenig RJ *See* Patel SR et al 39
Koenig RJ *See* Patel SR et al 79
Koh GY *See* Park SK et al 706
Koike J, Ujiie K, Owada A, Shiigai T, Matsui N, Nonoguchi H, Tomita K, Marumo F: Quasi-steadiness approximation for the two-compartment solute kinetic model 821
Koike J *See* Owada A et al 63:S-188
Koji T *See* Suzuki D et al 111
Kokot F, Więcek A: Evidence that the anemia of renal failure participates in overall uremic toxicity 62:S-83
Kon V *See* Nishimura H et al 345
Kondo S *See* Becker BN et al 87
Konecny K *See* Tomana M et al 509
König P *See* Trenkwalder E et al 1685
Konishi Y *See* Imanishi M et al 63:S-198
Koomans EA *See* Bosman PJ et al 1084
Koomans HA (abst) 560, 564, 565, 567
Koomans HA *See* Joles JA et al 761
Kopple JD, Gao X-L, Pei-Yuan D: Dietary protein, urea nitrogen appearance and total nitrogen appearance in chronic renal failure and CAPD patients 486
Kopple JD *See* Chazot C et al 1663
Kopple JD *See* Ding H et al 62:S-45
Kopple JD *See* Modification of Diet in Renal Disease Study Group et al 778
Korte R *See* Vester U et al 478
Kortz WJ *See* Kuruvila CK et al 61:S-89
Koya D *See* King GL et al 60:S-77
Kramer HJ *See* Meyer-Lehnert H et al 61:S-27
Krämer-Guth A *See* Wanner C et al 63:S-102
Kränzlin B *See* Obermüller N et al 1584
Krapf R (abst) 1429
Kreft B, Klouche M, Kreft R, Kirchner H, Sack K: Low efficiency of active immunization against diptheria in chronic hemodialysis patients 212
Kreft R *See* Kreft B et al 212
Kren S *See* Ibrahim HN et al 63:S-115
Kribben A, Anlauf M, Distler A, Gärtner H, Holzgreve H, Michaelis J, Röcker L, Schäfers R, Philipp U, Wellek S, Philipp T, HANE Trial Research Group: Hydrochlorothiazide, atenolol, nitrendipine, and enalapril in antihypertensive treatment. Influence on LVH, proteinuria and metabolic parameters 61:S-74
Kriz W *See* Obermüller N et al 1584
Kronenberg F *See* Trenkwalder E et al 1685
Kubara C (abst) 279
Kubo H *See* Kawaguchi Y et al 62:S-105
Kubota E *See* Murakami M et al 63:S-132
Kudo LH *See* Rouch AJ et al 1351
Kumar A (abst) 1131
Kumar A, Ota K, Wada J, Wallner EI, Charonis AS, Carone FA, Kanwar YS: Developmental regulation and partial-length cloning of tubulointerstitial nephritis antigen of murine metanephros 620
Kumar A *See* Kanwar YS et al 589

Kumar R *See* Griffin MD et al 1196
Kumar S (abst) 266
Kumar V *See* Zajicek H et al 61:S-32
Kumararatne DS (abst) 268
Kuncio GS *See* Yee J et al 120
Kurihara S *See* Akiba T et al 62:S-69
Kuroda T *See* Shimizu T et al 63:S-239
Kuroiwa M *See* Inoue S et al 1543
Kurokawa K *See* Akizawa T et al 62:S-72
Kurokawa K *See* Fukagawa M et al 62:S-60
Kurokawa K *See* Inishi Y et al 165
Kurokawa K *See* Keane WF et al 63:S-1
Kurokawa K *See* Nakao A et al 63:S-236
Kurokawa K *See* Nangaku M et al 182
Kurokawa K *See* Nangaku M et al 1570
Kurokawa K *See* Shimizu T et al 63:S-239
Kurokawa K *See* Wada T et al 63:S-182
Kuroyanagi R *See* Obata J- et al 63:S-229
Kurtz A *See* Jensen BL et al 1242
Kuruvila CK, McCalmon RT, Schreiber DP, Kortz WJ: Total lymphoid irradiation for pretransplant immunosuppression: Nine year follow-up 61:S-89
Kwan JTC (abst) 1132
Kyossev ZN, Reeves WB: N-glycosylation is not essential for enzyme activity of 11β-hydroxysteroid dehydrogenase type 2 682

L

Labeeuw M (abst) 863
Lacoste M *See* Daïkha-Dahmane F et al 21
Lafferty ME (abst) 1132
Lagarde C (abst) 862, 864
Lai L-W *See* Lien Y-HH et al 61:S-85
Lai Y-H *See* Chen H-C et al 1390
Laidlaw S *See* Chazot C et al 1663
Laing I (abst) 271
Lallemand D *See* Vrtovsnik F et al 1016
Lalouel J-M *See* Loghman-Adham M et al 229
Lam FT (abst) 276, 276
LaMarre I *See* Michel O et al 1532
Lambert J (abst) 567
Lam-Po-Tang MK (abst) 266
Lampreabe I (abst) 1137, 1137, 1157, 1158, 1159, 1160
Lan HY *See* Wu LL et al 63:S-221
Lang I (abst) 267
Langley RC Jr. *See* Fishbane S et al 217
Lanuza M (abst) 1144
Laouari D, Friedlander G, Burtin M, Silve C, Dechaux M, Garabedian M, Kleinknecht C: Subtotal nephrectomy alters tubular function: effect of phosphorus restriction 1550
Lardet G *See* Gaulier J-M et al 1700
Lario S (abst) 1136
Larsson E *See* Melin J et al 985
Laruelle E (abst) 864
Lass P (abst) 1128
Lasunción MA (abst) 1148
Lathrop L *See* Bostom AG et al 10
Lavau M *See* Michel O et al 1532
Laviades C (abst) 1152
Lavignac C (abst) 862
Lawrence P (abst) 1117
Lazarou L (abst) 1122
Lazarus JM *See* Chertow GM et al 1617
Le Meur Y (abst) 862, 862, 862
Le Pogamp P (abst) 864
Leblanc M *See* Argilés A et al 530
Ledoux S, Leroy C, Siegfried G, Prie D, Moullier P, Friedlander G: Overexpression of ecto-5′-nucleotidase promotes P-glycoprotein expression in renal epithelial cells 953
Lee DBN: Cyclosporine and the renin-angiotensin axis (Nephrology Forum) 248
Lee EY *See* Lee HB et al 60:S-60
Lee HB, Cha MK, Song KI, Kim JH, Lee EY, Kim SI, Kim J, Yoo MH: Pathogenic role of advanced glycosylation end products in diabetic nephropathy .. 60:S-60
Lee HB, Ha H: Introduction 60:S-1
Lee J- *See* Choi KC et al 60:S-23
Lee K-W *See* Mackenzie HS et al 63:S-140
Lee S-K, Goyal M, de Miguel M, Thomas P, Wharram B, Dysko R, Phan S, Killen PD, Wiggns RC: Renal biopsy collagen I mRNA predicts scarring in rabbit anti-GBM disease: comparison with conventional measures of function and histology 1000
Lemkes HHPJ (abst) 560
Lemmink HH (abst) 560
Lemoine RE (abst) 1426
Leone A *See* Kari JA et al 468
Lepert JC (abst) 865
Lerma J (abst) 1141, 1141
Lerma JL (abst) 1145, 1151, 1155, 1160
Lerna JL (abst) 1156
Leroux-Robert C (abst) 862, 862
Leroux-Robert Claude (abst) 862
Leroy C *See* Ledoux S et al 953
Leski M (abst) 1426
Levey AS *See* Modification of Diet in Renal Disease Study Group et al 778
Levi M *See* Zajicek H et al 61:S-32
Levin NW *See* HEMO Study Group et al 1395
Lew NL *See* Chertow GM et al 1617
Lew RA *See* Dean R et al 1261
Lewin E, Wang W, Olgaard K: Reversibility of experimental secondary hyperparathyroidism 1232
Lewis MA (abst) 265
Lewko B, Wendt U, Szczepanska-Konkel M, Stepinski J, Drewnowska K, Angielski S: Inhibition of endogenous nitric oxide synthesis activates particulate guanylyl cyclase in the rat renal glomeruli 654
Li FK (abst) 1127
Liaño F (abst) . 1139, 1139, 1147, 1152, 1158, 1158, 1158, 1160
Liaño FF (abst) 1149
Liébana A (abst) 1144, 1152
Liebana Cañada A (abst) 1146
Lieberthal W: Biology of acute renal failure: therapeutic implications (Nephrology Forum) 1102
Lien Y-HH, Lai L-W: Gene therapy for renal diseases. 61:S-85
Lieske JC, Norris R, Swift H, Toback FG: Adhesion, internalization and metabolism of calcium oxalate monohydrate crystals by renal epithelial cells 1291
Lightstone L (abst) 1125
Ligtenberg G (abst) 560, 567
Linas SL: Role of receptor mediated endocytosis in proximal tubule epithelial function 61:S-18
Linas SL *See* Berl T et al 61:S-1
Lindahl U (abst) 563
Lindgren PG *See* Metry G et al 1635
Lindholm B *See* Wang T et al 1068
Lindholm B *See* Wang T et al 1609

Ling H *See* Edelstein CL et al. 1271
Lipkin GW, Dawnay ABS, Harwood SM, Cattell WR, Raine AEG: Enhanced natriuretic response to neutral endopeptidase inhibition in patients with moderate chronic renal failure. 792
Lippoldt A *See* Gross V et al 1364
Lippuner K (abst) 1428
Liu Y (abst). 1116
Llado I (abst) 1142
Llamas F (abst) 1143, 1154
Lloyd SE *See* Akuta N et al 911
Locatelli F, Carbarns IRI, Maschio G, Mann JFE, Ponticelli C, Ritz E, Alberti D, Janin G, Zucchelli P, Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study: Long-term progression of chronic renal insufficiency in the AIPRI Extension Study. 63:S-63
Lockwood CM (abst) 272, 1116, 1124
Loetcher P (abst). 1123
Löffel M (abst) 1425
Löffler B-M (abst). 1423
Loghman-Adham M, Rohrwasser A, Helin C, Zhang S, Terreros D, Inoue I, Lalouel J-M: A conditionally immortalized cell line from murine proximal tubule (Technical Note) 229
Logroño JM (abst). 1152
Lombard ML (abst). 864
Longlands M (abst). 278
Lopes de Faria JB, Zoukhri D, Lorenzi M: Mesangial cell abnormalities in spontaneously hypertensive rats before the onset of hypertension 387
López A (abst). 1141, 1141, 1153, 1160
López JM (abst). 1145, 1146, 1146, 1146, 1152
López R (abst) 1144
López Rubio E (abst) 1143
López-Alburquerque T (abst) 1145
López-Brea M (abst) 1145
Lopez-Gomez JM (abst) 1142
López-Menchero R (abst). 1144
López-Novoa JM (abst). 1135, 1139, 1139, 1140
López-Pedret J (abst) 1147
Lopez-Vidaur I (abst) 1137
Lorente D (abst) 1137
Lorenzi M *See* Lopes de Faria JB et al. 387
Lorenzo I (abst). 1140, 1159
Lorho R *See* Argilés A et al 530
Lote CJ (abst) 1125
Lottermoser J *See* Grupp C et al. 1279
Lotti R *See* Pontremoli R et al 63:S-163
Loughna S (abst). 263
Loughrey B (abst) 1124
Loughrey CM (abst) 1133
Louisot P (abst). 863
Lowe PA (abst). 1123
Lowrie EG *See* Chertow GM et al 1617
Lucchesi A *See* Donadio C et al 63:S-166
Luft. FC *See* Gross V et al 1364
Lupia E *See* Striker GE et al. 63:S-120
Luque M (abst) 1136
Lutterman JA (abst) 559
Lwaleed BA (abst) 271

M

Ma L *See* Chertow GM et al. 1617
Macdougall IC (abst). 271
MacDowall P (abst). 267
Macdowell P (abst) 271, 272
Mackenzie HS, Ots M, Ziai F, Lee K-W, Kato S, Brenner BM: Angiotensin receptor antagonists in experimental models of chronic renal failure. 63:S-140
Mackenzie HS *See* Brenner BM et al 63:S-124
MacKenzie HS *See* Chertow GM et al 63:S-84
Mackin P (abst). 270
Mackness MI (abst). 1132
MacLeod A (abst). 1117
MacLeod AM (abst) 1127
Maddox DA, Barnes WD, Gennari FJ: Effect of acute increases in filtered HCO_3^- on renal hydrogen transporters: II. H^+-ATPase 446
Maesaka JK *See* Fishbane S et al 217
Mahiout A (abst). 265
Mahony JF *See* Ibels LS et al 61:S-67
Maioli M *See* Brocco E et al. 63:S-40
Malagolini N, Cavallone D, Serafini-Cessi F: Intracellular transport, cell-surface exposure and release of recombinant Tamm-Horsfall glycoprotein . . . 1340
Malcolm SM (abst) 1124
Mali WPThM (abst) 565
Malik A (abst). 1125
Mamtora H (abst) 267, 271, 272
Man in 't Veld AJ (abst). 562
Mandet C *See* Michel O et al 1532
Mann JFE *See* Locatelli F et al. 63:S-63
Mann JFE *See* van Hout BA et al. 63:S-159
Mannhalter C *See* Födinger M et al 517
Marcén R (abst) 1148, 1149, 1152
Margolin SB *See* Shimizu T et al. 63:S-239
Marigliano N (abst). 1138
Marín R (abst) 1136, 1136, 1142
Maroni BJ *See* Modification of Diet in Renal Disease Study Group et al 778
Marshall SM (abst) 270
Marti HP (abst) 1425, 1428
Martí V (abst) 1147
Martin A (abst). 863
Martin B (abst) 1145, 1151, 1151, 1155, 1156
Martin D (abst). 280
Martin J (abst). 1121, 1150
Martin J *See* Phillips AO et al. 973
Martin M (abst). 1151, 1151
Martín Mateo MC (abst). 1140
Martin P-Y *See* Ginès P et al 61:S-77
Martin P-Y *See* Weigert AL et al 61:S-41
Martina B (abst) 1423
Martinez A (abst) 1137
Martínez F (abst). 1154
Martinez I (abst). 1122
Martinez MP (abst) 1137, 1137, 1156, 1157, 1160
Martínez T (abst) 1157
Martínez V *See* García E et al 648
Martínez-Maldonado M *See* Challú A et al. 583
Martinez-Rodrigo J (abst). 1154
Martínez-Salgado C (abst). 1139
Martinoli C *See* Pontremoli R et al. 63:S-163
Martín-Vasallo P (abst). 1135
Marumo F *See* Akiba T et al. 62:S-69
Marumo F *See* Ishikawa S- et al 61:S-6
Marumo F *See* Koike J et al 821
Maruyama Y *See* Ueno M et al. 63:S-191
Marzo L (abst). 1156, 1157

Maschio G *See* Locatelli F et al 63:S-63
Mason JC (abst) 1120
Mason PJ (abst) 265
Massari PU: Disorders of bone and mineral metabolism after renal transplantation (Nephrology Forum) 1412
Massry SG, Smogorzewski M: Parathyroid hormone, chronic renal failure and the liver 62:S-5
Massry SG *See* Niwa T et al 62:S-1
Massry SG *See* Smogorzewski M et al 62:S-12
Masurier C *See* Michel O et al 1532
Matalone M *See* Ruggenenti P et al 63:S-54
Mathieson PW (abst) 278
Matias B *See* Chazot C et al 1663
Matos V (abst) 1425
Matousovic K *See* Tomana M et al 509
Matsell DG, Bennett T, Han X, Budreau AM, Chesney RW: Regulation of the taurine transporter gene in the S3 segment of the proximal tubule 748
Matsuda H *See* Murakami M et al 63:S-132
Matsuda I *See* Nakazato H et al 895
Matsuda I *See* Segawa C et al 1054
Matsui N *See* Koike J et al 821
Matsuo K, Nakamoto M, Yasunaga C, Goya T, Sugimachi K: Dialysis-related amyloidosis of the tongue in long-term hemodialysis patients 832
Matsuo T *See* Noda M et al 63:S-136
Matsusaka T *See* Nishimura H et al 345
Matsuyama T *See* Akuta N et al 911
Mattana J, Effiong C, Kapasi A, Singhal PC: Leukocyte-polytetrafluoroethylene interaction enhances proliferation of vascular smooth muscle cells via tumor necrosis factor-α secretion 1478
Mauer M, Fioretto P: Diabetic nephropathy as a model for the use of renal structural endpoints in clinical trials 63:S-155
Mauer M *See* Agodoa L et al 63:S-144
Mauer M *See* Brocco E et al 63:S-40
Mauron H (abst) 1429
Maxwell AP (abst) 1124, 1132, 1133
Maxwell PH, Ferguson DJP, Nicholls LG, Johnson MH, Ratcliffe PJ: The interstitial response to renal injury: Fibroblast-like cells show phenotypic changes and have reduced potential for erythropoietin gene expression ... 715
Maxwelt AP (abst) 1119
May RE, Himmelfarb J, Yenicesu M, Knights S, Ikizler TA, Schulman G, Hernanz-Schulman M, Shyr Y, Hakim RM: Predictive measures of vascular access thrombosis: A prospective study 1656
May T *See* Klaus G et al 45
Mayer G *See* Barnas U et al 63:S-78
Mayer G *See* Borchhardt K et al 1622
Mayer G *See* van der Kleij FGH et al 63:S-23
McArley A (abst) 275
McAteer JA *See* Kempson SA et al 1332
McCalmon RT *See* Kuruvila CK et al 61:S-89
McCausland J *See* Butkus A et al 628
McConnell M (abst) 269
McDonald S *See* Roy-Chaudhury P et al 103
McDonnell J *See* van Hout BA et al 63:S-159
McEwan J (abst) 269
McGraw ME (abst) 278
McGregor E (abst) 1132
McIntyre C (abst) 1125, 1134
McKnight JA *See* De'Oliveira JM et al 771
McLay JS *See* Chatterjee PK et al 699
McMahon AC (abst) 1118, 1119
McMaster D (abst) 1119
McNamee P (abst) 1132
McNulty CAM (abst) 266
McQuinn C *See* Striker GE et al 63:S-120
McTavish AJ *See* Kee N et al 309
McVey J (abst) 277
Medcalf JF, Walls J: New frontiers in continuous ambulatory peritoneal dialysis 62:S-108
Mehls O *See* Haffner D et al 802
Mehls O *See* Klaus G et al 45
Meijer DKF *See* Haas M et al 1693
Melhem M *See* Craven PA et al 60:S-46
Melin J, Hellberg O, Akyürek LM, Källskog O, Larsson E, Fellström BC: Ischemia causes rapidly progressive nephropathy in the diabetic rat 985
Mello-Aires M *See* Barreto-Chaves MLM et al 1035
Mendelsohn FAO *See* Dean R et al 1261
Mendiluce A (abst) 1148, 1150, 1150
Menzel D *See* Gonzalez CB et al 1206
Merayo C (abst) 1150
Mercer TH (abst) 1128
Merenmies JM *See* Bates CM et al 674
Merkx GFM (abst) 560
Merrill D *See* Modification of Diet in Renal Disease Study Group et al 778
Merville P (abst) 865
Mestecky J *See* Tomana M et al 509
Metry G, Wegenius G, Wilkström B, Källskog V, Hansell P, Lindgren PG, Hedenström H, Danielson BG: Lung density for assessment of hydration status in hemodialysis patients using the computed tomographic densitometry technique 1635
Meyer TW *See* Nelson RG et al 63:S-45
Meyer-Lehnert H, Bokemeyer D, Friedrichs U, Bäcker A, Kramer HJ: Cellular mechanisms of cyclosporine A-associated side-effects: Role of endothelin 61:S-27
Miao H-Q *See* Nagler A et al 1561
Michael-Grossman AR *See* Haseley LA et al 1375
Michaelis J *See* Kribben A et al 61:S-74
Michel O, Heudes D, LaMarre I, Masurier C, Lavau M, Bariety J, Chevalier J, Belair M-F, Mandet C: Reduction of insulin and triglycerides delays glomerulosclerosis in obese Zucker rats 1532
Michel R (abst) 1429
Miguel A (abst) 1144, 1144
Mihatsch MJ (abst) 1423
Mikhail A (abst) 1133
Milán JA (abst) 1147
Milford DV (abst) 275, 279
Milford EL *See* Chertow GM et al 63:S-84
Millar CGM (abst) 270, 1118
Millar DJ (abst) 274
Miñarro A (abst) 1156
Minguela I (abst) 1159, 1160
Minguela JI (abst) 1137, 1140
Minuth WW *See* Strehl R et al 1469
Mion CM *See* Argilés A et al 530
Mion H *See* Argilés A et al 530
Mise N *See* Kimura K et al 63:S-201
Misra M (abst) 267
Mistry C (abst) 1129, 1129
Mistry SK *See* Chatterjee PK et al 699
Mitch W *See* Agodoa L et al 63:S-144
Miyakawa Y *See* Nishi S et al 63:S-177

Miyashita K *See* Kimura K et al 63:S-201
Miyazaki M *See* Suzuki D et al 111
Miyazaki R *See* Gejyo F et al 62:S-75
Miyazaki S *See* Koda Y et al 1096
Miyazaki T, Ise M, Hirata M, Endo K, Ito Y, Seo H, Niwa T: Indoxyl sulfate stimulates renal transforming growth factor-β1 and progression of renal failure .. 63:S-211
Miyazaki T, Ise M, Seo H, Niwa T: Indoxyl sulfate increases the gene expressions of TGF-β1, TIMP-1, and pro-α1(I) collagen in uremic rat kidneys..... 62:S-15
Miyazaki T *See* Niwa T et al 62:S-23
Modesto A (abst) 865
Modification of Diet in Renal Disease Study Group , Kopple JD, Levey AS, Greene T, Chumlea WC, Gassman JJ, Hollinger DL, Maroni BJ, Merrill D, Scherch LK, Schulman G, Wang S-R, Zimmer GS: Effect of dietary protein restriction on nutritional status in the Modification of Diet in Renal Disease Study 778
Moffett P *See* Vicanek C et al..... 614
Mogensen CE *See* Poulsen PL et al 63:S-15
Moghal NE (abst)..... 275
Monge JM (abst)..... 1135
Monnens LAH (abst)..... 560, 564
Monroy A (abst) 1147
Montgomery H (abst) 269
Montinaro V *See* Schena FP et al 1439
Moolenaar F *See* Haas M et al 1693
Moore RR Jr., Hirata-Dulas CA, Kasiske BL: Use of urine specific gravity to improve screening for albuminuria (Technical Note) 240
Moorhead JF (abst)..... 1123
Moorhouse J *See* Stein A et al 1089
Morcos S *See* Ni Z et al 195
Morel D (abst)..... 261, 865
Morel P (abst)..... 1426
Moreno A (abst) 1147, 1154
Moreno Alba R (abst)..... 1147
Moreno F (abst) 1142, 1146, 1146, 1146
Moreno JA (abst) 1145
Moreno R (abst) 1156, 1157
Morera MA (abst)..... 1155
Morgan AG (abst) 265, 1127, 1131
Mori M *See* Chertow GM et al 63:S-84
Morii H *See* Nishizawa Y et al 62:S-90
Morillas C (abst)..... 1137
Morillas MJ (abst)..... 1137
Morin MP (abst)..... 864
Morinière P, Rodary-Vautier R, Fillioux-Morfaux V, Dehouck B, Esper NE, Remond A, Fournier A: Percutaneous recanalization of occlusion of central and proximal veins in chronic hemodialysis (Technical Note)..... 1406
Moritz K *See* Butkus A et al..... 628
Moriyama T, Kawada N, Akagi Y, Ando A, Horio M, Yamauchi A, Nagata K, Imai E, Hori M: TCV-116 inhibits interstitial fibrosis and HSP47 mRNA in rat obstructive nephropathy..... 63:S-232
Morris S (abst) 1133
Morris STW (abst) 1118
Morrisey K (abst) 262
Morrisey K *See* Phillips AO et al 973
Morrissey JJ, Klahr S: Rapid Communication: Enalapril decreases nuclear factor κB activation in the kidney with ureteral obstruction 926
Morrissey JJ *See* Klahr S et al..... 63:S-111
Morrissey K (abst)..... 1121
Mosconi L *See* Ruggenenti P et al 63:S-54
Moshage H (abst)..... 564
Mosig D (abst) 1430
Moskovitz B *See* Groshar D et al 817
Mosley K (abst)..... 261
Motellón JL (abst)..... 1139
Mothes D (abst)..... 863, 864
Mott JD, Khalifah RG, Nagase H, Shield CF III, Hudson JK, Hudson BG: Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility..... 1302
Mougenot B (abst) 865
Moullier P *See* Ledoux S et al..... 953
Mounier M (abst) 862
Moutabarrik A (abst) 863
Movaffaghi A (abst) 1425
MRFIT Research Group *See* Grimm RH Jr. et al 63:S-10
Muchaneta-Kubara EC (abst)..... 278
Mullen MJ *See* Kari JA et al..... 468
Müller E *See* Födinger M et al 517
Muller F *See* Daïkha-Dahmane F et al..... 21
Müller GA *See* Grupp C et al..... 1279
Müller-Esterl W *See* Dean R et al..... 1261
Mullins J (abst)..... 269
Mundel P *See* Henger A et al..... 687
Mundel P *See* Niemir ZI et al..... 393
Muñiz ML (abst)..... 1137, 1137, 1159, 1160
Muñiz R (abst)..... 1137, 1137
Muñoz de Bustillo E (abst)..... 1143, 1145, 1155
Muñoz E (abst)..... 1139
Murakami K, Tsuchiya K, Naruse M, Naruse K, Demura H, Arai J, Nihei H: Nitric oxide synthase I immunoreactivity in the macula densa of the kidney is angiotensin II dependent..... 63:S-208
Murakami K *See* Kimura K et al..... 63:S-201
Murakami M, Matsuda H, Kubota E, Wakino S, Honda M, Hayashi K, Saruta T: Role of angiotensin II generated by angiotensin converting enzyme-independent pathways in canine kidney..... 63:S-132
Murone C *See* Dean R et al 1261
Muser J (abst)..... 1425
Muso E *See* Ozaki K et al..... 694
Mutch DA *See* Kitching AR et al..... 52
Mydlík M, Derzsiová K, Žemberová E: Metabolism of vitamin B_6 and its requirement in chronic renal failure. 62:S-56
Myers BD *See* Nelson RG et al..... 63:S-45
Myers CR (abst) 276

N

Nadeau K (abst) 273
Nadeau KC *See* Chandraker A et al 1678
Nadig C (abst)..... 1428
Nagano H *See* Noda M et al 63:S-136
Nagase H *See* Mott JD et al 1302
Nagata K *See* Moriyama T et al 63:S-232
Nagler A, Katz A, Aingorn E, Miao H-Q, Condiotti R, Genina O, Pines M, Vlodavsky I: Inhibition of glomerular mesangial cell proliferation and extracellular matrix deposition by halofuginone, an inhibitor of collagen type I synthesis 1561
Nahorski S (abst)..... 1121
Naiki H *See* Gejyo F et al..... 62:S-75
Naish PF (abst) 1127, 1128

Naito T *See* Wada T et al 934
Nakagawa Y *See* Narita I et al 63:S-215
Nakakuki K *See* Gejyo F et al 62:S-75
Nakamaru T *See* Nishi S et al 63:S-177
Nakamoto M *See* Matsuo K et al 832
Nakamura T, Obata J-, Onizuka M, Kimura H, Ohno S, Yoshida Y, Kawachi H, Shimizu F: Candesartan prevents the progression of mesangioproliferative nephritis in rats 63:S-226
Nakamura T *See* Obata J- et al 63:S-229
Nakanishi I (abst) 863
Nakao A, Nosaka K, Ohishi N, Noiri E, Suzuki T, Taniguchi S, Seki G, Watanabe T, Kurokawa K, Shimizu T, Kimura S: Long-term effects of LTB_4 antagonist on lipid induced renal injury 63:S-236
Nakao M *See* Owada A et al 63:S-188
Nakayama H *See* Narita I et al 63:S-215
Nakayama M *See* Kawaguchi Y et al 62:S-105
Nakazato H, Hattori S, Furuse A, Kawano T, Karashima S, Tsuruta M, Yoshimuta J, Endo F, Matsuda I: Mutations in the CLCN5 gene in Japanese patients with familial idiopathic low-molecular-weight proteinuria 895
Nakazato M *See* Kinoshita H et al 1028
Nangaku M, Alpers CE, Pippin J, Shankland SJ, Adler S, Kurokawa K, Couser WG, Johnson RJ: A new model of renal microvascular endothelial injury 182
Nangaku M, Alpers CE, Pippin J, Shankland SJ, Kurokawa K, Adler S, Johnson RJ, Couser WG: Renal microvascular injury induced by antibody to glomerular endothelial cells is mediated by C5b-9 1570
Nangaku M *See* Shankland SJ et al 404
Narcy F *See* Daïkha-Dahmane F et al 21
Narita I, Nakayama H, Goto S, Takeda T, Sakatsume M, Saito A, Nakagawa Y, Arakawa M: Identification of genes specifically expressed in chronic and progressive glomerulosclerosis 63:S-215
Naruse K *See* Murakami K et al 63:S-208
Naruse M *See* Murakami K et al 63:S-208
Nativ O *See* Groshar D et al 817
Naves ML (abst) 1142
Navis G *See* Buter H et al 63:S-185
Navis G *See* de Vries PAM et al 244
Navis GJ (abst) 559, 561, 565
Navis GJ *See* van der Kleij FGH et al 63:S-23
Neilson EG *See* Yee J et al 120
Nelson RG, Meyer TW, Myers BD, Bennett PH: Course of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus 63:S-45
Nelson SR (abst) 266
Nemenoff RA *See* Edelstein CL et al 1271
Nemoto M *See* Shimizu T et al 63:S-239
Nephrology S (abst) 1153
Neumayer H-H *See* Budde K et al 733
Newman DJ (abst) 1123
Newman VO (abst) 268, 1117
Newstead CG (abst) 1120
Ni Z, Morcos S, Vaziri ND: Up-regulation of renal and vascular nitric oxide synthase in iron-deficiency anemia 195
Ni Z *See* Vaziri ND et al 1042
Nicholas B (abst) 279
Nicholls A (abst) 268
Nicholls DP (abst) 1119
Nicholls LG *See* Maxwell PH et al 715
Nicholson ML (abst) 1120, 1131
Nickeleit V (abst) 1429
Nickerson P (abst) 1424, 1424, 1430
Nicolson AG *See* Zhu G et al 992
Niederberger M *See* Ginès P et al 61:S-77
Nielsen FS *See* Hansen HP et al 63:S-49
Niemir ZI, Stein H, Dworacki G, Mundel P, Koehl N, Koch B, Autschbach F, Andrassy K, Ritz E, Waldherr R, Otto HF: Podocytes are the major source of IL-1α and IL-1β in human glomerulonephritides 393
Nihei H *See* Murakami K et al 63:S-208
Nilsson-Ehle P *See* Arnadottir M et al 1651
Nishi S, Ueno M, Shimada H, Karasawa R, Nakamaru T, Miyakawa Y, Arakawa M: Prognosis of Japanese membranous nephropathy patients with nephrotic syndrome 63:S-177
Nishi S *See* Koda Y et al 1096
Nishi S *See* Ueno M et al 63:S-191
Nishi T *See* Koda Y et al 1096
Nishikawa K *See* Noda M et al 63:S-136
Nishimura H, Matsusaka T, Fogo A, Kon V, Ichikawa I: A novel *in vivo* mechanism for angiotensin type 1 receptor regulation 345
Nishizawa Y, Shoji T, Kawagishi T, Morii H: Atherosclerosis in uremia: Possible roles of hyperparathyroidism and intermediate density lipoprotein accumulation 62:S-90
Nitschke R *See* Henger A et al 687
Niwa T, Nomura T, Sugiyama S, Miyazaki T, Tsukushi S, Tsutsui S: The protein metabolite hypothesis, a model for the progression of renal failure: An oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients 62:S-23
Niwa T, Ringoir S, Massry SG: Introduction 62:S-1
Niwa T *See* Miyazaki T et al 62:S-15
Niwa T *See* Miyazaki T et al 63:S-211
Nockher WA *See* Baer PC et al 1321
Noda M, Fukuda R, Matsuo T, Ohta M, Nagano H, Imura Y, Nishikawa K, Shibouta Y: Effects of candesartan cilexetil (TCV-116) and enalapril in 5/6 nephrectomized rats 63:S-136
Noiri E *See* Nakao A et al 63:S-236
Noiri E *See* Romanov V et al 93
Nomoto Y *See* Suzuki D et al 111
Nomura T *See* Niwa T et al 62:S-23
Nonoguchi H *See* Koike J et al 821
Noor MI (abst) 1126
Norfolk D (abst) 274
Noris M *See* Aiello S et al 171
Norman JT *See* Orphanides C et al 637
Norpoth M *See* Tramonti G et al 63:S-179
Norris R *See* Lieske JC et al 1291
Northridge D (abst) 1133
Nosadi R *See* Brocco E et al 63:S-40
Nosaka K *See* Nakao A et al 63:S-236
Nott CA (abst) 1119, 1122
Nouwen EJ *See* Helbert MJF et al 414
Novillo R (abst) 1138
Nundy S *See* Dash SC et al 482
Nuñez J (abst) 1148, 1150, 1150

O

Oba S *See* Kimura K et al 63:S-201
Obata J-, Nakamura T, Kuroyanagi R, Yoshida Y, Guo D-F, Inagami T: Cardesartan prevents the progression of glomerulosclerosis in genetic hypertensive rats 63:S-229

Obata J- *See* Nakamura T et al. 63:S-226
Oberbauer R *See* Borchhardt K et al 1622
Obermüller N, Kränzlin B, Verma R, Gretz N, Kriz W, Witzgall R: The renal osmotic stress induced cotransporter (ROSIT): Localization in the adult rat kidney, developmental expression and regulation after ischemic acute tubular necrosis 1584
O'Byrne V (abst). 266
O'Callaghan CA (abst) 1130
Oda H, Keane WF: Lipids in progression of renal disease 62:S-36
Oda H *See* O'Donnell MP et al. 63:S-218
O'Donaghue DJ (abst). 271, 272
O'Donnell MP, Crary GS, Oda H, Kasiske BL, Powell JR, Keane WF: Irbesartan lowers blood pressure and ameliorates renal injury in experimental non-insulin-dependent diabetes mellitus. 63:S-218
O'Donnell PJ (abst). 278
O'Donoghue DJ (abst). 267, 276
Oey PL (abst) 560, 567
Ogawa T *See* Tojo A et al. 1593
Ohashi K *See* Inoue S et al 1543
Ohishi N *See* Nakao A et al 63:S-236
Ohno S *See* Nakamura T et al. 63:S-226
Ohta M *See* Noda M et al. 63:S-136
Ohta M *See* Ozaki K et al. 694
Ohta S *See* Segawa C et al 1054
Okubo S, Ichikawa I: Role of angiotensin: Insight from gene targeting studies 63:S-7
Okuda T *See* Inishi Y et al 165
Okumura M *See* Imanishi M et al. 63:S-198
Oldroyd B (abst) 269
O'Leary DS *See* Rossi NF et al. 61:S-22
Olgaard K *See* Lewin E et al. 1232
Olivares J (abst) 1144
Olivas E (abst) 1143, 1154
Olive C (abst) 1122
Olive C, Allen AC, Harper SJ, Wicks ACB, Feehally J, Falk MC: Expression of the mucosal γδ T cell receptor V region repertoire in patients with IgA nephropathy. 1047
Oliveira DBG (abst) 1132
Oliver A (abst) 1159
Oliver JA (abst). 1137
Olmer M (abst). 864
Olmo A (abst) 1135, 1138
Omata K *See* Endo Y et al 63:S-205
Omata M *See* Kimura K et al 63:S-201
Omata M *See* Tojo A et al 1593
Onizuka M *See* Nakamura T et al. 63:S-226
Opatrný K Jr.: Hemostasis disorders in chronic renal failure 62:S-87
Orfao A (abst). 1141, 1141, 1153, 1160
Orfila C (abst). 865
Oriola J (abst). 1136
Orofino L (abst). 1147, 1158, 1158, 1158, 1160
Orphanides C, Fine LG, Norman JT: Hypoxia stimulates proximal tubular cell matrix production via a TGF-β_1-independent mechanism. 637
Ortiz M (abst). 1148
Orts M (abst). 1143
Ortuño J (abst). 1147, 1148, 1149, 1152, 1158, 1158, 1158, 1160
Osende J (abst). 1145
Osorio J (abst). 1157
Ossi E *See* Brocco E et al 63:S-40
Ostermann ME (abst) 1133
O'Sullivan DA *See* Griffin MD et al 1196
Osuna A (abst). 1135, 1157, 1157
Ota K *See* Kanwar YS et al. 589
Ota K *See* Kumar A et al 620
Ots M *See* Mackenzie HS et al 63:S-140
Otto HF *See* Niemir ZI et al. 393
O'Valle F (abst) 1138, 1157, 1157
Owada A, Nakao M, Koike J, Ujiie K, Tomita K, Shiigai T: Effects of oral adsorbent AST-120 on the progression of chronic renal failure: A randomized controlled study 63:S-188
Owada A *See* Koike J et al 821
Owen JS (abst) 264
Ozaki K, Takada N, Tsujimoto K, Tsuji N, Kawamura T, Muso E, Ohta M, Itoh N: Localization of insulin receptor-related receptor in the rat kidney 694
Ozanne D (abst) 1125

P

Paape ME (abst). 562
Pabinger I *See* Födinger M et al 517
Packard CJ (abst) 269
Paczek L *See* Heidland A et al 62:S-32
Page S (abst). 1129
Palao J (abst). 1137
Pallardó L (abst). 1154
Pallardó LM (abst) 1137
Paller MS: Integrins and repair after acute renal injury 61:S-52
Paller MS *See* Wijesekera DS et al 1511
Palmero J (abst) 1154
Palomar MR (abst) 1154
Palomar R (abst). 1147
Panadero J (abst) 1159
Panagiotopoulos S *See* Jerums G et al 63:S-87
Papillon J *See* Kee N et al. 309
Parada LF *See* Bates CM et al 674
Paredes D (abst) 1159
Parfitt AM: The hyperparathyroidism of chronic renal failure: A disorder of growth. 3
Park SK, Kang MJ, Kim W, Koh GY: Renal tubule regeneration after ischemic injury is coupled to the up-regulation and activation of cyclins and cyclin dependent kinases 706
Parkinson NA (abst) 277
Parks JH *See* Asplin JR et al. 1602
Parving H-H *See* Christensen PK et al 1369
Parving H-H *See* Hansen HP et al 63:S-49
Pascual J (abst) 1139, 1139, 1147, 1158, 1158, 1158, 1160
Pascual M (abst) 1429
Pastor L (abst). 1156, 1157
Patel SR, Xu Y, Koenig RJ, Hsu CH: Effect of glucose on the function of the calcitriol receptor and vitamin D metabolism 79
Patel SR, Xu Y, Koenig RJ, Hsu CH: Effect of glyoxylate on the function of the calcitriol receptor and vitamin D metabolism. 39
Patel SR *See* Hsu CH et al 62:S-65
Paúl Ramos FJ (abst). 1156, 1157
Pavenstädt H, Henger A, Briner V, Fischer K-G, Huber-Lang M, Schollmeyer P, Greger R: Agonist-induced activation of a non-selective ion current in glomerular endothelial cells. 157

Pavenstädt H *See* Henger A et al 687
Pawluczyk IZA (abst)..... 262, 1127
Peach R *See* Chandraker A et al..... 1678
Peacock S (abst) 274
Pedersen EM *See* Ringgaard S et al 1359
Pei-Yuan D *See* Kopple JD et al..... 486
Pelletier J *See* Vicanek C et al 614
Peralta C (abst)..... 1137
Pereira BJG *See* Cendoroglo M et al 1626
Pereira BJG *See* Fishbane S et al 1645
Pérez A (abst)..... 1153
Pérez Bañasco V (abst)..... 1146, 1149, 1150, 1152
Pérez Contreras J (abst) 1144
Pérez de Prado A (abst)..... 1145, 1152
Pérez del Barrio P (abst) 1144, 1149, 1150
Perez Garcia R (abst) 1149
Pérez J (abst)..... 1156, 1157
Pérez R (abst)..... 1140, 1145, 1152
Pérez-Bañasco V (abst)..... 1144
Perez-Garcia R (abst) 1148
Perico N *See* Gaspari F et al..... 63:S-151
Perna A *See* Ruggenenti P et al 63:S-54
Peters DJM (abst)..... 559
Peters S *See* Sandau K et al 378
Peters TJ (abst)..... 1133
Petrelli L *See* De Santo NG et al 62:S-111
Peyronnet P (abst)..... 862
Pfeilschifter J *See* Briner VA et al..... 61:S-45
Pfeilschifter J *See* Huwiler A et al..... 329
Pfeilschifter J *See* Sandau K et al 378
Pham K, Smoyer WE, Archer DC, Gabbai F, Kelly CJ: Oral feeding of renal tubular antigen abrogates interstitial nephritis and renal failure in Brown Norway rats 725
Phan S *See* Lee S-K et al..... 1000
Phelps RG (abst)..... 1124
Philipp T *See* Kribben A et al..... 61:S-74
Philipp U *See* Kribben A et al..... 61:S-74
Phillips AO (abst) 262, 1121
Phillips AO, Steadman R, Morrisey K, Martin J, Eynstone L, Williams JD: Exposure of human renal proximal tubular cells to glucose leads to accumulation of type IV collagen and fibronectin by decreased degradation 973
Phillips D (abst) 267
Phillips L (abst)..... 1127
Pickett TM (abst) 1120
Picton M (abst)..... 276
Pines M *See* Nagler A et al..... 1561
Pippin J *See* Nangaku M et al..... 182
Pippin J *See* Nangaku M et al..... 1570
Pippin J *See* Shankland SJ et al..... 404
Pipy B (abst)..... 865
Pirson Y (abst) 268
Pirson Y *See* Rhys C et al..... 208
Pisoni R *See* Ruggenenti P et al 63:S-54
Planells R (abst)..... 864
Plant WD (abst) 269
Polaschegg HD (abst) 1428
Poletti J (abst)..... 1429
Pollock CA *See* Ibels LS et al..... 61:S-67
Pollock CA *See* Johnson DW et al 1486
Ponticelli C *See* Locatelli F et al..... 63:S-63
Pontremoli R, Viazzi F, Sofia A, Tomolillo C, Ruello N, Bezante GP, Del Sette M, Martinoli C, Lotti R, Sacchi G, Deferrari G: Microalbuminuria: A marker of cardiovascular risk and organ damage in essential hypertension..... 63:S-163
Poronnik P *See* Johnson DW et al..... 1486
Porta I (abst)..... 1156
Porter CJ (abst)..... 1127, 1131
Portilla D: Carnitine palmitoyl-transferase enzyme inhibition protects proximal tubules during hypoxia 429
Portolés J (abst) 1143
Portoles JM (abst)..... 1154
Posthuma N (abst) 568
Potaux L (abst)..... 865
Poulsen PL, Ebbehøj E, Hansen KW, Mogensen CE: High normo- or low microalbuminuria: Basis for intervention in insulin-dependent diabetes mellitus.. 63:S-15
Poulter C (abst)..... 1117
Poux JM (abst) 864
Powell JR *See* O'Donnell MP et al 63:S-218
Power DA *See* Roy-Chaudhury P et al 103
Powis SH (abst)..... 1124
Poyser KA (abst)..... 1133
Praloran V (abst) 862
Pratt JR *See* Wang Y et al 371
Prescott RJ (abst)..... 269
Price CP (abst) 1123
Price DA *See* De'Oliveira JM et al..... 771
Prie D *See* Ledoux S et al..... 953
Prié D *See* Vrtovsnik F et al 1016
Primrose L (abst)..... 1131
Pringle JH (abst) 263, 1131
Provoost AP (abst) 566
Purgus R (abst)..... 864
Pusey CD (abst)..... 261, 265, 268, 272, 277, 1117
Pusey CD *See* Karkar AM et al..... 1313
Pusey CD *See* Tam FWK et al 1224

Q

Qing DP *See* Ding H et al..... 62:S-45
Quamme GA: Renal magnesium handling: New insights in understanding old problems..... 1180
Quaschning T *See* Wanner C et al..... 62:S-53
Quibell K (abst) 268
Quigley R *See* Sheu J-N et al 71
Quinn J (abst)..... 270

R

Raats CJI (abst)..... 560, 563
Rabelink TJ (abst)..... 564
Rabkin R *See* Hsu FW et al 363
Rabkin R *See* Yap J et al 1216
Radda GK (abst)..... 266
Radeke HH *See* Schwarz M et al 1521
Radl J *See* Tomana M et al..... 509
Raij L *See* del Castillo D et al..... 460
Raine AEG *See* Lipkin GW et al 792
Ralston SH (abst) 1131
Ramírez C (abst) 1135, 1138, 1157
Ramirez de Arellano M (abst) 1142, 1155, 1155
Ramos A (abst)..... 1137
Ramos D (abst)..... 1159
Ramos G. J (abst)..... 1154
Ratcliffe PJ *See* Maxwell PH et al..... 715
Ravine D (abst) 1122, 1126

Ravine D *See* Baboolal K et al 607
Ray C *See* Anderson RJ et al 61:S-36
Raynolds MV *See* Jeffers BW et al 473
Reaveley DA (abst) 267
Rebouillon PA *See* Tabouy LJ et al 1381
Reddy S *See* Degenhardt TP et al 1064
Redfern CPF (abst) 264
Rees A *See* Karkar AM et al 1759
Rees AJ (abst) 1124
Rees AJ *See* Karkar AM et al 1313
Rees AJ *See* Tam FWK et al 1224
Rees L *See* Kari JA et al 468
Reeves WB *See* Kyossev ZN et al 682
Refsum H *See* Guttormsen AB et al 495
Reichert LJM *See* Wetzels JFM et al 61:S-63
Reichrath J *See* Klaus G et al 45
Reidy J (abst) 1133
Reiss OK *See* Jacob AD et al 755
Remond A *See* Morinière P et al 1406
Remuzzi G *See* Aiello S et al 171
Remuzzi G *See* Bruzzi I et al 62:S-29
Remuzzi G *See* Gaspari F et al 63:S-151
Remuzzi G *See* Ruggenenti P et al 63:S-54
Ren Y *See* Ito S et al 63:S-128
Rensma PL *See* van Essen GG et al 63:S-58
Renucci JF (abst) 864
Repetto HA: The natural history of hemolytic-uremic syndrome in children (Nephrology Forum) 1708
Resch K *See* Schwarz M et al 1521
Revelles F (abst) 1138
Revert L (abst) 1147
Rey C *See* García E et al 648
Reyes A (abst) 1138
Reyes CE *See* Gonzalez CB et al 1206
Reynolds J (abst) 265, 268, 1117
Rhys C, Snyers B, Pirson Y: Rapid communication: Recurrent corneal erosion associated with Alport's Syndrome 208
Riesco A *See* Caramelo C et al 61:S-56
Rijtema MN (abst) 1430
Ringgaard S, Christiansen T, Bak M, Pedersen EM, Støkilde-Jørgensen H, Flyvbjerg A: Measurement of renal vein blood flow in rats by high-field magnetic resonance 1359
Ringoir S: An update on uremic toxins 62:S-2
Ringoir S *See* Niwa T et al 62:S-1
Ringrose TR (abst) 266
Rischen-Vos J (abst) 562, 562
Ritz E *See* Klaus G et al 45
Ritz E *See* Locatelli F et al 63:S-63
Ritz E *See* Niemir ZI et al 393
Ritz E *See* Schmidt S et al 63:S-27
Ritz R (abst) 1423
Rivalan J (abst) 864
Rivas-Cabañero L (abst) 1139
Rivera F (abst) 1136
Rivera M (abst) 1152
Rivera ME (abst) 1148
Roberts IS (abst) 276
Roberts ISD (abst) 271
Roberts RG (abst) 264
Robinson M (abst) 1129
Robson R (abst) 1123
Rochera A (abst) 1159
Röcker L *See* Kribben A et al 61:S-74
Rodary-Vautier R *See* Morinière P et al 1406
Roderick P (abst) 280, 1118, 1129, 1130
Rodger RSC (abst) 1118
Rodger S (abst) 1133
Rodríguez J *See* García E et al 648
Rodriguez J *See* Klaus G et al 45
Rodríguez JE (abst) 1136
Rodriguez ML (abst) 1159
Rodríguez P (abst) 1140, 1159
Rodríguez-Barbero A (abst) 1139
Rodríguez-López A (abst) 1135
Rodríguez-Puyol D (abst) 1139
Rodríguez-Puyol M (abst) 1139
Roe CJ *See* Wu LL et al 63:S-221
Roebuck A (abst) 1129
Roelfsema J (abst) 559
Roeser NF *See* Weinberg JM et al 140
Roger SD *See* Ibels LS et al 61:S-67
Rogerson M (abst) 1129
Rohrwasser A *See* Loghman-Adham M et al 229
Romanov V, Noiri E, Czerwinski G, Finsinger D, Kessler H, Goligorsky MS: Two novel probes reveal tubular and vascular Arg-Gly-Asp (RGD) binding sites in the ischemic rat kidney 93
Roos JC (abst) 565, 566
Rosenberg ME *See* Ibrahim HN et al 63:S-115
Rösler D (abst) 1429
Rossi NF, O'Leary DS, Scislo TJ, Caspers ML, Chen H: Central endothelin 1 regulation of arterial pressure and arginine vasopressin secretion via the AV3V region 61:S-22
Rossing P *See* Hansen HP et al 63:S-49
Rossique P (abst) 1147, 1154
Roubaty D (abst) 1424, 1424, 1430
Rouch AJ, Kudo LH: Indomethacin and staurosoporine reverse $\alpha 2$ inhibition of water transport in rat IMCD .. 1351
Rousselot M (abst) 863
Rovina L (abst) 1148
Roxborough HE (abst) 1132
Roy-Chaudhury P, Hillis G, McDonald S, Simpson JG, Power DA: Importance of the tubulointerstitium in human glomerulonephritis. II. Distribution of integrin chains $\beta 1$, $\alpha 1$ to 6 and αV 103
Rozing J (abst) 563
Rubio V (abst) 1153
Rüegger S (abst) 1423
Ruello N *See* Pontremoli R et al 63:S-163
Ruggenenti P, Perna A, Mosconi L, Matalone M, Pisoni R, Gaspari F, Remuzzi G, "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN): Proteinuria predicts end-stage renal failure in non-diabetic chronic nephropathies 63:S-54
Ruilope LM (abst) 1136, 1142
Ruiz F (abst) 1140
Ruiz LA (abst) 1157
Ruiz LM (abst) 1137
Ruiz MA (abst) 1149
Ruiz-Muñoz LM (abst) 1137, 1157
Ruiz-Nodar M (abst) 1145
Ruiz-Ortega M, Egido J: Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts 1497
Russell GI (abst) 1127
Russell JC (abst) 266
Rutherford PA (abst) 1128

Rutherford S (abst) 1128
Ryan JJ (abst) 265
Ryffel B (abst) 1424, 1430

S
Sacchi G *See* Pontremoli R et al 63:S-163
Sack K *See* Kreft B et al 212
Sacks SH (abst) 1122, 1130
Sacks SH *See* Wang Y et al 371
Sadek SA (abst) 1120
Saggar-Malik A (abst) 1122
Saito A *See* Narita I et al 63:S-215
Saito T *See* Ishikawa S- et al 61:S-6
Saito T *See* Ishikawa S- et al 61:S-6
Sakai H *See* Suzuki D et al 111
Sakai S *See* Koda Y et al 1096
Sakai T *See* Kimura K et al 63:S-201
Sakatsume M *See* Narita I et al 63:S-215
Sakurabayashi T *See* Koda Y et al 1096
Sala J (abst) 1142
Salama A (abst) 1125
Salant DJ (abst) 270
Salant DJ *See* Budde K et al 733
Salgueira M (abst) 1147
Saller A *See* Brocco E et al 63:S-40
Salmon JE *See* Haseley LA et al 1375
Salvanés F (abst) 1139
Sambataro M *See* Brocco E et al 63:S-40
Samo R (abst) 1155
Sampath A (abst) 1124
Samuelsson O *See* Attman P-O et al 63:S-98
San Millan JL (abst) 1122
Sánchez E (abst) 1142
Sanchez J (abst) 1159
Sanchez L (abst) 1148, 1150, 1158
Sánchez M (abst) 1136
Sanchez O (abst) 1138
Sánchez Perales MC (abst) 1146, 1149, 1150, 1152
Sánchez Rodríguez JL (abst) 1145
Sánchez S (abst) 1151, 1151
Sánchez Tárraga L (abst) 1143, 1154
Sanchez Tomero JA (abst) 1143
Sánchez-Perales C (abst) 1144
Sánchez-Tomero JA (abst) 1139, 1145, 1155
Sancho A (abst) 1154
Sandau K, Pfeilschifter J, Brüne B, Peters S: Nitric oxide and superoxide induced p53 and Bax accumulation during mesangial cell apoptosis 378
Sanjuán A (abst) 1156, 1157
Santos F *See* García E et al 648
Sanz JC (abst) 1145
Sanz P (abst) 1143, 1155
Sanz-Guajardo D (abst) 1142, 1146, 1146, 1146
Saruta T *See* Murakami M et al 63:S-132
Sasaki S *See* Ishikawa S- et al 61:S-6
Sato T (abst) 563
Sato T *See* Heidenreich S et al 318
Saunders HJ *See* Johnson DW et al 1486
Savage COS (abst) 268, 272, 276
Savage DA (abst) 1124
Savidge J (abst) 263
Savill J (abst) 265, 1116
Saxena S *See* Dash SC et al 482
Sayegh MH (abst) 273
Sayegh MH *See* Chandraker A et al 1678
Schächinger H (abst) 1423
Schaedeli F (abst) 1428
Schaeffer J *See* Schwalbe S et al 1077
Schäfers R *See* Kribben A et al 61:S-74
Schalekamp MA *See* Zietse R et al 60:S-33
Schalling M *See* Serlachius E et al 901
Schaub M (abst) 273
Schaub St (abst) 1427
Scheffer H (abst) 559
Schena FP: Report on the first meeting of the chairmen of the national and international registries 1422
Schena FP, Gesualdo L, Grandaliano G, Montinaro V: Progression of renal damage in human glomerulonephritides: is there sleight of hand in winning the game? 1439
Scherberich JE *See* Baer PC et al 1321
Scherch LK *See* Modification of Diet in Renal Disease Study Group et al 778
Schlatter E, Ankorina-Stark I, Haxelmans S, Hohage H: Moxonidine inhibits Na^+/H^+ exchange in proximal tubule cells and cortical collecting duct 454
Schmid R *See* Födinger M et al 517
Schmidt A *See* Borchhardt K et al 1622
Schmidt A *See* van der Kleij FGH et al 63:S-23
Schmidt M *See* Heidenreich S et al 318
Schmidt S, Ritz E: Genetic determinants of diabetic renal disease and their impact on therapeutic interventions 63:S-27
Scholey JW *See* Ingram AJ et al 60:S-70
Schollmeyer P *See* Henger A et al 687
Schollmeyer P *See* Pavenstädt H et al 157
Schrander-v.d. Meer AM (abst) 560
Schreiber DP *See* Kuruvila CK et al 61:S-89
Schreiner GF *See* Johnson RJ et al 1169
Schrier RW *See* Edelstein CL et al 1271
Schrier RW *See* Jeffers BW et al 473
Schrier RW *See* Weigert AL et al 61:S-41
Schroeder NJ (abst) 1125, 1134
Schulman G *See* HEMO Study Group et al 1395
Schulman G *See* Ikizler TA et al 62:S-96
Schulman G *See* May RE et al 1656
Schulman G *See* Modification of Diet in Renal Disease Study Group et al 778
Schwab SJ: Hemodialysis vascular access: An ounce of prevention 1704
Schwalbe S, Holzhauer M, Schaeffer J, Galanski M, Koch K-M, Floege J: β2-Microglobulin associated amyloidosis: A vanishing complication of long term hemodialysis? 1077
Schwarz M, Radeke HH, Resch K, Uciechowski P: Lymphocyte-derived cytokines induce sequential expression of monocyte- and T cell-specific chemokines in human mesangial cells 1521
Scislo TJ *See* Rossi NF et al 61:S-22
Scoble JE (abst) 264, 1119, 1133, 1133
Sebekova K *See* Heidland A et al 62:S-32
Seed M (abst) 267
Segawa C, Wada T, Takaeda M, Furuichi K, Matsuda I, Hisada Y, Ohta S, Takasawa K, Takeda S-, Kobayashi K-, Yokoyama H: *In situ* expression and soluble form of P-selectin in human glomerulonephritis 1054
Seki G *See* Nakao A et al 63:S-236
Selim S *See* Striker GE et al 63:S-120
Sempere T (abst) 1137
Sen M (abst) 1132

Seo H *See* Miyazaki T et al. 62:S-15
Seo H *See* Miyazaki T et al. 63:S-211
Seo J-K *See* Ha S-K et al 60:S-28
Serafini-Cessi F *See* Malagolini N et al 1340
Serlachius E, Svennilson J, Schalling M, Aperia A: Protein kinase C in the developing kidney: Isoform expression and effects of ceramide and PKC inhibitors. . 901
Serón D (abst). 1156
Serrano A (abst). 1143, 1154
Serrano Angeles P (abst) 1146, 1152
Serrano M (abst) 1150
Serrano P (abst) 1144
Shabmir E *See* Chazot C et al 1663
Shah SV *See* Kaushal GP et al 438
Shaikh SJK (abst). 1133, 1134
Shankland SJ: Cell-cycle control and renal disease 294
Shankland SJ, Floege J, Thomas SE, Nangaku M, Hugo C, Pippin J, Henne K, Hockenberry DM, Johnson RJ, Couser WG: Cyclin kinase inhibitors are increased during experimental membranous nephropathy: Potential role in limiting glomerular epithelial cell proliferation *in vivo* 404
Shankland SJ *See* Nangaku M et al. 182
Shankland SJ *See* Nangaku M et al. 1570
Shapiro JI: Pathogenesis of cardiac dysfunction during metabolic acidosis: Therapeutic implications 61:S-47
Shapiro JI *See* Jacob AD et al. 755
Sharp D (abst). 266
Sharpstone P (abst) 268, 270, 1119
Shaw JA (abst). 263, 1131
Sheerin NS (abst) 1122
Sherman RA *See* Kapoian T et al. 839
Sherwood RA (abst) 1133
Sheu J-N, Baum M, Harkins EW, Quigley R: Maturational changes in rabbit renal cortical phospholipase A_2 activity. 71
Shibouta Y *See* Noda M et al 63:S-136
Shield CF III *See* Mott JD et al 1302
Shigematu T *See* Kawaguchi Y et al 62:S-105
Shihab FS, Bennett WM, Tanner AM, Andoh TF: Angiotensin II blockade decreases TGF-β1 and matrix proteins in cyclosporine nephropathy. 660
Shihab FS *See* Yee J et al 120
Shiigai T *See* Koike J et al 821
Shiigai T *See* Owada A et al 63:S-188
Shimada H *See* Nishi S et al 63:S-177
Shimada H *See* Ueno M et al 63:S-191
Shimizu F *See* Nakamura T et al. 63:S-226
Shimizu F *See* Shimizu T et al. 63:S-239
Shimizu S *See* Wada T et al. 63:S-182
Shimizu T, Fukagawa M, Kuroda T, Hata S, Iwasaki Y, Nemoto M, Shirai K, Yamauchi S, Margolin SB, Shimizu F, Kurokawa K: Pirfenidone prevents collagen accumulation in the remnant kidney in rats with partial nephrectomy 63:S-239
Shimizu T *See* Nakao A et al. 63:S-236
Shiraga H *See* Akuta N et al. 911
Shirai K *See* Shimizu T et al 63:S-239
Shirato I *See* Kimura K et al 63:S-201
Shirley DG (abst) 264
Shoji T *See* Nishizawa Y et al 62:S-90
Short AK (abst). 1116
Short CD (abst) 276, 1132
Shyr Y *See* May RE et al. 1656
Sieber R (abst) 1429
Siebler T *See* Haffner D et al 802
Siegfried G *See* Ledoux S et al 953
Silve C *See* Laouari D et al. 1550
Simeon GP *See* van Hout BA et al 63:S-159
Simpson JG *See* Roy-Chaudhury P et al 103
Singhal PC *See* Mattana J et al 1478
Sirvent AE (abst). 1138
Situlin R *See* Guarnieri G et al. 62:S-41
Skill J (abst) 279
Skinner J (abst). 264
Sluiter WJ (abst). 561
Sluiter WJ *See* van Essen GG et al 63:S-58
Smet RD, Glorieux G, Hsu CH, Vanholder R: *p*-Cresol and uric acid: Two old uremic toxins revisited. 62:S-8
Smilde T (abst) 560
Smith D *See* Davies S et al 223
Smith J (abst). 261, 1117
Smith J *See* Karkar AM et al. 1313
Smith J *See* Tam FWK et al 1224
Smith SA (abst). 274
Smits HFM *See* Bosman PJ et al. 1084
Smits P (abst) 559
Smogorzewski M, Massry SG: Uremic cardiomyopathy: Role of parathyroid hormone 62:S-12
Smogorzewski M *See* Massry SG et al. 62:S-5
Smoyer WE *See* Pham K et al. 725
Smye SW (abst). 1120
Snijders SV (abst) 566
Snyers B *See* Rhys C et al 208
Sofia A *See* Pontremoli R et al 63:S-163
Sola R (abst). 1159
Soldevila A (abst) 1159
Solís A (abst) 1137, 1140, 1157
Song KI *See* Lee HB et al. 60:S-60
Soper CPR (abst) 266
Spaeny-Dekking LHA (abst). 564
Spanel P *See* Davies S et al. 223
Spanish Study Group HCV (abst). 1148
Spokes K *See* Joannidis M et al 130
Springall T (abst). 1122
Spruit L (abst). 559
S.S.Dhillon (abst) 276
Stahl RAK *See* Wolf G et al 1250
State OI (abst) 273
Statius van Eps LW (abst). 565, 566
Steadman R (abst) 262, 262, 1121
Steadman R *See* Phillips AO et al. 973
Stec F *See* Argilés A et al 530
Steele A (abst). 1424
Steffes MW: Glycemic control and the initiation and progression of the complications of diabetes mellitus . . 63:S-36
Stegeman CA (abst). 559, 562
Stegeman CA *See* van Essen GG et al 63:S-58
Stehouwer CDA (abst) 567
Steiger J (abst) 1424, 1424, 1430
Stein A, Moorhouse J, Iles-Smith H, Baker F, Johnstone J, James G, Troughton J, Bircher G, Walls J: Role of an improvement in acid/base status and nutrition in CAPD patients. 1089
Stein H *See* Niemir ZI et al 393
Steiner P *See* Strehl R et al. 1469
Steinhausen M *See* Endlich K et al. 202
Steinhauslin F (abst) 1425
Steinmann-Niggli K (abst). 1425
Stepinski J *See* Lewko B et al 654

Sterzel RB *See* Budde K et al 733
Steurer W (abst) 1424
Steward CA *See* Kapoian T et al 839
Stewart M (abst) 268
Stewart PM (abst) 1125
St.J. Drey N (abst) 1129
Stoermann-Chopard C (abst) 1426
Støkilde-Jørgensen H *See* Ringgaard S et al 1359
Stone N (abst) 280
Strachan J (abst) 1132
Strange PG (abst) 278
Straver B (abst) 567
Streather CP (abst) 264
Strehl R, Kloth S, Aigner J, Steiner P, Minuth WW: P_{CD}Ampl, a new antigen at the interface of the embryonic collecting duct epithelium and the nephrogenic mesenchyme 1469
Striker G *See* Agodoa L et al 63:S-144
Striker GE, Lupia E, Elliot S, Zheng F, McQuinn C, Blagg C, Selim S, Vilar J, Striker LJ: Glomerulosclerosis, arteriosclerosis, and vascular graft stenosis: Treatment with oral heparinoids 63:S-120
Striker LJ *See* Striker GE et al 63:S-120
Strom TB (abst) 1424
Strom TB *See* Zhu G et al 992
Stuart-Tilley AK *See* Joannidis M et al 130
Stylianou E (abst) 1116
Suc JM (abst) 865
Sudo M *See* Hiraoka M et al 811
Sugaya T *See* Kimura K et al 63:S-201
Sugimachi K *See* Matsuo K et al 832
Sugimoto T *See* Haneda M et al 60:S-66
Sugiyama S *See* Niwa T et al 62:S-23
Sukhatme VP *See* Zhu G et al 992
Sundaram S *See* Cendoroglo M et al 1626
Sundelöf M *See* Eklöf A-C et al 742
Sunder-Plassmann G *See* Födinger M et al 517
Suria S (abst) 1147, 1154
Sutmuller M (abst) 563, 563
Sutton T (abst) 266
Suzuki D, Miyazaki M, Jinde K, Koji T, Yagame M, Endoh M, Nomoto Y, Sakai H: In situ hybridization studies of matrix metalloproteinase-3, tissue inhibitor of metalloproteinase-1 and type IV collagen in diabetic nephropathy 111
Suzuki M *See* Koda Y et al 1096
Suzuki N *See* Kimura K et al 63:S-201
Suzuki S *See* Gejyo F et al 62:S-75
Suzuki T *See* Nakao A et al 63:S-236
Suzuki Y *See* Ueno M et al 63:S-191
Svarstad E *See* Guttormsen AB et al 495
Svendsen KH *See* Grimm RH Jr. et al 63:S-10
Svennilson J *See* Serlachius E et al 901
Swift H *See* Lieske JC et al 1291
Szczepanska-Konkel M *See* Lewko B et al 654

T

T. Wee PM (abst) 560
Tabernero JM (abst). 1141, 1141, 1145, 1151, 1151, 1155, 1156, 1160
Tabouy LJ, Chauvet-Monges A-MT, Carles GP, Brunet PJ, Braguer DL, Rebouillon PA, Berland YF, Crevat AD: Calcium channel blockers correct in vitro mitochondrial toxicity of cellulose acetate 1381
Takada M *See* Chandraker A et al 1678
Takada N *See* Ozaki K et al 694
Takada T *See* Kihara I et al 63:S-171
Takaeda M *See* Segawa C et al 1054
Takasawa K *See* Segawa C et al 1054
Takeda S- *See* Segawa C et al 1054
Takeda T *See* Narita I et al 63:S-215
Takeuchi K *See* Endo Y et al 63:S-205
Takkinen R (abst) 1426
Tallon S (abst) 1154
Tam FWK (abst) 261
Tam FWK, Smith J, Karkar AM, Pusey CD, Rees AJ: Interleukin-4 ameliorates experimental glomerulonephritis and up–regulates glomerular gene expression of IL-1 decoy receptor 1224
Tam FWK *See* Karkar AM et al 1313
Tamimi NA (abst) 278
Tanaka S *See* Imanishi M et al 63:S-198
Taniguchi S *See* Nakao A et al 63:S-236
Tanner AM *See* Shihab FS et al 660
Tarif N, Bakris GL: Angiotensin II receptor blockade and progression of nondiabetic-mediated renal disease. 63:S-67
Taschner PEM (abst) 560
Tato A (abst) 1147, 1148, 1152, 1158, 1158, 1160
Tato AM (abst) 1149
Tattersall JE (abst) 1119, 1128
Tay Y-C *See* Chen L et al 61:S-60
Taylor CM (abst) 275, 279
Taylor DJ (abst) 266
Tazawa H *See* Akiba T et al 62:S-69
Tegzess AM (abst) 559
ten Berge RJM (abst) 564
ten Voorde BJ (abst) 567
Tenorio T (abst) 1148, 1149, 1152
Teppo A-M *See* Fagerudd JA et al 63:S-195
ter Maaten JC (abst) 565, 566
ter Wee PM (abst) 565, 566, 566, 567, 568
Terreros D *See* Loghman-Adham M et al 229
Teruel (abst) 1153
Teruel A (abst) 1138
Teruel JL (abst) 1148, 1149, 1152
Terzi F *See* Iimura O et al 962
Teschner M *See* Heidland A et al 62:S-32
Teta D (abst) 1425, 1427
Thakkar H (abst) 1123
Thakker RV *See* Akuta N et al 911
Thiel G (abst) . 1423, 1423, 1424, 1424, 1424, 1426, 1427, 1427, 1430, 1430
Thiemermann C (abst) 270
Thomas GL (abst) 263, 279
Thomas M *See* Argilés A et al 530
Thomas ME (abst) 264
Thomas P *See* Lee S-K et al 1000
Thomas SE *See* Shankland SJ et al 404
Thomas TH (abst) 275, 275, 279
Thomas TH *See* Vareesangthip K et al 503
Thompson CH (abst) 266
Thompson EM (abst) 261
Thompson MA *See* de Toledo FGS et al 152
Thomson AE: Non-insulin dependent diabetes mellitus in nephrology: Where do we go from here? 61:S-83
Thonney M (abst) 1430
Thorpe SR *See* Degenhardt TP et al 1064
Thuraisingham RC (abst) 262, 1119, 1122
Tikkanen I: Comparison of renin-angiotensin to calcium channel blockade in renal disease 63:S-19

Tilney NL (abst) 273
Tilney NL *See* Chandraker A et al 1678
Timmerman JJ (abst) 561
Timmerman JJ *See* Heidenreich S et al. 318
Tipping PG *See* Kitching AR et al 52
Tiwari SC *See* Dash SC et al. 482
Tizard EJ (abst) 278
Toback FG *See* Lieske JC et al 1291
Tobin A (abst). 1121
Todeschini M *See* Aiello S et al 171
Togawa M *See* Haneda M et al. 60:S-66
Togawa M *See* Kikkawa R et al. 62:S-39
Toigo G *See* Guarnieri G et al 62:S-41
Tojo A, Welch WJ, Bremer V, Kimoto M, Kimura K, Omata M, Ogawa T, Vallance P, Wilcox CS: Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney . 1593
Tojo A *See* Kimura K et al 63:S-201
Toledo A (abst) 1147, 1154
Tomana M, Matousovic K, Julian BA, Radl J, Konecny K, Mestecky J: Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG.. 509
Tomás JF (abst). 1139
Tomita K *See* Koike J et al. 821
Tomita K *See* Owada A et al. 63:S-188
Tomolillo C *See* Pontremoli R et al. 63:S-163
Tompkins L (abst). 269
Tong P *See* Vareesangthip K et al. 503
Tönshoff B *See* Haffner D et al. 802
Topley N (abst). 265, 1117, 1123
Torban E *See* Vicanek C et al. 614
Tornero F (abst) 1144
Torra R (abst). 1122
Torra R, Badenas C, Darnell A, Brú C, Escorsell A, Estivill X: Rapid communication: Autosomal dominant polycystic kidney disease with anticipation and Caroli's disease associated with a PKD1 mutation 33
Torras A (abst) 1136
Torregrosa I (abst) 1159
Torres VE *See* Griffin MD et al 1196
Tóth-Heyn P (abst) 1430
Tramonti G, Ferdeghini M, Donadio C, Annichiarico C, Norpoth M, Bianchi R, Bianchi C: Tumor-associated trypsin inhibitor (TATI) and renal function. 63:S-179
Tramonti G *See* Donadio C et al. 63:S-166
Traoré HA *See* Vester U et al. 478
Traoré M *See* Vester U et al. 478
Traver JA (abst) 1139, 1141, 1143, 1145, 1145, 1148, 1155
Trenkwalder E, Gruber A, König P, Dieplinger H, Kronenberg F: Increased plasma concentrations of LDL-unbound apo(a) in patients with end-stage renal disease 1685
Troncoso S *See* Gonzalez CB et al 1206
Troughton J *See* Stein A et al 1089
Tryggvason K (abst) 564
Tsai J-C *See* Chen H-C et al 1390
Tsai J-H *See* Chen H-C et al. 1390
Tsalamandris C *See* Jerums G et al. 63:S-87
Tsao T *See* Hsu FW et al 363
Tsao T *See* Yap J et al 1216
Tse WY (abst). 268
Tsubakihara Y (abst). 863
Tsuchida S *See* Kihara I et al 63:S-171
Tsuchiya K *See* Murakami K et al. 63:S-208
Tsuji N *See* Ozaki K et al 694
Tsujimoto K *See* Ozaki K et al 694
Tsukahara H *See* Hiraoka M et al. 811
Tsukamoto Y *See* Akizawa T et al 62:S-72
Tsukushi S *See* Niwa T et al 62:S-23
Tsunoda K *See* Endo Y et al. 63:S-205
Tsuruta M *See* Nakazato H et al. 895
Tsutsui S *See* Niwa T et al. 62:S-23
Turner AN (abst) 265, 277, 1124
Turney JH (abst). 269, 269, 273, 274
Turnpenny P (abst) 268
Tyce GM *See* de Toledo FGS et al 152

U

Ucci AA *See* Cendoroglo M et al 1626
Uciechowski P *See* Schwarz M et al. 1521
Ueda N *See* Kaushal GP et al. 438
Uehlinger DE (abst) 1428
Ueland PM *See* Guttormsen AB et al. 495
Ueno M, Kawashima S, Nishi S, Shimada H, Karasawa R, Suzuki Y, Maruyama Y, Arakawa M: Tubulointerstitial lesions in non-insulin dependent diabetes mellitus. 63:S-191
Ueno M *See* Nishi S et al 63:S-177
Ujiie K *See* Koike J et al. 821
Ujiie K *See* Owada A et al 63:S-188
Ullian ME: The Wistar-Furth rat as a model of mineralocorticoid resistance. 61:S-10
Underhill GS (abst). 1120
Ungar T (abst) 269
Unwin RJ (abst) 265
Urbizu JM (abst). 1140

V

V. Dorp WT (abst) 560
Valderrábano F (abst) 1140, 1142, 1145, 1146, 1146, 1146, 1148, 1149, 1152, 1159
Valdivielso JM (abst). 1139
Vale L (abst). 1117
Vallance DT *See* Kari JA et al 468
Vallance P *See* Tojo A et al 1593
Valle A (abst) 1136
Vallon J-J *See* Gaulier J-M et al 1700
Vamvakas EC (abst) 1429
Van Damme J (abst). 1116
van de Ven PJG (abst) 565
van den Born J (abst) 560, 563
van den Heuvel LPWJ (abst). 560, 564
Van der Biest I *See* Helbert MJF et al 414
van der Kleij FGH, Schmidt A, Navis GJ, Haas M, Yilmaz N, de Jong PE, Mayer G, de Zeeuw D: Angiotensin converting enzyme insertion/deletion polymorphism and short-term renal response to ACE inhibition: Role of sodium status. 63:S-23
van der Kooij SW (abst) 561
van der Pijl JW (abst) 560
van der Vliet JJ (abst). 564
van der Voort J (abst). 1130
Van der Wal AM (abst) 563
van der Woude FJ (abst). 560
van Dijk HA (abst) 560
van Dixhoorn MGA (abst) 563
Van Dokkum RPE (abst) 566
van Eendenburg JDH (abst) 563
van Es LA (abst). 560, 561, 562, 564
van Es LA *See* Heidenreich S et al 318

van Essen GG (abst) 561
van Essen GG, Apperloo AJ, Rensma PL, Stegeman CA, Sluiter WJ, de Zeeuw D, de Jong PE: Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline? 63:S-58
van Gelder T (abst) 562, 562
van Gijlswijk-Janssen DJ (abst) 561
van Goor H (abst) 564
van Guldener C (abst) 567
van Hout BA, Simeon GP, McDonnell J, Mann JFE: Economic evaluation of benazepril in chronic renal insufficiency 63:S-159
van Huffelen AC (abst) 567
van Kooten C (abst) 562
van Paassen P (abst) 565
van Riemsdijk IC (abst) 567
van Ypersele de Strihou C: Are biocompatible membranes superior for hemodialysis therapy? 62:S-101
Vane JR (abst) 270
Vanhille Ph (abst) 865
Vanholder R *See* Smet RD et al 62:S-8
Vanrenterghem YFC: Impact of new immunosuppressive agents on late graft outcome 63:S-81
Varagunam M (abst) 263
Vareesangthip K (abst) 279
Vareesangthip K, Tong P, Wilkinson R, Thomas TH: Insulin resistance in adult polycystic kidney disease 503
Varghese Z (abst) 1123
Vasile A *See* Guarnieri G et al 62:S-41
Vaziri ND, Ding Y, Ni Z, Gonick HC: Altered nitric oxide metabolism and increased oxygen free radical activity in lead-induced hypertension: effect of lazaroid therapy 1042
Vaziri ND *See* Ni Z et al 195
Vazquez MI (abst) 1149
Veerkamp JH (abst) 564
Veldhuis J *See* García E et al 648
Velussi M *See* Brocco E et al 63:S-40
Venkatachalam MA *See* Weinberg JM et al 140
Verbrugh HA (abst) 566
Verde E (abst) 1140, 1145, 1148, 1149, 1152, 1159
Vergara E (abst) 1135
Verma R *See* Obermüller N et al 1584
Verrier Jones K (abst) 1130
Vervoort G (abst) 559
Vester U, Kardorff R, Traoré M, Traoré HA, Fongoro S, Juchem C, Franke D, Korte R, Gryseels B, Ehrich JHH, Doehring E: Urinary tract morbidity due to *Schistosoma haematobium* infection in Mali 478
Viazzi F *See* Pontremoli R et al 63:S-163
Viberti G, Chaturvedi N: Angiotensin converting enzyme inhibitors in diabetic patients with microalbuminuria or normoalbuminuria 63:S-32
Vicanek C, Ferretti E, Goodyer C, Torban E, Moffett P, Pelletier J, Goodyer P: Regulation of renal EGF receptor expression is normal in Denys-Drash syndrome 614
Vickers M *See* Haffner D et al 802
Vidal S (abst) 1140
Viladoms J (abst) 1142, 1155
Vilar J *See* Striker GE et al 63:S-120
Villarroya A (abst) 1156
Virgili F *See* Brocco E et al 63:S-40
Virto R (abst) 1152
Vishwanath BS (abst) 1426
Vizcarra D (abst) 1159
Vlassara H *See* Fishbane S et al 1645
Vleming L-J (abst) 564
Vlodavsky I *See* Nagler A et al 1561
Vogel G (abst) 1425, 1427
Vogelbach P (abst) 1424, 1427, 1430
von Daeniken D (abst) 1429
von Eichel B *See* Klaus G et al 45
von Felten A (abst) 1428
Vosnides G: Hepatitis C in renal transplantation (Nephrology Forum) 843
Vozmediano C (abst) 1148
Vozmediano MC (abst) 1140, 1145, 1149, 1152, 1159
Vrtovsnik F, Couete S, Prié D, Lallemand D, Friedlander G: Lovastatin-induced inhibition of renal epithelial tubular cell proliferation involves a $p21^{ras}$ activated, AP-1-dependent pathway 1016
Vrtovsnik F *See* Iimura O et al 962

W

Wada J *See* Kanwar YS et al 589
Wada J *See* Kumar A et al 620
Wada T, Hamakawa S, Hori Y, Kaname S, Shimizu S, Kurokawa K, Katoh T: Immunohistochemical localization of latent transforming growth factor-β binding protein in IgA nephropathy 63:S-182
Wada T, Naito T, Griffiths RC, Coffman TM, Kelley VR: Systemic autoimmune nephritogenic components induce CSF-1 and TNF-α in MRL kidneys 934
Wada T *See* Segawa C et al 1054
Waddington SN (abst) 261
Wahi MM *See* Grimm RH Jr. et al 63:S-10
Wakelin D (abst) 265
Wakino S *See* Murakami M et al 63:S-132
Waldek S (abst) 267, 271, 272
Waldherr R *See* Niemir ZI et al 393
Walker B (abst) 275
Walker R (abst) 1122
Walker SW (abst) 269
Wallace S (abst) 1117
Wallner EI *See* Kanwar YS et al 589
Wallner EI *See* Kumar A et al 620
Wallnöfer A (abst) 1426
Walls J (abst) 264, 1117, 1121
Walls J *See* Medcalf JF et al 62:S-108
Walls J *See* Stein A et al 1089
Walter SJ (abst) 265
Wang H *See* Zajicek H et al 61:S-32
Wang S-R *See* Modification of Diet in Renal Disease Study Group et al 778
Wang T, Heimbürger O, Cheng H-, Waniewski J, Bergström J, Lindholm B: Effect of increased dialysate fill volume on peritoneal fluid and solute transport 1068
Wang T, Waniewski J, Heimbürger O, Werynski A, Lindholm B: A quantitative analysis of sodium transport and removal during peritoneal dialysis 1609
Wang W *See* Lewin E et al 1232
Wang Y, Pratt JR, Hartley B, Evans B, Zhang L, Sacks SH: Expression of tissue type plasminogen activator and type 1 plasminogen activator inhibitor, and persistent fibrin deposition in chronic renal allograft failure 371
Wang Y *See* Chen L et al 61:S-60
Waniewski J *See* Wang T et al 1068

Waniewski J *See* Wang T et al. 1609
Wanner C, Greiber S, Krämer-Guth A, Heinloth A, Galle J: Lipids and progression of renal disease: Role of modified low density lipoprotein and lipoprotein(a) 63:S-102
Wanner C, Zimmermann J, Quaschning T, Galle J: Inflammation, dyslipidemia, and vascular risk factors in hemodialysis patients 62:S-53
Wartna ES *See* Haas M et al. 1693
Warwick GL (abst). 1129, 1129
Warwicker P (abst). 268, 1122, 1125
Watanabe T *See* Nakao A et al. 63:S-236
Watson AR (abst). 267
Watson CJ (abst). 277
Waugh DA *See* Ibels LS et al 61:S-67
Wauters JP (abst). 1425, 1427
Weavind G (abst) 1129
Webb NJA (abst). 271, 277
Weening JJ (abst) 564
Weerackody RP *See* Chatterjee PK et al. 699
Wegenius G *See* Metry G et al 1635
Weigert AL, Martin P-Y, Schrier RW: Vascular hyporesponsiveness in cirrhotic rats: Role of different nitric oxide synthase isoforms 61:S-41
Weimar W (abst) 562, 562, 567
Weimar W *See* Zietse R et al 60:S-33
Weinberg JM, Roeser NF, Davis JA, Venkatachalam MA: Glycine-protected, hypoxic, proximal tubules develop severely compromised energetic function 140
Welch WJ *See* Tojo A et al. 1593
Wellek S *See* Kribben A et al 61:S-74
Wendt U *See* Lewko B et al 654
Werynski A *See* Wang T et al 1609
West N (abst) 276
Westendorp RGJ (abst) 564
Weston C (abst) 1119
Wetzels JFM (abst). 559
Wetzels JFM, Reichert LJM: Efficacy of immunosuppressive treatment in patients with membranous nephropathy and renal insufficiency ... 61:S-63
Wever PC (abst) 564
Wharram B *See* Lee S-K et al. 1000
Wheeler DC (abst) 278
Whitaker S (abst) 863
White KE (abst) 270
Whiting PH (abst). 1131
Whittle CJ (abst). 278
Whitworth C (abst). 269
Wicks A (abst). 1122
Wicks ACB *See* Olive C et al 1047
Wiçcek A *See* Kokot F et al 62:S-83
Wieneke G (abst) 560
Wieneke GH (abst). 567
Wieslander AP (abst) 274
Wiggns RC *See* Lee S-K et al 1000
Wijesekera DS, Zarama MJ, Paller MS: Effects of integrins on proliferation and apoptosis of renal epithelial cells after acute injury 1511
Wilcox C *See* Agodoa L et al. 63:S-144
Wilcox CS *See* Tojo A et al. 1593
Wilkes M (abst). 1119
Wilkinson JM (abst) 1124
Wilkinson R (abst). 275, 275, 279
Wilkinson R *See* Vareesangthip K et al. 503
Wilkinson T (abst). 265
Wilkström B *See* Metry G et al 1635
Will EJ (abst). 1120, 1129
Willekes-Koolschijn N *See* Joles JA et al 761
Williams AJ (abst) 266, 275, 1130
Williams GH *See* De'Oliveira JM et al 771
Williams JD (abst). 262, 262, 265, 1117, 1121, 1121, 1123, 1126
Williams JD *See* Baboolal K et al 607
Williams JD *See* Phillips AO et al. 973
Williams JM (abst) 279
Williams N *See* Baboolal K et al 607
Williams PS (abst). 278
Williams S (abst). 276
Willis F (abst) 272
Wilson B (abst) 273
Wilson P *See* Zajicek H et al. 61:S-32
Winaver JM *See* Better O et al 886
Winearls C (abst) 274
Winney RJ (abst) 269
Wintour EM *See* Butkus A et al 628
Winyard PJD (abst). 1131
Wisnieski JJ *See* Haseley LA et al. 1375
Witowski J (abst). 1123
Witzgall R *See* Obermüller N et al 1584
Wolbink-Kamp AM (abst). 564
Wolf G, Assmann KJM, Stahl RAK: Overexpression of aminopeptidase A abolishes the growth promoting effects of angiotensin II in cultured mouse mesangial cells 1250
Wölfl G *See* Födinger M et al. 517
Wolfreys K (abst) 263
Wong W (abst). 273, 1119
Wood GNI (abst) 1132
Woodrow G (abst) 269
Woodside JV (abst). 1133
Woolf AS (abst) 263, 1124, 1131
Wu LL, Yang N, Roe CJ, Cooper ME, Gilbert RE, Atkins RC, Lan HY: Macrophage and myofibroblast proliferation in remnant kidney: Role of angiotensin II 63:S-221

X

Xu Y *See* Patel SR et al 39
Xu Y *See* Patel SR et al 79

Y

Yagame M *See* Suzuki D et al. 111
Yagüe A (abst) 1135
Yalniz MT (abst). 564
Yamaguchi H *See* Kinoshita H et al 1028
Yamaguchi T *See* Inishi Y et al. 165
Yamamoto T *See* Kihara I et al. 63:S-171
Yamauchi A *See* Moriyama T et al 63:S-232
Yamauchi S *See* Shimizu T et al 63:S-239
Yanagihara T *See* Kihara I et al 63:S-171
Yang B (abst) 263, 279
Yang N *See* Wu LL et al. 63:S-221
Yaoita E *See* Kihara I et al 63:S-171
Yaoita H *See* Endo Y et al 63:S-205
Yap J, Tsao T, Fawcett J, Fielder PJ, Keller GA, Rabkin R: Effect of insulin-like growth factor binding proteins on the response of proximal tubular cells to insulin-like growth factor-1 1216
Yaqoob M (abst). 263

Yaqoob MM (abst) 262, 271, 1119, 1122
Yarnell JWG (abst) 1133
Yassa H (abst) 1120
Yasunaga C *See* Matsuo K et al 832
Yee J, Kuncio GS, Bhandari B, Shihab FS, Neilson EG: Identification of promoter activity and differential expression of transcripts encoding the murine stromelysin-1 gene in renal cells 120
Yenicesu M *See* May RE et al 1656
Yilmaz N *See* Borchhardt K et al 1622
Yilmaz N *See* van der Kleij FGH et al 63:S-23
Yokoro S *See* Akuta N et al 911
Yokota N *See* Kinoshita H et al 1028
Yokoyama H *See* Segawa C et al 1054
Yoneda H *See* Kimura K et al 63:S-201
Yoo MH *See* Lee HB et al 60:S-60
Yoshida Y *See* Nakamura T et al 63:S-226
Yoshida Y *See* Obata J- et al 63:S-229
Yoshimuta J *See* Nakazato H et al 895
Yoshioka K *See* Imanishi M et al 63:S-198
Young GA (abst) 269
Young IS (abst) 1119, 1132, 1133
Yu L: Nitric oxide in acute renal failure: Foe or friend? . 61:S-39
Yuasa Y *See* Koda Y et al 1096
Yung S (abst) 1123
Yzermans JNM (abst) 562

Z

Zager RA, Burkhart K: Decreased expression of mitochondrial-derived H_2O_2 and hydroxyl radical in cytoresistant proximal tubules 942
Zager RA, Iwata M, Conrad DS, Burkhart KM, Igarashi Y: Altered ceramide and sphingosine expression during the induction phase of ischemic acute renal failure 60
Zajicek H, Wang H, Kumar V, Wilson P, Levi M: Role of glycosphingolipids in the regulation of renal phosphate transport 61:S-32
Zappella S *See* Aiello S et al 171
Zarama MJ *See* Wijesekera DS et al 1511
Zárraga S (abst) 1160
Zebski H *See* Gleiter CH et al 338
Zeiler M (abst) 1423, 1423
Žemberová E *See* Mydlík M et al 62:S-56
Zhang L *See* Wang Y et al 371
Zhang S *See* Loghman-Adham M et al 229
Zhao L (abst) 1116
Zheng F *See* Striker GE et al 63:S-120
Zheng X-X *See* Zhu G et al 992
Zhu G, Nicolson AG, Zheng X-X, Strom TB, Sukhatme VP: Adenovirus-mediated β-galactosidase gene delivery to the liver leads to protein deposition in kidney glomeruli 992
Zhuo J *See* Butkus A et al 628
Zhuo J *See* Dean R et al 1261
Ziai F *See* Mackenzie HS et al 63:S-140
Zietse R (abst) 567
Zietse R, Weimar W, Schalekamp MA: Atrial natriuretic peptide in diabetic nephropathy 60:S-33
Zimmer GS *See* Modification of Diet in Renal Disease Study Group et al 778
Zimmermann J *See* Wanner C et al 62:S-53
Zipperle L (abst) 1426
Ziyadeh FN, Han DC: Involvement of transforming growth factor-β and its receptors in the pathogenesis of diabetic nephropathy 60:S-7
Zoja C *See* Aiello S et al 171
Zoukhri D *See* Lopes de Faria JB et al 387
Zucchelli P *See* Locatelli F et al 63:S-63